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 Abstract 
Short sleep durations are common amongst adults across the world. They have 
been linked to metabolic disorders, and, more specifically, impaired glycaemic 
control. Acute and chronic physical activity are known to have beneficial effects on 
metabolic health, and therefore may be able to attenuate the link between short 
sleep and impaired glycaemic control. The purpose of this thesis was to explore the 
potential for exercise to alter glycaemic control in short sleep durations. Specifically, 
the aims were threefold: (a) to understand the impaired glycaemic response to 
glucose intake over consecutive nights of sleep restriction (Chapter 4); (b) to 
investigate if exercise could alleviate the sleep restriction induced impairment in 
insulin sensitivity (Chapter 5); and (c) to determine if these factors act in a similar 
manner when transferred to the free-living environment (Chapter 6). The findings in 
Chapter 4 demonstrated that the number of nights of sleep restriction did not appear 
to affect the impairment in glycaemic control. These findings informed the study in 
Chapter 5, which used a randomised cross-over design to explore the potential for 
acute exercise to attenuate the impairment in glucose regulation after a single night 
of sleep restriction. The findings suggest that sprint interval exercise may be 
beneficial for the late postprandial period after sleep restriction, as demonstrated by 
a reduced insulin area under the curve. However, when examined in the free-living 
environment (Chapter 6), habitual short sleep duration did not show any evidence of 
impairing markers of glycaemic control when confounding factors such as sex, diet, 
and body composition were taken into consideration. Collectively, the studies in this 
thesis confirm that short-term short sleep impairs glucose regulation and suggest 
that exercise may be beneficial for glucose regulation after short sleep in the acute 
setting, but findings may be contradictory in chronic settings. Further study is 
warranted to establish the effects of different exercise modalities on glucose 
regulation after sleep restriction and to fully understand the link between habitual 
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sleep duration, physical activity, and glycaemic control. However, a session of sprint 
interval exercise could be recommended to individuals after acute sleep restriction 
to alleviate the impairment in insulin sensitivity.   
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Chapter 1 – Introduction 
 
Insufficient sleep is thought to be becoming increasingly common and has recently 
been branded a ‘public health problem’ by the US Centers for Disease Control and 
Prevention (Hafner et al., 2017). The National Sleep Foundation recommends a 
sleep duration of 7 to 9 hours for adults aged 18-64 years old (Hirshkowitz et al., 
2015). However, the Great British Bedtime Report stated that despite this 
recommendation, 74% of individuals sleep less than 7 hours each night (The Sleep 
Council, 2017). The same report also identified a recent increase in the number of 
individuals sleeping for less than 5 hours each night, rising from 7% in 2013 to 12% 
in 2017. Comparable findings have been demonstrated across the world, with data 
from the US showing an increased prevalence of short sleep from the 1980s to the 
2000s (Luckhaupt et al., 2010), and data from the National Health Interview Survey 
in the United States demonstrating a decrease of approximately 10-15 minutes in 
sleep duration from 1985 to 2012 (Ford et al., 2015). Further analysis of this data 
shows more pronounced decreases in sleep duration from 2013-2017 (Sheehan et 
al., 2019). However, conflicting evidence exists. Some research suggests that the 
incidence of short sleep (less than six hours) only decreased in specific populations 
between 1975 and 2006, such as full-time workers (Knutson et al., 2010), or only in 
specific countries (Bin et al., 2013). Findings from the American Time Use Survey 
suggest an increase in sleep durations from 2003 to 2016 (Basner and Dinges, 
2018). However, this increase was small, averaging an increase of just under one 
and a half minutes each year, and it could be speculated that this may not be a 
significant amount to improve health outcomes.  
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Shorter sleep durations tend to be the result of a later bedtime, rather than an 
earlier wake time, as demonstrated by research which collected sleep schedules of 
individuals across the world using a smartphone application (Walch et al., 2016). 
Time use surveys have found work time to be the most common factor associated 
to sleep time (Basner et al., 2014). Those who work more, or spend more time 
commuting or travelling for other purposes tend to have shorter sleep times than 
those who have shorter work hours or travel less. Other reasons for short sleep 
durations could be due to socialising and participating in leisure time activities such 
as watching television (Basner et al., 2014).   
In the UK, over 1.5 million working hours are lost each year due to either absence or 
a decline in performance associated with insufficient sleep (Hafner et al., 2017). 
This is estimated to cost the economy around £40 billion. Thus, there is a need to 
explore how to combat the consequences of sleep deprivation and attempt to 
reduce the economic burden.   
Parallel to the decrease in sleep duration, the prevalence of type 2 diabetes and 
insulin resistance has increased, with more than double the number of prevalent 
cases of type 2 diabetes being recorded in 2013 compared to 2000 (Sharma et al., 
2016). With the ever-decreasing sleep durations it has been suggested that 
insufficient sleep is contributing to the increased incidence of type 2 diabetes 
(Gangwisch, 2009). Indeed, sleep loss has been associated with many of the 
leading causes of death in the UK, such as cardiovascular disease, diabetes, and 
hypertension in both males and females (Luyster et al., 2012). The cost of 
insufficient sleep may therefore be even higher than £40 billion when the cost of 
treating these health issues are also taken into consideration. 
Whilst the link between sleep and glucose metabolism is becomingly increasingly 
recognised, many questions still remain surrounding this association, including if the 
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effect of sleep restriction on metabolic function is cumulative, and if it is possible to 
attenuate the impairment in metabolic function which results from sleep restriction.  
Exercise is a commonly used tool to improve metabolic health. Acute exercise can 
markedly improve insulin sensitivity for up to two days (Bird & Hawley, 2017). 
Additionally, regular physical activity can lower the risk of developing metabolic 
disorders such as type 2 diabetes (Warburton et al., 2006), with adults who achieve 
more physical activity showing superior insulin sensitivity than those who are less 
active (Balkau et al., 2008). Thus, exercise could be suggested as a potential 
intervention to benefit glucose regulation after short sleep. However, studies 
investigating exercise and glucose regulation in situations of acute or habitual short 
sleep are limited, therefore further research in this area is warranted.  
Accordingly, the overall aim of this thesis is to present studies to address the gaps 
in current knowledge surrounding the relationship between sleep duration and 
glycaemic control, and the effect exercise has on this relationship.  
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2 Chapter 2 - Literature Review 
 Introduction 
This review of the literature will present an overview of sleep physiology and 
glycaemic control and highlight the potential for exercise to alter this relationship. 
Specifically, it will first outline the structure of sleep, provide a critique on methods to 
measure sleep, and give an overview of the interaction between sleep and lifestyle 
factors such as physical activity and diet. An outline of glucose homeostasis and 
measurement of glucose regulation will then be presented and key literature 
exploring sleep duration and glycaemic control will be reviewed. Finally, the 
potential for exercise and physical activity to benefit metabolic function will be 
discussed.  
 Sleep physiology 
Sleep is a reversible behavioural state in which an individual is disengaged and 
unresponsive to the surrounding environment. The regulation of sleep can be 
described by a two-process framework consisting of process S - a sleep-dependent 
process – and process C – a sleep-independent process (Borbely et al., 2016). 
Process S refers to the homeostatic drive to sleep and increases directly with time 
spent awake. In particular, this homeostatic mechanism is responsible for the 
regulation of slow-wave sleep (Dijk, 2009). The biological systems driving process S 
remain largely unknown, however adenosine accumulation is emerging as a likely 
contributor (Landolt, 2008). Process C - the circadian rhythm - is controlled by a 
central circadian oscillator known as the superchiasmatic nucleus, and is influenced 
by zeitgebers including light and dark cycles, food intake, and physical activity 
(Lewis et al., 2018; Stephan, 2002; Wever et al., 1983). This process regulates the 
daily rhythms of physiological functions such as glucose metabolism, as well as 
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promoting sleepiness and wakefulness. The circadian system influences core body 
temperature and melatonin, which are key factors in the initiation of sleep. An 
increase in melatonin combined with a drop in body temperature and increased 
homeostatic pressure promotes sleep (Luyster et al., 2012).  
2.2.1 Sleep structure 
Sleep typically consists of non-rapid eye movement (NREM) sleep followed by rapid 
eye movement (REM) sleep which occurs in cycles lasting approximately 90 
minutes. NREM sleep is further divided into stage 1 (N1) and 2 (N2), sometimes 
referred to as light sleep, and stage 3 (N3), commonly known as slow-wave sleep 
(SWS) or deep sleep (Fuller et al., 2006). In healthy adults, stage two sleep usually 
dominates, forming about 45-55% of total sleep time, followed by slow wave sleep 
(15-25%) and REM sleep (20-25%), then finally stage 1 sleep which makes up the 
remainder (Carskadon & Dement, 2011). Typically, the percentage of slow wave 
sleep (SWS) within a cycle is inversely related to the number of sleep cycles, with 
latter sleep cycles containing less SWS than those in the first part of the sleep 
period. In contrast, there is usually a direct relationship between the number of 
sleep cycles and percentage of REM, N1 and N2 sleep (Sharma and Kavuru, 2010).  
Each sleep stage has a unique set of characteristics, allowing the different stages to 
be distinguished using polysomnography (PSG). REM sleep is very similar to 
wakefulness with respect to brain wave activity. As the name suggests, there is eye 
movement during this stage, as well as irregular breathing and surges in cardiac 
function. Memory consolidation occurs during REM sleep, with information stored in 
short term memory being processed and moved to long-term memory (Boyce et al., 
2017). Stage 1 sleep acts as a transition between wakefulness and sleep, and is 
characterised by the disappearance of alpha waves and the appearance of theta 
waves. Muscle activity begins to decrease during this stage. Brain wave activity 
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slows and eye movement ceases as an individual transitions into stage 2 sleep. 
Stage 2 sleep can be recognised by the presence of sleep spindles and K-
complexes, which are bursts of brain activity and high amplitude waves, 
respectively. The spindles in stage 2 sleep are thought to contribute to memory 
consolidation (Gais et al., 2002). The appearance of delta waves signifies the 
beginning of stage 3 sleep, during which restorative processes such as tissue 
growth and repair take place (Fuller et al., 2006).  
Sleep structure may be altered under conditions of sleep restriction (Webb and 
Agnew Jr., 1965). It has been shown that delaying bed time by 1 h and advancing 
wake time by 2 h results in a decrease in stage 2 sleep and increased REM sleep 
after 3 nights (Elmenhorst et al., 2008). Similar findings were noted when sleep was 
restricted to 0000 to 0300 for 4 nights, with decreased stage 2 sleep, however stage 
3 and 4 sleep increased in this study (Wu et al., 2010). This is in agreement with 
previous findings as reviewed by Carskadon and Dement (2011) who state that slow 
wave sleep is usually favoured following a period of sleep loss, with REM sleep 
recovery only occurring after slow wave sleep debt has been repaid. In general, this 
suggests that individuals will show higher proportions of SWS when they are more 
sleep deprived. The changes in sleep architecture during sleep loss may provide a 
useful method to indicate whether individuals in a sleep restriction study are truly 
sleep restricted. 
2.2.2 Measuring Sleep  
The differences in brain wave activity and bodily movements enables determination 
of sleep structure by polysomnography (PSG). Considered the ‘gold-standard’ 
method of measuring sleep duration and architecture, this multi-parametric test 
consists of measurements of brain wave activity by electroencephalography (EEG), 
eye movements by electrooculography (EOG), muscle activity by electromyography 
7 
 
(EMG), heart rhythm by electrocardiography (ECG), breathing rate and airflow, and 
oxygen saturation (Marino et al., 2013). Polysomnography provides detailed 
feedback about sleep and, in addition to diagnosing some sleep disorders, can be 
useful to gain information on sleep architecture in sleep studies. Output variables 
from polysomnography include total sleep time (TST – the total time spent asleep), 
sleep latency (SL – the duration from “lights out” to the onset of sleep), REM latency 
(the duration from “lights out” to the onset of REM sleep), wake after sleep onset 
(WASO – the duration of wakefulness that occurs after initial onset of sleep), sleep 
efficiency (SE – the percentage of time in bed spent asleep), and duration and 
percentage of each sleep stage (NREM and REM). However, much of the time 
polysomnography must be conducted in a sleep laboratory, meaning individuals 
must stay in an unfamiliar environment which may affect sleep (Tamaki et al., 2005). 
Portable PSG equipment may be used in the home environment, however still 
requires set up by an experienced researcher which may not always be feasible. 
For use in sleep studies it is therefore advantageous to include a familiarisation 
night which allows individuals to become accustomed to sleeping in the laboratory 
and wearing the polysomnographic equipment, accounting for the first night effect or 
reverse first night effect. The necessary addition of this night may be viewed as a 
disadvantage to using polysomnography to measure sleep due to the additional cost 
and inconvenience. Other potential limitations include the specialist knowledge 
required to set up the equipment and the time and additional cost of analysis of the 
recordings. 
Consequently, in situations where polysomnography is unfeasible, such as sleep 
studies conducted in the free-living environment or with larger populations, sleep 
may be measured using actigraphy. Actigraphy monitors are usually watch-shaped 
devices most commonly worn on the wrist. The recording of movement, temperature 
and light exposure enables measurement of sleep and activity phases. Although 
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unable to provide specific information regarding sleep architecture, actigraphy is a 
valid tool for determining total sleep duration, WASO, SOL, and sleep efficiency 
(Marino et al., 2013). Wrist actigraphy has been compared with polysomnography in 
multiple studies and has shown high correlations (above 90% agreement) between 
measures for distinguishing between sleep and wakefulness in healthy adults 
(Ancoli-Israel et al., 2003). 
Another common method of measuring sleep variables is through the use of sleep 
logs. Sleep logs are arguably inferior to other methods due to their subjective 
nature, and correlate poorly with objective measures such as actigraphy and PSG in 
a range of populations (Ancoli-Israel et al., 2003). Comparison of PSG to subjective 
sleep measures in the Sleep Heart Health Study showed participants overestimated 
their total sleep duration by around one hour (Silva et al., 2007). However, in 
situations where PSG is not feasible, sleep logs may be combined with actigraphy. 
Often when actigraphy is being used wearers are asked to press a button on the 
watch to provide a marker of when they are intending to sleep and when they wake. 
This marker allows distinction between daytime stillness and actual sleep. If this 
button is not pressed, a sleep diary can provide a useful alternative to determine 
bed and wake time (Lauderdale et al., 2008b). 
2.2.3 Sleep restriction studies 
Whilst there is an abundance of knowledge on what happens during sleep, there are 
still many unanswered questions surrounding why sleep occurs, and the amount of 
sleep which is optimal for health. To understand more about the purpose of sleep, 
studies of partial or total sleep deprivation are often conducted to explore the 
physiological consequences of insufficient sleep. Partial sleep deprivation (sleep 
restriction) may be more ecologically valid than total deprivation, reflecting sleep 
durations experienced regularly by individuals due to lifestyle demands such as 
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work. Studies which utilise multiple consecutive days of sleep restriction may be of 
particular importance as these can highlight not only the consequences of short 
sleep, but whether there is an accumulation of these consequences (Banks & 
Dinges, 2007). Yet, at present there are few studies that have examined whether or 
not there is a difference between one night and multiple nights of sleep restriction 
on either physiological or psychological outcomes, so it would be beneficial to 
determine this to inform future research study protocols. 
 
 Sleep, physical activity and diet 
2.3.1 The influence of physical activity and diet on sleep 
Sleep may be influenced by lifestyle habits such as physical activity and dietary 
intake. A recent meta-analysis concluded a small beneficial effect of acute exercise, 
defined as a single session of exercise, on sleep duration, SOL, SE, SWS time, 
WASO, and stage 1 sleep time (Kredlow et al., 2015). In the same meta-analysis 
similar findings were demonstrated for regular exercise, defined as multiple 
sessions of exercise. Furthermore, three sessions of aerobic exercise each week 
have been shown to increase sleep duration by around 45 minutes despite no 
significant changes in time in bed (Baron et al., 2013).  
It is possible that the type of exercise may influence the benefit on sleep outcomes. 
Chronic resistance exercise has beneficial effects on sleep quality, but studies 
examining the effect of acute exercise on sleep are lacking so it is unclear whether 
findings would be similar (Kovacevic et al., 2018). The review by Kovacevic et al. 
(2018) also demonstrates a relationship between intensity and frequency of physical 
activity and sleep quality, with higher intensity and more frequent bouts producing 
superior effects on multiple aspects of sleep quality including perceived sleep 
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quality, SOL, sleep efficiency, and WASO. In contrast, an earlier review (Kredlow et 
al., 2015) reported no influence of intensity of acute exercise on changes in sleep 
variables, however, the review reported comparable results regarding duration of 
acute exercise bouts.  
Another aspect of lifestyle which may influence sleep is dietary intake. Several 
studies have investigated whether diet impacts sleep duration or other aspects of 
sleep. Specifically, total energy, fat, and fibre intake have all been commonly found 
to have associations with sleep duration (Dashti et al., 2015). Early experimental 
studies examining carbohydrate intake on sleep demonstrated decreased SWS and 
increased REM sleep with a high carbohydrate, low fat diet compared to a normal or 
high fat, low carbohydrate diet (Phillips et al., 1975; Porter & Horne, 1981). 
Decreases in sleep onset latency have also been observed after high carbohydrate 
diets (Lindseth et al., 2013). In the same study individuals had around 3 less wake 
episodes during sleep when consuming a high protein diet in which 56% of total 
energy came from protein compared to a control diet where protein made up 15% of 
total energy. Changes in sleep quality and quantity arising from high protein and 
carbohydrate diets may be due to increases in tryptophan, serotonin and melatonin. 
These sleep-promoting substances have been shown to increase with carbohydrate 
and protein intake (Wurtman et al., 2003), providing a potential link between dietary 
composition and sleep.  
2.3.2 The influence of sleep on physical activity and diet 
The relationships between physical activity and sleep, and diet and sleep, appear to 
be reciprocal. Cross-sectional studies have demonstrated lower levels of physical 
activity in individuals with shorter sleep durations and poorer sleep quality (Stefan et 
al., 2018; Štefan et al., 2018). Intervention studies have mimicked these findings. 
Healthy males showed a decrease in physical activity in the free-living environment 
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after one night of 4.25 hours of sleep compared to one night of 8.25 hours of sleep, 
with a 13% decrease in total activity and a lower proportion of time spent doing high 
intensity activity (Schmid et al., 2009). Additionally, longer sleep onset latencies are 
predictive of shorter exercise durations the following day (Baron et al., 2013). 
Given that there is a direct relationship between physical activity and sleep 
efficiency, it is unsurprising that there is an inverse relationship between sleep 
efficiency and sedentary time (Gubelmann et al., 2018). However, interestingly, 
there does not appear to be any association between sleep duration and sedentary 
behaviour (Saleh & Janssen, 2014). This cross-sectional study used 7-day 
actigraphy data for sleep duration and sedentary time in 1371 adults. There was no 
difference in sedentary time between sleep duration quintiles. 
Experimental short sleep duration causes increases in appetite and total energy and 
fat intake, despite no changes in energy expenditure (St-Onge et al., 2011). Energy 
intake was approximately 6% greater during 5 nights of 5 hours sleep compared to 
5 nights of 9 hours sleep (Markwald et al., 2013). Furthermore, changes in appetite 
hormones have been observed in healthy males after 2 nights of sleep restriction to 
4 hours, with an 18% decrease in leptin and 28% increase in ghrelin compared to 2 
nights of 10 hours sleep (Spiegel et al., 2004). Similarly, altered appetite hormones 
have been observed after just 1 night of sleep restriction to 4.5 hours compared to a 
control night of 8.5 hours (Broussard et al., 2016). Twenty-four hour levels of ghrelin 
were increased approximately 7%, as well as increased post-prandial levels of 
ghrelin after all meals. Energy intake was increased by an average of 340 
kilocalories in the sleep restriction condition, with the extra intake coming from an 
increased intake of carbohydrates and increased snacking. A decrease of around 
200-250 kilocalories per day is thought to be sufficient to elicit a change in 
bodyweight over the long term (Hall et al., 2017), therefore  the increase in energy 
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intake combined with a decrease in physical activity following short or poor sleep 
may lead to obesity and metabolic dysfunction.  
 
 Glucose Metabolism 
2.4.1 Glucose homeostasis  
In order to sustain normal functioning, glucose absorption, uptake and production 
must be balanced to ensure blood glucose concentrations are kept within the 
normal range of approximately four to seven mmol/L (Saltiel & Kahn, 2001). The 
regulation of blood glucose concentration is primarily under the control of two 
hormones - glucagon and insulin - which operate in a negative feedback manner to 
maintain levels within the normal range. Figure 2.1 (Roder et al., 2016) provides an 
overview of how these hormones control the uptake and release of glucose.  
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Figure 2.1 Overview of glucose homeostasis from 'Pancreatic regulation of glucose 
homeostasis.' (Roder et al. 2016). Licensed under CC BY-NC-ND 4.0. 
 
In the post-absorptive state (i.e. during a period of fasting) blood glucose 
concentration reaches a nadir, with typical values of around 3.0-5.0 mmol/L 
depending on the length of the fasting period (Gerich, 1993). At this point, glucagon 
encourages the breakdown of glycogen in the liver (glycogenolysis), inhibits 
formation of glycogen, and promotes formation of glucose from other substrates 
such as lactate and amino acids (gluconeogenesis). This combination of glycogen 
breakdown and glucose production prevents blood glucose concentrations falling 
below the normal range, known as hypoglycaemia. In the post-absorptive state, 
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insulin concentrations are low, and most glucose uptake occurs by insulin 
independent mechanisms according to tissue demand (Gerich, 2000).  
When blood glucose concentration rises above normal levels, usually in the post-
prandial state, insulin is released by the pancreatic beta cells to return blood 
glucose to within the normal range. The release of insulin promotes glucose uptake 
and storage as well as blunting gluconeogenesis and glycogenolysis (Saltiel & 
Kahn, 2001). The suppression of gluconeogenesis and glycogenolysis by insulin are 
thought to be more important in regulating blood glucose concentrations in the post-
prandial state than its excitatory actions (Sonksen and Sonksen, 2000). In the 
peripheral tissues, insulin-stimulated glucose uptake occurs predominantly in 
skeletal muscle tissue (DeFronzo & Tripathy, 2009). When insulin binds to receptors 
in the skeletal muscle, a signalling cascade known as the insulin signalling pathway 
(Figure 2.2) is triggered, which ultimately leads to translocation of GLUT-4 
molecules to the membrane. Glucose is then taken up into the peripheral tissues by 
facilitated diffusion and either used immediately or converted to glycogen to be 
stored in the liver or muscle (Adeva-Andany et al., 2016). Typically, blood glucose 
peaks around 15-30 minutes post ingestion of a meal or glucose bolus. Similarly, 
large increases in insulin are observed at this time and serve to counteract the 
increase in glucose concentration by facilitating glucose disposal. The glucose and 
insulin profiles in the postprandial state are of particular interest as they can be 
indicative of hyperglycaemia and insulin resistance - two primary characteristics of 
type 2 diabetes (American Diabetes Association, 2009). 
 
 
15 
 
 
 
 
 
Figure 2.2. Insulin signalling pathway facilitating insulin mediated glucose uptake by translocation of 
GLUT4. 
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2.4.2 Impaired glucose metabolism 
When blood glucose homeostasis is compromised, blood glucose may increase to 
concentrations outside the normal range. This can occur either in the fasted state, 
postprandial state, or both. This is often characterised as decreased insulin 
sensitivity, which may lead to a period of hyperglycaemia. Chronic hyperglycaemia, 
and decreased insulin sensitivity can lead to the development of metabolic disorders 
such as type 2 diabetes mellitus (T2D).  
Impaired glucose metabolism can manifest in several ways. Firstly, as impaired 
fasting glucose, which occurs when blood glucose concentration falls between 6.1 
mmol/L and 6.9 mmol/L in the post-absorptive period. Impaired fasting glucose may 
be present without impaired glucose tolerance (Meyer et al., 2006). Secondly, 
impaired glucose tolerance, which occurs when there is compromised insulin action 
in the early and late postprandial phase resulting in a prolonged bout of 
hyperglycaemia (Meyer et al., 2006). Individuals with impaired glucose tolerance are 
six times more likely to develop type 2 diabetes compared to individuals free from 
any metabolic abnormalities (Santaguida et al., 2005). Thirdly, blood glucose 
concentrations may be increased significantly above normal values in either the 
fasting or 2 h postprandial state, indicating type 2 diabetes. Reference values for 
blood glucose concentrations as defined by the World Health Organization (2006) 
are given in Table 2.1. 
Currently, poor diet, obesity and physical inactivity are thought to be the biggest risk 
factors for developing a metabolic disease related to impaired glucose metabolism, 
such as type 2 diabetes (Qin et al., 2010; Steyn et al., 2004). However, as will be 
presented in section 2.5 of this chapter, it is becoming increasingly recognised that 
sleep may also play an important role in maintaining healthy glucose metabolism. 
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Table 2.1. WHO classification criteria for normal glucose tolerance, IFG, IGT and 
T2D. 
 Fasting 2 h OGTT HbA1c 
Normal <6.1 mmol/l <7.8 mmol/l 20-42 mmol/mol 
IFG 6.1 – 6.9 mmol/l   
IGT  7.8 - 11.0 mmol/l  
T2D ≥ 7.0 mmol/l ≥ 11.1 mmol/l ≥ 48 mmol/mol 
(6.5%)  
World Health Organisation cut-off values for normal glucose tolerance, impaired fasting 
glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes (T2D) according to 
fasting, 2 h oral glucose tolerance test (OGTT) concentrations and glycated haemoglobin 
concentrations (HbA1c). 
 
2.4.3 Measurement of glycaemic control 
The ability to measure markers of glycaemic control is of extreme importance for 
both clinical practice and research studies. The gold standard method of 
measurement is the hyperinsulinemic-euglycaemic clamp (DeFronzo et al., 1979). 
For the clamp technique, insulin concentrations are raised using a continuous 
insulin infusion. Glucose is then infused at a rate which will maintain euglycaemia. 
The rate of glucose infusion is indicative of whole body glucose uptake, and 
therefore reflects tissue insulin sensitivity. This method is a direct measure of insulin 
resistance and enables quantification of insulin sensitivity under steady-state 
conditions. However, the clamp technique is complex and expensive, requiring 
specialist knowledge and frequent blood sampling in addition to a constant insulin 
infusion over several hours (Singh & Saxena, 2010). Due to the complex nature of 
the clamp, other methods to estimate insulin resistance and glucose control have 
been developed, including the intravenous glucose tolerance test (IVGTT), oral 
glucose tolerance test (OGTT) and several insulin sensitivity indexes such as 
homeostatic model of assessment (HOMA) and Matsuda index (Singh & Saxena, 
2010). Each of these surrogate markers have advantages and disadvantages which 
must be considered prior to deciding which is most suitable for use. In research 
studies investigating glucose control and sleep, the commonly used surrogate 
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markers for measuring glycaemic control are the OGTT, IVGTT, HOMA, and 
Matsuda index.  
The IVGTT (Bergman et al., 1979) involves administration of an intravenous glucose 
bolus following an overnight fast. Blood samples are obtained at regular intervals 
and glucose and insulin are measured. Minimal model analysis can then be 
conducted which enables estimation of insulin sensitivity and glucose effectiveness 
(Muniyappa et al., 2008). Despite being less labour-intensive than the clamp 
method, the IVGTT still requires intravenous delivery of a glucose bolus and blood 
sampling over three hours, making it time consuming.   
A less labour-intensive method of measuring glycaemic control is the OGTT. The 
standard OGTT involves ingestion of 75 grams of glucose dissolved in 300 ml of 
water following a period of fasting (Muniyappa et al., 2008). Blood is sampled prior 
to ingestion of the glucose drink and at several timepoints during the following two 
hours. Glucose and insulin are measured from the blood samples and can give an 
indication of glucose control and, as outlined in the section above, diabetes risk.  
Furthermore, estimates of insulin sensitivity can be derived from the OGTT. HOMA 
uses fasting glucose and insulin concentrations to estimate insulin sensitivity. It is 
calculated as: 
HOMA-IR = 
fasting plasma glucose (mmol/l) x fasting plasma insulin (µIU/ml) 
22.5
 
 As fasting measurements are used, HOMA primarily reflects hepatic insulin 
sensitivity (Abdul-Ghani et al., 2007). Alternatively, if an estimate of whole body 
insulin sensitivity is required, the Matsuda Index may be a more suitable measure 
(Matsuda & DeFronzo, 1999):  
10000
√(fasting insulin (µIU/ml) × fasting glucose (mmol/l)) × (mean glucose (mmol/l) × mean insulin (µIU/ml)) 
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The Matsuda Index is highly correlated (r = 0.73) with whole-body glucose disposal 
during a euglycaemic clamp and uses concentrations over the two hour OGTT, 
making it a more dynamic measure of insulin sensitivity than HOMA (Matsuda & 
DeFronzo, 1999; Otten et al., 2014). The Matsuda index is thought to be reflective 
of skeletal muscle glucose uptake since it uses postprandial measurements 
(Rynders et al., 2016). However, surrogate measures of insulin sensitivity such as 
the Matsuda Index show poor correlation with insulin sensitivity in the post-exercise 
period, underestimating the increase in insulin sensitivity in both moderate and high 
intensity exercise protocols (Rynders et al., 2016). Therefore, these measures 
should be used with caution if measured in close proximity to an exercise bout. 
2.4.4 Alternative markers of glycaemic control 
The measures mentioned previously all provide information on glycaemic control in 
the acute setting, since outcomes represent glucose tolerance at the specific time 
the test is conducted. For measurement of chronic glucose control, glycated 
haemoglobin (HbA1c) is commonly used (American Diabetes Association, 2006). 
Glycated haemoglobin is a haemoglobin molecule which has formed a covalent 
bond with glucose. HbA1c represents an average of glucose control over the 
previous three months, which is the approximate lifespan of the red blood cell 
(Nathan et al., 2007). Whilst HbA1c may act as a diagnostic criteria for diabetes, it is 
also useful as a predictor of future diabetes risk (Edelman et al., 2004). Individuals 
with HbA1c concentrations above 42 mmol/mol (6%) have a five-year risk of 25-
50% for developing type 2 diabetes, approximately twenty times higher compared to 
those with HbA1c concentrations below 31 mmol/mol (5%) (Zhang et al., 2010). As 
HbA1c is a measure of chronic glycaemic control, it is less influenced by the 
previous days behaviours. 
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There are also multiple alternative markers which are associated with HbA1c and 
reflective of glycaemic control. Adiponectin is a hormone produced by adipose 
tissue. It contributes to the regulation of glycaemic control by increasing fatty acid 
oxidation, thus reducing serum fatty acid concentrations and hepatic and skeletal 
muscle intracellular triglycerides (Diez & Iglesias, 2003). Research has established 
an inverse association between adiponectin concentrations and risk of developing 
type 2 diabetes, with a relative risk of 0.72 for each 1-log μg/ml increase in 
adiponectin (Li et al., 2009). Negative correlations have been demonstrated 
between adiponectin and HbA1c and adiponectin and fasting glucose across the 
glucose tolerance spectrum in middle aged adults (Fernandez-Real et al., 2004). In 
addition, circulating adiponectin concentrations show a direct correlation with 
IVGTT, OGTT, and clamp derived insulin sensitivity (Cnop et al., 2003; Tschritter et 
al., 2003). 
Lipid profiles may also provide information about glycaemic control status. Higher 
fasting levels of triglycerides and lower high density lipoprotein (HDL) have been 
identified as markers of insulin resistance (Laws & Reaven, 1992). Insulin 
resistance is thought to decrease HDL concentrations by reduced synthesis of 
ApoA-I, increased hepatic triglyceride lipase (HTGL), and decreased lipoprotein 
lipase (LPL) (Bjornstad & Eckel, 2018). Increased triglycerides are also thought to 
occur in insulin resistance due to increased HGTL and decreased LPL, as well as 
increased hepatic VLDL synthesis (Bjornstad & Eckel, 2018). Furthermore, 
combining these values to obtain a triglyceride-to-HDL ratio has been established 
as one of the best indicators to identify insulin resistant individuals (McLaughlin et 
al., 2003). Cut-points of 1.47 mmol/L for triglyceride concentration and 1.8 (SI units) 
for triglyceride-to-HDL ratio have been suggested to indicate insulin resistance 
(McLaughlin et al., 2003). Low density lipoprotein (LDL) and LDL-to-HDL ratio have 
demonstrated moderate positive correlations with HbA1c, with LDL-to-HDL showing 
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a sensitivity of 98% and specificity of 56% as a predictive biomarker of glycaemic 
control (Artha et al., 2019), Therefore, when determining metabolic status of an 
individual, adiponectin, triglycerides, and cholesterol may all be used as indicators 
of glycaemic control. This may be of advantage in large studies where glycaemic 
status is required as these markers can be measured from a single blood sample 
using relatively simple techniques. 
 
 Sleep and glycaemic control 
Glucose control typically exhibits a 24-hour pattern, with peak glucose tolerance 
occurring in the morning and reaching a nadir in the middle of the night. Studies 
have shown that sleep plays an important role in maintaining this pattern of glucose 
control, and in particular the peak glucose tolerance in the morning. Sleep can 
impact glucose and insulin concentrations independent of circadian effects (Shea et 
al., 2005). Shea and colleagues demonstrated alterations in glucose during sleep 
which were not explained by circadian effects, and, similarly, Van Cauter and 
colleagues (1991) observed changes in glucose during daytime sleep which mimic 
changes that occur during night time sleep, suggesting alterations can occur 
independent of circadian patterns. During sleep, brain glucose utilisation is 
decreased and there is a reduction in systemic glucose uptake (Boyle et al., 1994). 
Furthermore, plasma lipid profiles show a diurnal pattern, with triglycerides and free 
fatty acids reaching a nadir during normal sleeping hours (Pan & Hussain, 2007). 
Taken together, it is apparent that sleep plays an important role in glucose 
regulation, and thus any alterations to sleep patterns may influence glycaemic 
control.  
It has been proposed that humans have evolved with “thrifty” genes (Neel, 1962). 
As the brain functions using solely glucose as a fuel source, insulin resistance may 
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have been beneficial to prevent brain hypoglycaemia in previous years when 
carbohydrate intake was scarce and diets were predominantly meat- and fish-based 
(Pijl, 2011). However, in combination with the current Western style diet and 
environment where high-calorie foods are widely available, these previously 
advantageous mechanisms to promote higher glucose concentrations may make 
individuals more susceptible to developing type 2 diabetes.  
 
 Short sleep duration and metabolic dysfunction  
Epidemiological evidence has linked chronic short sleep duration to a number of 
adverse health outcomes, including cardiovascular disease, obesity, and type 2 
diabetes (Luyster et al., 2012). Compared to individuals reporting a sleep duration of 
7 hours each night, a habitual sleep duration of 6 hours or less each night may 
double the risk of developing type 2 diabetes in adult males, even when 
confounding factors such as smoking status and waist circumference are accounted 
for (Yaggi et al., 2006). Similar findings were demonstrated in a sample of males 
and females taken from the National Health and Nutrition Survey, with those 
individuals sleeping less than 5 hours each night having an increased likelihood of 
having developed type 2 diabetes at follow-up (Ayas et al., 2006). The risk of 
developing type 2 diabetes in short sleepers has been shown to be similar to that of 
more known risk factors such as physical inactivity (Anothaisintawee et al., 2016). 
Additionally, a recent meta-analysis examining the effect of sleep restriction on 
insulin sensitivity demonstrated an effect size similar to the effect of physical activity 
on insulin sensitivity (Zhu et al., 2019). 
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2.6.1 Sleep duration and glucose metabolism  
2.6.1.1 Cross sectional evidence – sleep duration and metabolic markers 
The increased risk of developing metabolic disorders such as type 2 diabetes in 
individuals with chronic short sleep durations may be due to altered glucose 
metabolism. Several cross-sectional studies have demonstrated an association 
between sleep duration and HbA1c levels (Nakajima et al., 2008; Ohkuma et al., 
2013; Twedt et al., 2015). However, the majority of these studies used individuals 
who already had a metabolic disorder such as type 2 diabetes. A meta-analysis 
examining sleep duration and glycaemic control in those with type 2 diabetes 
showed that short sleep was consistently associated with higher HbA1c 
concentrations (Lee et al., 2017), with a pooled mean difference of 0.23%. Similar 
findings were reported for long sleep durations, but to a slightly lesser extent. This 
U-shaped association between sleep duration and HbA1c levels indicates poorer 
glycaemic control in those with type 2 diabetes who do not achieve the optimal 
amount of sleep each night. However, due to the cross-sectional design of these 
studies, it is not possible to determine the causality or direction of the relationship. 
Whether a similar association between sleep duration and HbA1c levels exists in 
healthy non-diabetic individuals, or not, is uncertain. Both Nakajima and colleagues 
(2008) and Hancox and Landuis (2012) demonstrated a significant negative 
relationship between HbA1c and sleep duration, with durations of less than seven 
hours showing higher HbA1c levels. Similarly, Potter et al. (2017) showed a trend 
for a negative association. On the other hand, a recent study failed to demonstrate a 
relationship between sleep duration and HbA1c in non-diabetic individuals without 
sleep disorders (Whitaker et al., 2018), and in a study by Nakajima et al. (2017) the 
increased odds ratio for poorer HbA1c with short sleep duration was mitigated when 
other lifestyle factors such as exercise and alcohol and smoking intake were 
adjusted for. Thus, it is possible that lifestyle factors such as diet and exercise may 
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contribute to the relationship between sleep duration and HbA1c and should 
therefore be taken into consideration in any studies examining the relationship 
between sleep and glycaemic control. 
In addition to HbA1c, studies have examined the relationship between sleep 
duration and serum lipids. Some studies observed no association between serum 
lipid profiles and sleep duration (Anujuo et al., 2015; Bos et al., 2019), whilst others 
have found higher triglyceride and lower HDL concentrations in short sleepers 
(Bjorvatn et al., 2007; Kaneita et al., 2008). Kaneita and colleagues (2008) observed 
a relative risk of 1.51 for high triglyceride concentrations and 5.85 for low HDL 
cholesterol in women sleeping less than five hours compared to between six and 
seven hours each night. A lower risk of high LDL was also demonstrated in males 
achieving at least eight hours of sleep each night. In contrast Anujuo et al. (2015) 
demonstrated positive associations between short sleep and total cholesterol and 
short sleep and low HDL cholesterol, but only in individuals of Moroccan and South-
Asian Surinamese ethnic origins. The majority of ethnicity groups did not display 
any associations between sleep duration and lipid profiles.  
There are some limitations in these studies which should be considered. Firstly, in 
the studies which demonstrated a relationship between sleep duration and HbA1c, 
sleep duration was self-reported and variable. Self-reported measures may 
overestimate sleep duration compared with objective measures such as actigraphy 
(Lauderdale et al., 2008a). Short sleepers may overestimate sleep duration by 
around one hour, and normal sleepers by approximately half an hour. Subjective 
measures of sleep should therefore be avoided where possible due to the potential 
for bias. Furthermore, sleep quality is difficult to ascertain from subjective measures 
of sleep, therefore it is unclear whether sleep fragmentation may be contributing to 
the alterations in metabolic markers. 
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The different methods employed to determine sleep duration may partly explain the 
inconsistent findings between studies. Sleep was measured by actigraphy in the 
study by Whitaker and colleagues (2018), in contrast to others that used subjective 
measures (Hancox & Landhuis, 2012; Nakajima et al., 2008; Nakajima et al., 2017; 
Ohkuma et al., 2013). Additionally, although some studies attempted to account for 
confounding factors, body mass index was often used to indicate body composition. 
Body mass index does not distinguish between fat tissue and lean tissue, and is 
therefore thought to have limitations when used as the only measure of body 
composition. Impaired glucose metabolism tends to be associated with fat mass 
(Bower et al., 2017), so using a method which can identify fat mass, such as DXA 
scanning, would improve these studies. Therefore, additional research in this area 
using objective and gold-standard methods is warranted as presence of an 
association may have implications for predicting future risk of developing a 
metabolic disorder.  
2.6.1.2 Experimental evidence – sleep duration and metabolic outcomes 
There is a plethora of studies which have used experimental sleep restriction to 
examine the impact of reduced sleep duration on glucose metabolism. A variety of 
sleep restriction protocols have been used, ranging from a single night of 4 hours 
sleep (Donga et al., 2010) to 14 nights of 5.5 hours sleep each night (Nedeltcheva 
et al., 2009). Likewise, several different methods have been used to measure 
glucose metabolism. Some studies utilised a hyperinsulinemic-euglycaemic clamp 
(Buxton et al., 2010; Donga et al., 2010; Rao et al., 2015), which enables a detailed 
insight into glucose metabolism as mentioned above. Others employed IVGTTs 
(Broussard et al., 2012; Buxton et al., 2010; Nedeltcheva et al., 2009; Spiegel et al., 
1999) or less complex methods such as an OGTT or a mixed macronutrient meal 
(Eckel et al., 2015; Schmid et al., 2011; Wang et al., 2016). Although less detail can 
be obtained using the OGTT or mixed meal method, these are arguably more 
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ecologically valid. Despite the differing methodologies, these studies are consistent 
in their conclusion that sleep restriction is detrimental to glucose metabolism.  
Two weeks of sleep restriction by 3 hours each night resulted in an approximately 
10% increase in 2 h glucose values during an OGTT, and around a 20% decrease 
in insulin sensitivity (Nedeltcheva et al., 2009). Additionally, after only a single night 
of sleep restriction to four hours, endogenous glucose production was increased 
and glucose disposal was decreased during a hyperinsulinemic-euglycaemic clamp, 
and whole body insulin sensitivity was reduced by around 20% (Donga et al., 2010). 
However, the sleep protocol employed in this study permitted sleep from 0100 to 
0500 in the sleep restriction condition, compared to 2300 to 0730 in the control 
condition. Whilst this keeps midpoint of sleep consistent, it presents the limitation 
that duration between wake time and the hyperinsulinemic-euglycaemic clamp was 
different between conditions. This may influence findings, as research has 
demonstrated an impact of morning circadian misalignment on insulin sensitivity 
(Eckel et al., 2015). 
The evidence presented above clearly demonstrates a role of sleep duration in 
glucose regulation. So far, however, no research has examined whether the 
impairment in glucose regulation is related to the number of nights or hours per 
night of sleep loss. Obtaining this evidence from the current literature would be 
challenging due to widely varying methodologies regarding measurement of glucose 
regulation and sleep restriction protocols employed.  
2.6.2 Underlying mechanisms 
Whilst it is well established that there is a link between both chronic and acute short 
sleep duration and impaired glucose metabolism, why this occurs remains elusive. 
Several mechanisms (Figure 2.3) have been proposed in the literature including 
altered sympathetic activation (Spiegel et al., 2004), decreased brain glucose 
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utilisation, increased systemic inflammation (Mullington et al., 2010; Vgontzas et al., 
2004), altered circadian gene expression (Cedernaes et al., 2015), changes in 
energy metabolism in skeletal muscle (Vondra et al., 1981) and altered peripheral 
insulin signalling (Broussard et al., 2012; Rao et al., 2015). Studies examining these 
potential mechanisms have provided mixed findings, suggesting there may be 
multiple mechanisms contributing to the impaired glucose regulation after sleep 
restriction.  
Changes in the HPA axis and sympathetic activation have been observed after 
sleep restriction ranging from a single night to seven nights. Late afternoon and 
evening cortisol levels were increased after six nights of four hours sleep and seven 
nights of five hours sleep in healthy males (Buxton et al., 2010; Spiegel et al., 1999). 
Similarly, a single night of four hours sleep increased cortisol levels by 37% the 
following evening compared to an eight hour sleep (Leproult et al., 1997). However, 
during a hyperinsulinemic euglycaemic clamp conducted the morning after a single 
night of four hours sleep, cortisol levels did not differ from the control condition 
(Donga et al., 2010). This suggests that the impact of sleep restriction on cortisol 
levels may be more pronounced in the evening than the morning. Increased levels 
of cortisol in the evening have been demonstrated to have a larger impact on 
glucose regulation than elevated morning concentration, with increases in insulin 
concentrations and an approximately 30% decrease in insulin clearance (Plat et al., 
1999). Additionally, limited studies have observed an increase in catecholamines 
following sleep restriction (Buxton et al., 2010; Irwin et al., 1999). However, the 
increases in epinephrine and norepinephrine observed by Buxton and colleagues 
(2010) did not correlate with changes in insulin sensitivity during a hyperinsulinemic 
euglycaemic clamp, suggesting altered sympathetic activity may not be a main 
contributor to impaired glucose regulation after sleep restriction. 
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Increased inflammation has been demonstrated after sleep restriction in some 
studies (Irwin et al., 2006; Meier-Ewert et al., 2004), but findings were less 
consistent in others, with only some inflammatory markers increasing (Haack et al., 
2007). Several studies also noted a sex-specific change in inflammation, with 
increased NF-kB occurring only in females in a study by Irwin and colleagues 
(2008), and increased TNF-alpha in males but not females in another study 
(Vgontzas et al., 2004). The inconsistent findings suggest that whilst inflammation 
may play a role in impaired glucose regulation after sleep restriction, it may depend 
on the protocol and population used, highlighting the possibility that the underlying 
mechanisms are multi-factorial.  
Reduced peripheral insulin sensitivity has been repeatedly demonstrated after sleep 
restriction (Broussard et al., 2012; Donga et al., 2010; Rao et al., 2015), suggesting 
that a change in insulin signalling in either skeletal muscle and/or adipose tissue is 
plausible. Few studies have attempted to directly assess changes in peripheral 
insulin signalling. Broussard and colleagues (2012) investigated insulin signalling in 
adipocytes following four nights of sleep restriction to 4.5 hours. Akt phosphorylation 
was reduced in the sleep restricted condition compared to four nights of control 
sleep. Similarly, peripheral insulin signalling was investigated in skeletal muscle 
following two nights of sleep restriction (Sweeney et al., 2017). A decrease in whole 
body insulin sensitivity was also noted, with skeletal muscle Akt activity tending to 
be lower after sleep restriction. As outlined previously, Akt plays a key role in the 
insulin signalling pathway in peripheral tissues, ultimately leading to GLUT4 
translocation in skeletal muscle – the primary area of glucose uptake in the 
postprandial state. Therefore, alterations in the insulin signalling pathway, involving 
Akt or another step of the pathway, provides a plausible mechanism for the 
disruption of whole-body glucose regulation after sleep restriction. Future research 
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should explore whether interventions targeting the insulin signalling pathway can 
alleviate the impairment in whole body insulin sensitivity after sleep loss.   
 
 
Figure 2.3. Potential mechanisms linking short sleep duration to impaired glycaemic control. 
 
 
 Glucose metabolism and exercise 
2.7.1 Regular physical activity and glycaemic control 
Regular exercise is well-known to be beneficial for overall health, decreasing the 
risk of early mortality and development of several diseases including cardiovascular 
disease, cancer, and diabetes (Warburton et al., 2006). Inactive individuals have an 
increased risk of developing type 2 diabetes independent of other confounding 
factors such as BMI, waist circumference, and energy intake (Ekelund et al., 2012). 
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The total volume of habitual physical activity is significantly associated with HbA1c 
and shows a significant inverse dose-response relationship in individuals who are at 
moderate or high risk for developing type 2 diabetes (Gay et al., 2016). Similarly, 
adults achieving more moderate-to-vigorous activity (MVPA) also have a lower 
HbA1c than those completing less moderate-to-vigorous activity (Gay et al., 2016) 
with each 30 minute per day increment of MVPA equating to a decrease in HbA1c 
of 0.07 mmol/mol (0.8%) (Bakrania et al., 2017). A reduction in HbA1c of around 
0.5% is deemed to be clinically significant (Little and Rohlfing, 2013), suggesting 
that the additional 30 minutes of physical activity each day is beneficial for metabolic 
health. A recent meta-analysis of intervention studies which aimed to increase 
physical activity demonstrated that for each additional 100 minutes of physical 
activity completed each week, HbA1c was reduced by around 0.14% (1.5 
mmol/mol) (Boniol et al., 2017). This reduction was present regardless of the type or 
intensity of exercise, suggesting that individuals who exercise more may have 
improved glycaemic control regardless of the type of exercise they choose to do, 
although it may be necessary to exceed an extra 100 minutes per week to bring 
about clinically meaningful differences  
2.7.2 Acute exercise and glycaemic control 
An acute bout of exercise can also exert positive effects on metabolic health. 
Improved insulin sensitivity is often observed after a just single session of exercise 
(Bird & Hawley, 2017). This increase in insulin sensitivity may last for up to 72 hours 
following the exercise bout, although research has displayed varying findings on the 
duration and extent of the improvement (Bird & Hawley, 2017).  
Increased insulin sensitivity in healthy individuals has been demonstrated following 
various modalities of exercise, including resistance exercise (Breen et al., 2011), 
steady-state continuous exercise (Rynders et al., 2014), and high intensity exercise 
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(Ortega et al., 2015; Rynders et al., 2014). However, high intensity exercise may be 
superior to continuous steady state exercise for increasing insulin sensitivity. 
Rynders and colleagues (2014) observed larger decreases in insulin and glucose 
area under the curve after high intensity exercise, compared to work matched 
moderate intensity exercise. Similarly, sprint interval exercise has produced superior 
improvements in insulin sensitivity compared to continuous exercise when 
measured 30 minutes after cessation of exercise (Ortega et al., 2015).  
2.7.3 Mechanisms mediating improved insulin sensitivity after 
exercise 
Several potential mechanisms have been proposed to explain the metabolic benefit 
of regular exercise. These include altered storage of adipose tissue away from 
metabolically active tissues, reduced overall adiposity, and an accumulation of the 
effects of multiple bouts of acute exercise (Gay et al., 2016; Johnson et al., 2009). 
However, as the link between physical activity and HbA1c still persists when BMI 
and waist circumference are accounted for, it could be suggested that the 
improvement in glycaemic control in regularly active individuals is a cumulative 
result of repeated bouts of acute exercise which causes changes in metabolic 
pathways. 
The mechanisms underlying the increase in glucose uptake and insulin sensitivity 
following acute exercise are likely multi-factorial. During exercise, muscle 
contraction promotes glucose uptake into the muscle, independent of insulin. This 
contraction-stimulated glucose uptake is thought to continue for a few hours after 
cessation of exercise, which may be partly responsible for the improvements in 
glycaemic control immediately after an exercise bout (Goodyear & Kahn, 1998). The 
elevated glucose uptake may be due to enhanced GLUT-4 translocation to the cell 
surface. GLUT-4 expression at the cell surface is significantly increased for 22 h 
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after a single bout of endurance exercise (Greiwe et al., 2000). Moreover, there is 
an increased sensitivity to insulin in skeletal muscle following exercise. 
Phosphorylation of AS160 and Akt, two key members of the insulin signalling 
pathway, are increased for up to 26 h after cessation of an exercise bout (Breen et 
al., 2011). Limited evidence also suggests AMPK may be involved in the 
improvements in insulin sensitivity response to exercise (Hawley & Lessard, 2008). 
As mentioned in the previous section, Akt is a part of the insulin signalling pathway 
which may be compromised after sleep restriction. Consequently, exercise may be 
able to attenuate the insulin sensitivity impairment after sleep duration through its 
ability to upregulate or change the expression of proteins in the insulin signalling 
pathway. Similarly, Saner and colleagues (2018) have suggested that mitochondrial 
adaptations to exercise may be able to attenuate the impairment in insulin sensitivity 
after sleep loss. 
At present, only two studies have examined the impact of exercise on metabolic 
outcomes during periods of short sleep. Both of these previous studies were 
conducted in a setting of total sleep deprivation, with one using an acute bout of 
exercise (VanHelder et al., 1993) and the other using a two-week interval training 
protocol prior to sleep deprivation (De Souza et al., 2017). Two weeks of prior 
exercise was observed to alleviate the increases in glucose and insulin after total 
sleep deprivation, and acute exercise partially improved insulin responses to an 
OGTT after sleep deprivation (VanHelder et al., 1993). However, these studies 
arguably have limitations in that total sleep deprivation was used and exercise was 
conducted prior to sleep loss. It is likely that short sleep durations are more common 
than total sleep deprivation, and that on occasion sleep loss may be unplanned. 
Therefore, it would be of interest to investigate the effect of exercise following partial 
sleep restriction to address this gap in the literature. Given that acute exercise has a 
positive effect on glucose uptake in skeletal muscle and therefore enhances insulin 
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sensitivity, it may be a useful non-pharmacological intervention to prevent metabolic 
impairments occurring after periods of either acute or chronic sleep loss.  
In addition to the insulin sensitivity benefit of exercise, as mentioned earlier exercise 
may have a beneficial effect on several markers of sleep quality including sleep 
efficiency and total sleep time. Hence, in situations where short sleep is 
unavoidable, a bout of exercise may be beneficial in producing a higher quality 
sleep, indirectly combating the impairment in glucose regulation by increasing 
insulin sensitivity through a better sleep.  
 
 Conclusion 
Thus far, this literature review has highlighted the many ways in which sleep can 
impact health, including interactions with other health behaviours such as diet and 
exercise. The literature identifies a clear role of sleep in the maintenance of glucose 
homeostasis. However, previous studies used a wide variety of methodologies 
making comparison between studies challenging. Whether or not glycaemic control 
is altered in a linear fashion by repeated nights of sleep restriction remains elusive. 
Furthermore, the ability of exercise to positively impact glycaemic control has not 
been well studied in a sleep restricted population.  
2.8.1 Aims and Objectives 
This thesis shall explore the relationship between sleep and glycaemic control, and 
how exercise contributes to this relationship. Specifically, the aims of the thesis are: 
 
• To understand the impact of the number of nights of sleep restriction has on 
the impairment in glycaemic control. This will determine how many nights of 
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sleep restriction are required to impair glycaemic control to inform further 
sleep restriction research and the cumulative impact of sleep restriction on 
the risk of type 2 diabetes, 
 
• To assess whether an acute bout of exercise can attenuate the negative 
effects of sleep restriction on glycaemic control, 
 
• To examine if the relationship between sleep, glycaemic control, and 
physical activity persists in the free-living environment when other 
behavioural factors which also influence glycaemic control are taken into 
consideration. 
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Chapter 3 - General Methods 
 
This chapter will describe the methods which were used in the studies presented in 
Chapters 4, 5 and 6. An outline of the studies presented in this thesis is given in 
Figure 3.1 below. 
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Figure 3.1. Outline of research studies undertaken. CON = control condition. SR = sleep 
restriction condition). OGTT = oral glucose tolerance test. AUC = area under the curve. 
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 Recruitment 
Recruitment for studies was conducted by placing poster advertisements around 
Northumbria University and the surrounding community, and through word of mouth. 
Individuals who expressed an interest in participating were provided with the 
Participant Information Sheet (Appendix A) and given a minimum of 24 hours to 
read it and decide whether or not they would like to take part in the study. If they 
decided to participate, a day and time was arranged for the initial visit, during which 
they would also have the opportunity to ask questions before completing written 
informed consent (Appendix B). All studies were conducted in accordance with the 
Declaration of Helsinki and study protocols were approved through the University of 
Northumbria Online Ethics System. 
 
 Anthropometric measures 
For all studies presented in this thesis stature and body mass were measured. For 
these measurements, shoes were removed and light clothing was worn. Stature 
was measured to the nearest 0.1 cm using a free-standing stadiometer (Chapter 5 – 
SECA, Germany) or Harpenden wall-mounted stadiometer (Chapters 4 and 6 – 
Seritex, NJ, USA). Body mass was measured to the nearest 0.1 kg using digital 
scales (SECA). Body mass index (BMI) was calculated by dividing body mass in 
kilograms by stature in metres squared (kg/m2).  
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 Measurement of sleep duration 
3.3.1 Polysomnography 
Polysomnography was used in Chapter 4 to measure sleep in the laboratory. 
Polysomnographic recordings were obtained on the familiarisation night to screen 
for sleep disorders and nights 1 and 3 of each condition to determine sleep 
architecture. Surface electrodes were placed according to the international 10-20 
system at sites Cz, C3, C4, Fpz1, Fpz2, F3, F4, P3, P4, O1, O2, A1 and A2 (Klem et 
al., 1999). Electrodes were also placed at the outer canthus of each eye and on the 
chin for EOG and EMG respectively. During the familiarisation stay, pulse oximetry, 
a snore microphone, and lower limb EMG were also used to enable any sleep 
disorders to be detected prior to the experimental trials. Any individuals with sleep 
disorders would be excluded from the study. To determine sleep stages recordings 
were scored automatically by DOMINO software (Somnomedics, Germany) using 
AASM criteria (Kushida et al., 2005). 
3.3.2 Actigraphy 
Actigraphy (GENEActiv, Activinsights, Kimbolton, UK) was used during studies to 
measure sleep during the experimental and entraining phases. Actigraphy monitors 
assess accelerations in three-dimensional axes over time to give an output of 
gravitational units. Algorithms can then be used to distinguish between sleep and 
wake.  
The studies in Chapters 4, 5 and 6 used GENEActiv actigraphy monitors to monitor 
sleep duration. GENEActiv actigraphy monitors are tri-axial accelerometers, 
assessing acceleration in the x-, y-, and z-axis. The GENEActiv actigraphy monitors 
also contain light and temperature sensors to improve accuracy of wear time.  
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The absence of movement is used as a surrogate of sleep and therefore can give 
concurrent detail of sleep and activity periods. Actigraphy is commonly used as an 
alternative when total sleep time is required and PSG is not feasible (Marino et al., 
2013). High levels of agreement (>90%) have been demonstrated between 
actigraphy and PSG when used to distinguish between sleep and wake periods 
(Ancoli-Israel et al., 2003).  
In all studies throughout this thesis, actigraphy monitors were set up with a 
measurement frequency of 10 Hz. Participants were instructed to wear the 
actigraphy monitor continuously on the non-dominant wrist. For measurement of 
sleep, participants were instructed to press the button on the actigraphy watch upon 
going to bed with the intention to sleep and upon wakening in the morning. This 
allowed determination between intended sleep and time in bed. If participants forgot 
to press the button, bed and wake time were determined from the sleep diaries. 
Data were extracted in 60 s epochs and imported to the GENEActiv sleep macro 
available at open.geneactiv.org. 
3.3.2.1 Validity of actigraphy for measurement of sleep time 
Few studies have specifically assessed validity of the GENEActiv actigraphy 
monitor (Activinsights). Therefore, the GENEActiv actigraphy monitor (Activinsights) 
was assessed against polysomnographic derived total sleep time for criterion 
validity. Validity was measured using data obtained in the study presented in 
Chapter 4. Polysomnographic data and actigraphy data were collected 
simultaneously for two control nights (8 hour sleep opportunity) and two nights of 
sleep restriction (4 hour sleep opportunity) in the Northumbria Sleep Research 
Laboratory.  
Upon completion of each trial period, actigraphy monitors were removed and data 
was extracted. For sleep data, files were converted to 60 s epochs before being 
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imported into the GENEActiv sleep macro (available at open.geneactiv.org). The 
macro uses the Sadeh algorithm (Sadeh et al., 1994) to determine sleep, and gives 
an output for variables including total sleep time, sleep efficiency, and activity 
periods during sleep time. 
Statistical analysis was performed using Microsoft Excel (V.2016) and SPSS 
statistical software (IBM, New York, USA). Descriptive statistics for total sleep 
duration (min) and were calculated and are presented as mean ± SD. Inferential 
statistics were assessed by Bland-Altman plots to determine any systematic bias 
and paired t-tests to detect any differences between methods. Limits of agreements 
of ± 90 min were deemed to be satisfactory, as the subsequent studies which this 
validation study was designed to inform would have substantial differences in sleep 
restriction (> 2 h) between groups.   
Due to technical issues with some actigraphy monitors and PSG equipment, 
concurrent actigraphy and PSG sleep data was available for 10 nights in control 
(CON) and 10 nights in sleep restriction (SR). Mean total sleep time during the 
control condition, determined by polysomnography, was 428 ± 18 min (7.1 ± 0.3 h) 
whereas mean total sleep time determined by actigraphy was 384 ± 53 (6.4 ± 0.9 h). 
The limits of agreement between the two assessment tools were -36 to 126 min (-
0.6 to 2.1 h) with actigraphy showing underestimation by 45 min (0.75 h) (Figure 
3.1). During the sleep restricted condition, mean total sleep time determined by 
polysomnography, was 218 ± 20 min (3.6 ± 0.3 h) whereas mean sleep time 
determined by actigraphy was 211 ± 15 min (3.5 ± 0.25 h). The limits of agreement 
were -23 to 35 min (-0.4 to 0.6 h) with actigraphy showing underestimation by 6 min 
(0.1 h) (Figure 3.2). Paired t-tests did not show any evidence of differences between 
methods (P = 0.221 in SR and P = 0.110 in CON). 
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Figure 3.2. Bland-Altman plots for total sleep time (TST) measured by polysomnography 
(PSG) and actigraphy (ACT) in CON and SR. Bold dotted line represents mean bias. 
Dashed lines represent 95% limits of agreement (LOA). LOA are 45 ± 81 min (CON) and 6 ± 
29 min (SR). 
 
The difference in sleep duration between PSG and GENEActiv actigraphy during 
the sleep restricted condition shows very good agreement between the two 
methods. These results indicate that GENEActiv accelerometers can be used as a 
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valid tool to estimate total sleep duration when sleep is restricted to approximately 4 
hours. The mean bias of 6 min during SR compared to 45 min during CON suggests 
that actigraphy is better at determining total sleep time in shorter sleep durations 
than longer durations. One possible explanation for this discrepancy may be that 
participants were less mobile because of a higher contribution of N3 due to sleep 
debt during the sleep restriction condition. This has also been suggested by Marino 
and colleagues (2013) who highlighted higher specificity of actigraphy in shorter 
sleep durations. 
The degree of variation between PSG and accelerometers shown in the present 
study during the control condition is in contrast to those presented by Full and 
colleagues (2018) who have shown differences between 6 minutes underestimation 
to 4 minutes overestimation when comparing accelerometers to PSG for total sleep 
time. However, results from the present study are comparable to those from Van 
Hees et al. (2018) who showed a mean absolute error of 71 minutes between PSG 
and GENEActiv accelerometers for the sleep period time window duration. The 
limits of agreement observed in the current study are similar to previous studies 
comparing actigraphy to PSG (de Souza et al., 2003; Weiss et al., 2010) While our 
small sample size may be influenced by extreme scores, these results do highlight a 
degree of underestimation of total sleep time when using accelerometers. Future 
research should account for this mismatch when designing sleep studies when PSG 
is not feasible. 
3.3.3 Self-reported measures 
3.3.3.1 Sleep logs 
Seven-day sleep logs were used in conjunction with actigraphy (sleep log shown in 
Appendix D). Participants were asked to complete these each morning 
approximately 30 minutes after waking. The sleep log was adapted from Carney 
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and colleagues (2012) to include the Karolinska Sleepiness Scale (Akerstedt & 
Gillberg, 1990). The Karolinska Sleepiness Scale has been previously used in sleep 
deprivation studies and is correlated with polysomnography measurements derived 
from EEG (Akerstedt & Gillberg, 1990).  
3.3.3.2 Morningness-eveningness questionnaire 
The morningness-eveningness questionnaire (MEQ) (Horne & Ostberg, 1976) was 
used to determine chronotype in the studies presented throughout this thesis. The 
MEQ consists of 19 questions. A number of points are given for each question 
depending on the answer selected, and these points are combined to give an 
overall total between 16 and 86. There are five categories in total: extreme evening 
type (16-30 points), moderate evening type (31-41 points), intermediate (42-58 
points), moderate morning type (59-69 points), and extreme morning type (70-86 
points). Any individuals who were classed as extreme morning or extreme evening 
type were excluded due to potential circadian misalignment.  
3.3.3.3 Pittsburgh Sleep Quality Index 
The Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989) is a questionnaire 
developed to measure sleep quality and pattern over the past 30 days. Questions 
relate to seven domains (subjective sleep quality, sleep latency, sleep efficiency, 
sleep duration, sleep disturbances, daytime dysfunction, and use of medication to 
assist sleep) and a global score is given, with a score of 5 or above indicating a 
“poor sleeper”. In the studies in Chapters 4 and 5, the PSQI was used to exclude 
any individuals who were deemed to be poor quality sleepers.  
3.3.3.4 Sleep Disorders Symptom Checklist-17  
The Sleep Disorders Symptom Checklist-17 (SDS-CL-17) is an instrument 
developed to screen individuals for sleep disorders prior to participation in a 
research study (Klingman et al., 2017). Individuals are given a list of statements and 
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asked to rate how often this applies to them. Each question or group of questions 
relate to a specific sleep disorder; either obstructive sleep apnoea, restless leg 
syndrome, insomnia, narcolepsy, circadian rhythm disorder, or parasomnias. A 
score above the cut-point for a sleep disorder category indicates presence of that 
sleep disorder. In the study presented in Chapter 6, the SDS-CL-17 was used to 
exclude individuals with sleep disorders as this may influence study findings.   
 
 Physical activity  
Actigraphy (GENEActiv, Activinsights) was used during studies to measure physical 
activity. Actigraphy is a useful tool to measure physical activity in the free-living 
environment. Algorithms can be used to give a description of intensity of activity in 
metabolic equivalents of a task (METs). 
In all studies throughout this thesis, actigraphy monitors were set up with a 
measurement frequency of 10 Hz for measurement of physical activity. Participants 
were instructed to wear the actigraphy monitor continuously on the non-dominant 
wrist. Data were extracted in 60 s epochs, consistent with previous studies (Esliger 
et al., 2011), and imported to the GENEActiv Everyday Living macro available at 
open.geneactiv.org. 
3.4.1 Validation of actigraphy for measurement of physical activity 
Few studies have validated the GENEActiv monitor for physical activity (Esliger et 
al., 2011; Powell et al., 2017). When assessed on a mechanical shaker, the 
GENEActiv accelerometer has previously been shown to have good reliability (intra-
CV of 1.4% and inter-CV of 2.1%) and excellent validity (r = 0.98) (Esliger et al., 
2011). To assess the validity of the GENEActiv actigraphy monitor for physical 
activity, the monitors were assessed against indirect calorimetry assessments. 
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Indirect calorimetry is an accurate method for measurement of energy expenditure 
and is often used to assess validity of accelerometers (Ndahimana & Kim, 2017).  
11 participants (4 males and 7 females) were recruited by advertisement and word 
of mouth at Northumbria University. Mean (±SD) age, stature and mass were 29 ± 
10 yr, 170.7 ± 8.6 cm and 66.2 ± 12.0 kg respectively. Volunteers were eligible for 
the study if they were aged 18 to 40 yr, and in good health. Exclusion criteria 
included any symptoms of cardiac or respiratory conditions as assessed by a 
Physical Activity Readiness Questionnaire (PARQ). Participants were also excluded 
if they had any current or previous musculoskeletal injuries or any other 
contraindicators to exercise in the past 6 months. The study protocol was reviewed 
and approved by the Faculty of Health and Life Sciences Research Ethics 
Committee at Northumbria University (Ethics number: 17105) and written informed 
consent was obtained from all participants prior to beginning the study.  
Participants arrived at the laboratory in a rested state and following a 12-hour fast 
having avoided vigorous activity for 24 hours prior to the laboratory visit. To 
determine resting metabolism, participants lay on a medical plinth for 15 minutes. 
Participants were then fitted with an actigraphy monitor on the non-dominant wrist 
and were fitted with a face mask to collect expired air. Participants then remained 
on the medical plinth and rested quietly for a further 15 minutes, during which, the 
last 5 minutes were collected for analysis. Expired air samples were collected into 
an online gas analyser (Oxycon Pro, Jaeger, Germany). Resting metabolic rate was 
determined using the abbreviated Weir formula (Weir, 1949). To validate physical 
activity intensity during a sedentary activity, participants sat at a desk to perform a 
computer-based task for 5 min. During this sedentary activity, participants were 
asked to type a written script onto a laptop and make formatting changes. During 
this period, laboratory conditions were kept constant at 23°C, 51% humidity and 
1025 hPa.  
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Following the sedentary task, participants used a treadmill (h/p/cosmos, Germany) 
to validate light, moderate and vigorous activity. Participants were asked to 
complete a submaximal test. The test began with participants walking at a speed of 
2 km/h. At 3-min intervals, the treadmill speed was increased by 2 km/h until the 
ventilatory threshold was reached. Ventilatory threshold was determined by a non-
linear increase in minute ventilation (VE) relative to the volume of oxygen utilisation 
(V̇O2) (Reybrouck et al., 1986). 
For physical activity data, files were converted into 15 s epochs before being 
imported into the GENEActiv everyday living macro (available at 
open.geneactiv.org). The cut-points used to define sedentary, light, moderate, and 
vigorous activity were <386, 386-439, 440-1811 and >1811 g/min respectively, 
based on values determined by a validation study (Esliger et al., 2011). Statistical 
analysis was performed using Microsoft Excel (V.2016) and SPSS statistical 
software (IBM).  
Descriptive statistics for physical activity intensity (MET.min) were calculated and 
are presented as mean ± SD. Inferential statistics were assessed by Bland-Altman 
plots to determine any systematic bias and paired t-tests to detect any differences 
between methods. Limits of agreement of ± 4 MET.min were classed as satisfactory 
as it was thought this would be sufficient to detect differences between lower and 
moderate-to-vigorous intensity activities.  
Physical activity intensity during the sedentary activity, determined by indirect 
calorimetry was 1.4 ± 0.2 MET.min, whereas actigraphy estimated the sedentary 
activity to be 1.2 ± 0.2 MET.min. The limits of agreement were -0.5 to 0.8 MET.min 
with actigraphy showing underestimation by 0.2 MET.min (Figure 3.3). Indirect 
calorimetry determined mean light activity intensity (2 km/h), moderate activity 
intensity (4 km/h) and vigorous activity intensity (8 km/h) to be 2.7 ± 0.6 MET.min, 
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4.7 ± 0.9 MET.min and 12.0 ± 3.0 MET.min respectively. The limits of agreement 
with actigraphy for light, moderate and vigorous activity were -1.3 to 2.0 MET.min, -
2.5 to 3.0 MET.min, and -7.4 to 3.7 MET.min respectively, with actigraphy showing 
a bias of 0.4 MET.min, 0.2 MET.min, and -1.8 MET.min for light, moderate and 
vigorous activity (Figure 3.2). There were no significant differences between 
methods at any intensity (sedentary P = 0.097; light P = 0.193; moderate P = 0.574; 
vigorous P = 0.067). 
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Figure 3.3. Bland-Altman plots for comparison of indirect calorimetry (IC) and actigraphy 
(ACT) for measurement of activity. Bold dotted line represents mean bias. Dashed lines 
represent 95% limits of agreement (LOA). LOA are 0.2 ± 0.6 MET.min (sedentary), 0.4 ± 1.6 
MET.min (light), 0.3 ± 2.7 MET.min (moderate) and -1.8 ± 5.5 MET.min (vigorous). 
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Physical activity tended to show good agreement between measurement methods, 
with mean bias for all activity levels less than 2 MET.mins. While actigraphy showed 
very good agreement with indirect calorimetry at lower intensities, variation was 
greater during moderate and vigorous activity. Nonetheless, the average difference 
and limits of agreement are small for all levels of activity, indicating that GENEActiv 
accelerometers are a valid tool to assess MET.min. 
 
 Diet 
In all studies presented in this thesis, 3-day food diaries (Appendix C) were used to 
determine habitual dietary intake. A recording period of three days was selected as 
this can provide an overview of habitual diet whilst ensuring compliance does not 
decrease due to a long recording period (Ortega et al, 2015). Participants were 
instructed to document every food or drink item consumed, the time at which it was 
consumed, the cooking method, and the estimated amount. Food diaries were 
completed on two weekdays and one weekend day Energy and macronutrient 
intake for the three days were calculated using Microdiet software (version 4.4; 
Downlee Systems Ltd., UK). An average daily intake from the three days was then 
calculated for energy (megajoules/d), carbohydrate (g/d), fat (g/d), and protein (g/d).  
In the experimental studies (Chapter 4 and 5), participants were provided with 
individualised diets. Individualisation of diets to maintain habitual intake was 
possible due to the within-subjects design of the studies in these chapters, and 
enhances ecological validity compared to the use of standardised diets. In the study 
in Chapter 4 diet was provided throughout the four days of each experimental trial, 
and in the study in Chapter 5 diet was provided the day prior to each condition. 
Diets were matched for habitual energy intake, and macronutrients were kept within 
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10% of habitual intake. Diet was identical across conditions to prevent results being 
confounded by differences in dietary intake. 
 
 OGTT 
Oral glucose tolerance tests (OGTT) were conducted in the studies presented in 
Chapters 4 and 5. For the OGTT, participants were provided with a beverage 
containing 82.5 g dextrose (MyProtein, UK) mixed with 300 ml water. They were 
instructed to consume the drink within 5 minutes. During the OGTT, blood samples 
were drawn prior to consumption (baseline (0)) and 15, 30, 45, 60, 90 and 120 min 
following consumption. 
3.6.1 Repeatability of OGTT 
To assess the repeatability of the OGTT, an intraindividual coefficient of variation 
was calculated (CV%) from the 4 control trials in the study presented in Chapter 4. 
Briefly, 10 participants underwent 4 consecutive day OGTTs conducted in a rested, 
fasted state. Blood samples were collected at regular intervals and analysed for 
glucose and insulin. CV% were calculated for peak glucose, total area under the 
curve of glucose and insulin as well as the early phase (0-60 min) and late phase 
(60-120 min) post prandial response. Repeatability measurements for the average 
CV(%) across the four control trials are displayed in Table 3.1. 
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Table 3.1. Repeatability of measures during consecutive day OGTTs. 
Variable CV(%) 
Glucose AUC 
  Total 
  Early 
  Late 
 
10.2 
5.5 
16.5 
Insulin AUC 
  Total   
  Early 
  Late 
 
20.5 
21.7 
29.3 
Peak glucose 13.7 
Glucose and insulin area under the curve (AUC) for total (0-120 min), early (0-60 min) and 
late (60-120 min) phase of the OGTT. 
 
The daily variation observed in insulin AUC mimics previous research using 
consecutive day OGTTs (Gordon et al., 2011), which may suggest insulin has a 
higher natural biological variation than glucose. Additionally, the insulin assay had a 
higher variability than the glucose measurement method, which has been suggested 
to contribute to the higher variation observed in insulin compared to glucose 
responses (Utzschneider et al., 2007). The variability in glucose and insulin 
measures which we have highlighted must be considered when interpreting results 
from an intervention study. For a change to be meaningful it must lie outside of the 
natural variation. Work conducted by Gordon et al. (2011) shows that increases in 
glucose and insulin area under the curves of 63.5 mmol/L/120 min and 7061 
pmol/L/120 min and decreases in glucose and insulin area under the curves of 80.9 
mmol/L/120 min and 7237 pmol/L/120 min lie outside of the normal day-to-day 
variation and can be classed as clinically significant changes.    
 
 Blood collection and processing  
In Chapters 4 and 5 the cannulation technique was used for blood collection to 
enable multiple blood draws. A cannula (20-gauge, Terumo, Japan) was inserted 
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into an antecubital vein and a connector (BD Connecta, Becton Dickinson, New 
Jersey, USA) was attached. For each sample a 10 ml syringe was used to transfer 
blood from the connector to a vacutainer. 8 ml of blood was collected for each 
sample into 10 ml serum vacutainers (Becton Dickinson, ). Vacutainers were 
inverted 5 times to ensure thorough mixing. The samples were left to clot at room 
temperature for 30 min then centrifuged at 3500 rpm for 15 min at 4°C. Serum was 
aliquoted into microtubes. At this stage a small amount of serum from each sample 
was transferred into a capillary tube and placed into an Eppendorf tube containing 1 
ml of hemolysing solution (EKF Diagnostics, Cardiff, UK) to allow determination of 
serum glucose. The remaining serum was frozen at -80°C until further analysis. 
In Chapter 6 blood was collected by the venepuncture technique. A needle was 
inserted into the antecubital vein in the arm and approximately 10 ml of blood was 
drawn into a serum vacutainer (Becton Dickinson). The sample was allowed to clot 
for 30 min then centrifuged at 3500 rpm for 15 min at 4°C. Serum was aliquoted into 
a microtube. A small amount was taken up into a capillary tube and placed in 
hemolysing solution for measurement of glucose. The remaining serum was frozen 
at -80°C until further analysis. 
3.7.1 Serum glucose  
Serum glucose was measured immediately after centrifugation. The Biosen C-line 
(EKF Diagnostics) was calibrated using a standard of known concentration (12 
mmol/L). The sample was then measured to determine glucose concentration in 
mmol/L. The Biosen C-line uses the enzymatic-amperometric method to determine 
glucose concentration. In this method an enzymatic reaction converts glucose to 
gluconic acid and hydrogen peroxide, and glucose is determined through 
measurement of hydrogen peroxide (Artigues et al., 2017). 
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3.7.2 Insulin 
For measurement of serum insulin in Chapters 4 and 5, samples were defrosted on 
ice. Serum insulin was then measured using commercially available enzyme-linked 
immunoassays (Mercodia, Sweden) conducted according to manufacturer’s 
instructions. Briefly, thawed samples were vortexed and added to a 96-well plate in 
duplicate. Standards were prepared according to manufacturer’s guidance and 
added in duplicate. Samples and standards were incubated with enzyme conjugate 
before being manually washed 6 times. Substrate was then added and after 
incubation the reaction was stopped. A microplate reader (Anthos 2010, Biochrom, 
Cambridge, UK) and read at an optical density of 450 nm. A standard curve was 
created by plotting absorbance against concentration and a linear trendline was 
added. The concentration of each sample was determined, and an average of the 
duplicates was taken as the final concentration. 
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Chapter 4 - An Investigation into the Cumulative Effects of 
Sleep Restriction on Glycaemic Control 
 Introduction 
It is well-known that insufficient sleep leads to changes in glycaemic control 
(Knutson et al., 2007). Adverse metabolic events are evident across a range of 
sleep restriction protocols. Early research demonstrated decreased glucose 
tolerance after 6 nights of 4 h sleep each night (Spiegel et al., 1999) and, more 
recently, a 19% reduction in whole-body insulin sensitivity, estimated by Matsuda 
Index, was observed when habitual sleep duration was reduced by 50% for 2 nights 
(Sweeney et al., 2017). Similarly, IVGTT-derived disposition index is decreased 
30% after two weeks of 5.5 h compared to 8.5 h sleep, indicating increased insulin 
resistance (Nedeltcheva et al., 2009). Markedly, even a single night of sleep 
restriction appears to have metabolic consequences, manifest as a 20% reduction 
in glucose disposal rate during a hyperinsulinemic euglycaemic clamp (Donga et al., 
2010). 
Whilst previous research consistently demonstrates altered glucose metabolism and 
insulin sensitivity after sleep restriction, the varying sleep protocols and insulin 
sensitivity measurement methods employed do not enable accurate comparison 
between studies. However, it does appear that studies employing more nights of 
sleep restriction may show a greater impact on insulin sensitivity, with single night 
studies showing a 20% decrease in insulin sensitivity after sleep restriction (Donga 
et al., 2010), a two-night study showing a 40% increase in insulin after a mixed meal 
in the sleep restriction condition (Schmid et al., 2011), and a three-night study 
demonstrating increased insulin levels of around 60% after a meal (Klingenberg et 
al., 2013). The insulin sensitivity measurement method varies widely between these 
studies so whilst one can speculate, comparisons between these studies must be 
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interpreted with caution. Thus, it remains unclear if there is a cumulative effect of 
sleep loss on metabolism or if the alterations are similar regardless of severity, 
either in number of nights of sleep loss or hours per night. 
The aim of the current study was to address the question: is the extent of the 
impairment in insulin sensitivity related to the number of nights of sleep restriction? 
This question has not yet been addressed in previous research and is important to 
inform the design of future studies aiming to examine mechanisms or interventions 
to attenuate metabolic impairments following sleep loss. It was hypothesised that 
each night of sleep restriction would lead to a greater decrease in insulin sensitivity. 
 
 Methods 
4.2.1 Participants 
12 volunteers were recruited by poster advertisement around Northumbria 
University to participate in this randomised crossover study. Individuals were eligible 
for the study if they were aged 18 to 40 yr, a non-smoker and had a regular sleep 
pattern (7 to 9 hr each night) as assessed using the PSQI (Buysse et al., 1989). 
Exclusion criteria were shift work or travel across time zones in the past 4 weeks, 
the presence of any sleep, metabolic, neurological, psychiatric, inflammatory 
disorder, or blood clotting disorders, a history of drug or alcohol abuse, a score 
greater than 5 on the PSQI, as this is indicative of poor sleep quality (Buysse et al., 
1989), or a psychological or linguistic inability to give written informed consent. 
Individuals who were considered ‘extreme morning’ (score of 31 or less) or ‘extreme 
evening’ (score of 70 or more) types according to a morningness-eveningness 
questionnaire (Horne and Ostberg, 1976) were also excluded. Female participants 
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completed both experimental conditions during the follicular phase of the menstrual 
cycle, which was determined by a menstrual cycle questionnaire. 
4.2.2 Study Design 
The study employed a within-subject randomised crossover study design. 
Participants took part in a 1-night familiarisation stay and two 4-night experimental 
conditions – control (CON) and sleep restriction (SR). Participants were permitted to 
leave the laboratory during the days in the experimental conditions, and returned 
each evening at 1900. They were asked to avoid exercise, consumption of caffeine 
and alcohol, and napping whilst outside of the laboratory. Wrist actigraphy was used 
to ensure compliance during this time.  
Randomisation was done using an online randomisation tool 
(www.randomization.com) to generate a list for the 12 participants to assign them to 
the first condition. As participants were recruited they were assigned to the list in 
chronological order. Four participants completed the control condition first. The 
study protocol was reviewed and approved by the Faculty of Health and Life 
Sciences Research Ethics Committee at Northumbria University (HLSES120117) 
and written informed consent (Appendix B1) was obtained from all participants prior 
to beginning the study. 
4.2.3 Study conditions 
The familiarisation night and both experimental conditions were carried out in the 
Northumbria Sleep Research Laboratory at Northumbria University. During CON, 
time in bed was 8 h/night (2300 – 0700), and 4 h/night (0300 – 0700) during SR. 
Time to bed was delayed during the SR condition to ensure that assessments of 
insulin sensitivity were conducted at the same time from wakening in both 
conditions. A washout period of at least 3 weeks, and a maximum of 5 weeks, was 
given between conditions to prevent carryover effects.  
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4.2.4 Experimental Protocol 
4.2.4.1 Familiarisation  
Prior to the first experimental condition, participants underwent a one-night sleep 
study in the laboratory for familiarisation. The purpose of this night was to allow 
participants to become accustomed to the sleep laboratory environment and 
wearing the polysomnographic equipment during sleep. This session also acted as 
a screening visit to identify and exclude any individuals with sleep disorders. Time in 
bed during familiarisation was kept consistent with self-reported habitual time in 
bed.  
In the morning, stature and body mass were measured using a Harpenden wall-
mounted stadiometer (Seritex) and digital scale (SECA), and BMI was calculated as 
detailed in Chapter 3. 
4.2.4.2 Entraining 
A 1-week entraining period was carried out prior to each experimental condition. 
During entraining, participants were instructed to keep a consistent bed time and 
wake time, which was individualised according to their habitual hours. Habitual bed 
time ranged from 2202 h to 0045 h and habitual wake time ranged from 0619 h to 
0836 h. Compliance was measured by wrist actigraphy and a 7-d sleep log 
(Appendix D) which participants completed each morning 30 minutes after waking, 
as detailed in Chapter 3. 
4.2.4.3 Experimental trials 
Participants arrived at the laboratory at 1900 on the first evening of each 
experimental condition. After being briefed on their stay at the laboratory, they were 
told which condition they were assigned to upon arrival. Participants remained in the 
lounge until bed time and were permitted to carry out sedentary activities such as 
watching television, reading, or playing board games during this time. Researchers 
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were present at all times to ensure participants did not fall asleep before their 
specified bed time. On nights 1 and 3 of each condition, polysomnography was set-
up 30 min prior to their permitted bedtime.  
Participants were wakened at 0700 each morning. If necessary, electrodes were 
removed upon wakening. Participants were then taken to the physiology laboratory 
where they remained seated for 10 minutes before blood pressure and heart rate 
were measured using an automated blood pressure monitor (Dinamap V100, GE 
Healthcare, Illinois, USA). A cannula was then inserted into the antecubital vein to 
allow regular blood draws. 
After insertion of the cannula, a baseline blood sample was obtained. Following this, 
an oral glucose tolerance test (OGTT) was conducted, as described in Chapter 3. 
Blood samples were drawn at regular intervals for 2 h. 
Following completion of the OGTT, participants were provided with food and drink to 
consume for the remainder of the day. The food and drink provided were based on 
their habitual diet, as detailed in Chapter 3. Participants were only permitted to 
consume the food and drink provided, but were allowed water which they could 
consume ad libitum. Participants were then debriefed and thanked for their 
participation before leaving the laboratory at approximately 1030 each morning.  
4.2.4.4 Blood collection and processing 
For blood sampling the cannulation technique was used to enable multiple blood 
draws, as detailed in Chapter 3. During the OGTT, blood samples were drawn prior 
to consumption (baseline (0)) and 15, 30, 45, 60, 90 and 120 min following 
consumption of the drink. Glucose concentration was measured immediately using 
a Biosen glucose analyser (EKF Diagnostics). The remaining serum was frozen at -
80°C until further analysis. 
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4.2.4.5 Blood sample analysis 
As previously mentioned, serum glucose was measured immediately after 
centrifugation using the Biosen C-line automatic analyser (EKF Diagnostics). Insulin 
was measured using commercially available ELISA kits (Mercodia, Sweden), as 
detailed in Chapter 3. Intra- and inter- assay coefficients of variation were 6% and 
14%, respectively.  
4.2.5 Data Analysis 
4.2.5.1 Sample Size Estimation 
A sample size calculation was conducted using Minitab version 17 (Minitab, 
Pennsylvania, USA) based on previous data investigating insulin sensitivity 
following 2 nights of sleep restriction in healthy males (Sweeney et al., 2017). Based 
on a mean difference in insulin AUC of 998.5 and standard deviation of 1027, a 
sample size of 11 would give 83% power. We therefore aimed to recruit 12 
individuals to allow for a dropout, however, due to one individual withdrawing from 
the study because of being uncomfortable having a cannula inserted and another 
being excluded due to issues obtaining blood samples, final power was 78%. 
4.2.5.2 Statistical Analysis 
All statistical analysis was performed using SPSS statistical software version 22 
(IBM). P < 0.05 was used to indicate statistical significance. Descriptive statistics for 
participant characteristics and sleep duration were calculated and are presented as 
mean ± SD to show the variability of the values. Data for glucose and insulin are 
presented as mean ± SEM to give an indication of the sample mean in relation to 
the population mean. Total (0-120 min), early (0-60 min) and late (60-120 min) 
phase area under the curve for glucose and insulin were calculated for each OGTT 
using the trapezoidal rule. To estimate fasting level of insulin resistance, HOMA-IR 
(Matthews et al., 1985) was calculated using the following equation: 
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HOMA-IR = 
fasting plasma glucose (mmol/l) x fasting plasma insulin (µIU/ml) 
22.5
 
An estimate of whole-body insulin sensitivity during the OGTT was determined 
using Matsuda index, which was calculated by: 
Matsuda index = 
10000
√(fasting insulin (µIU/ml) × fasting glucose (mmol/l)) × (mean glucose (mmol/l) × mean insulin (µIU/ml)) 
 
To assess for differences in glycaemic control following sleep restriction, the data 
were checked for normality using Shapiro-Wilk tests prior to analysis. Any data 
which were found to be skewed were transformed appropriately. Linear mixed 
modelling was used to compare conditions and days. Post-hoc tests were 
conducted on significant main effects using the Sidak method.  
 
 Results 
4.3.1 Participant characteristics 
12 participants volunteered to take part in this study, however one participant was 
excluded and another withdrew, for reasons stated above. Participant 
characteristics for the remaining 10 participants are presented in Table 4.1. 
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Table 4.1. Participant characteristics 
M:F 5:5 
Age (y) 26 ± 5  
Stature (cm) 174 ± 9 
Body mass (kg) 73 ± 12 
BMI (kg/m2) 24 ± 2  
PSQI score 3 ± 1 
Morningness-eveningness 
score 
52 ± 8 
Data are mean ± SD. n = 10. PSQI score of 5 or below indicates good sleep quality. 
Morningness-eveningness score between 42-58 indicates intermediate, 41 or below 
indicates evening, and 59 or above indicates morning type. 
 
4.3.2 Sleep characteristics 
During the entraining periods mean bed and wake time measured by actigraphy 
was 2250 h and 0714 h, respectively. Mean time in bed (TIB) was 472 ± 43 min (7.9 
± 0.7 h), which did not differ from TIB in the control condition (480 ± 0 min [8.0 ± 0.0 
h]; P = 0.88), but was significantly higher than TIB in SR (240 ± 0 min [4.0 ± 0.0 h]; 
P < 0.01). Likewise, total sleep time was similar between entraining and control (378 
± 53 min [6.3 ± 0.9 h] vs. 390 ± 60 min [6.5 ± 1.0 h]; P = 0.60), but was significantly 
less than entraining in SR (216 ± 13 min [3.6 ± 0.2 h]; P < 0.01). 
A summary of sleep variables measured by polysomnography on the first and third 
night of each condition is presented in Table 4.2. Stage 3 sleep measured as a 
percentage of total sleep time on nights 1 and 3 of each condition was significantly 
higher in the sleep restriction condition compared to control (P < 0.001). However, 
there was no main effect of night or interaction effect (P = 0.145 and P = 0.940, 
respectively). Sleep efficiency showed a trend for a main effect of condition (P = 
0.099), but no evidence of an effect of night (P = 0.278) or interaction effect (P = 
0.278). 
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Table 4.2. Summary of sleep variables measured by polysomnography. 
 C1 C3 SR1 SR3 p-value 
TST (min) 392 ± 24 428 ± 11 219 ± 6 218 ± 6 < 0.001* 
SE (%) 73 ± 9 88 ± 2 90 ± 2 90 ± 2 0.099 
WASO (min) 62 ± 20 33 ± 4 17 ± 4 14 ± 4 0.010* 
REM (%) 25 ± 3 20 ± 5 18 ± 4 15 ± 2 0.114 
N1 (% TST) 22 ± 3 21 ± 5 20 ± 4 18 ± 2 0.358 
N2 (% TST) 36 ± 2 37 ± 3 28 ± 3 31 ± 3 0.007* 
N3 (% TST) 18 ± 2 19 ± 2 33 ± 4 36 ± 3 < 0.001* 
C1 = control night 1; C3 = control night 3; SR1 = sleep restriction night 1; SR3 = sleep 
restriction night 3. Time in bed was 8 h/night in control and 4 h/night in sleep restriction 
condition. P-value for main effect of condition from conducting condition x day ANOVA. * 
denotes significant main effect of condition. Total sleep time (TST) is the total amount of 
sleep time in a sleep period. Sleep efficiency (SE) is the total time spent asleep compared to 
the total time in bed. Wake after sleep onset (WASO) refers to wake periods which occur 
following initial onset of sleep. REM, N1, N2 and N3 refer to sleep stages rapid eye 
movement, stage 1, stage 2 and stage 3 sleep, respectively.  
 
4.3.3 Physical activity and blood pressure 
Physical activity did not differ between conditions. Sedentary to light activity was 
significantly higher in SR compared to CON (mean difference +180 min; P = 0.006), 
but did not display evidence for an effect of day (P = 0.191) or interaction (P = 
0.354). Moderate-to-vigorous physical activity was similar between conditions (P = 
0.710) and days (P = 0.665), and did not show an interaction effect (P = 0.917). 
Systolic and diastolic blood pressure were similar between conditions (P = 0.158 
and P = 0.619) and showed no effect of day (P = 0.596 and P = 0.391) or interaction 
effect (P = 0.749 and P = 0.766). 
4.3.4 Glucose and insulin 
Findings for glucose and insulin are presented in Figure 4.1 and Table 4.3. 
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4.3.4.1 Glucose 
When comparing glucose area under the curve between CON and SR, glucose 
showed a significant effect of condition (P < 0.001), but no evidence for an effect of 
day (P = 0.620), or day x condition interaction (P = 0.152) (Figure 3.1). The main 
effect of condition demonstrated higher glucose AUC in SR compared to CON (P < 
0.001). Early phase glucose AUC tended to be higher in SR compared to CON (P = 
0.053), and late phase AUC was higher in SR than CON (P = 0.020). Similar to total 
AUC, no differences were observed between days or interaction effects were 
observed for early or late AUC. Mean peak glucose was higher in the sleep 
restriction condition than the control condition (8.98 mmol/L in CON vs. 9.85 mmol/L 
in SR; P = 0.003). However, there was no evidence of an overall effect of day (P = 
0.367), or interaction effect (P = 0.131).  
4.3.4.2 Insulin 
Results for total AUC for insulin are presented in Figure 4.1. Similar to glucose, 
insulin AUC showed a significant effect of condition (P = 0.033) when comparing 
CON with SR. However, no effect of day (P = 0.863) or interaction effect (P = 
0.285). Early phase insulin AUC demonstrated a main effect of condition (P = 0.001) 
but no significant effect of day (P = 0.265) or interaction effect (P = 0.445). Late 
phase insulin AUC showed similar outcomes, with a significant difference between 
condition (P = 0.005) but not for day (P = 0.986) or condition x day (P = 0.206). 
4.3.4.3 Matsuda and HOMA 
No evidence of an effect of condition (P = 0.276), day (P = 0.425), or interaction 
effect (P = 0.318) were found for Matsuda index. Likewise, HOMA did not 
demonstrate any significant effect of condition (P = 0.802), day (P = 0.285), or 
interaction effect (P = 0.388).  
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Figure 4.1. Glucose and insulin area under the curve (AUC) during a 120 min oral glucose 
tolerance test after 1-4 nights of 8 h time in bed (control – CON) or 4 h time in bed (sleep 
restriction – SR) each night. (A) Glucose AUC during CON and SR. (B) Insulin AUC during 
CON and SR. * indicates significant main effect of condition (P < 0.05). n = 10. 
64 
 
 
Table 4.3. AUC and insulin sensitivity indexes for glucose and insulin. 
Total (0-120 min), early (0-60 min), and late (60-120 min) AUC during oral glucose tolerance test for insulin and glucose, Matsuda index and HOMA during 
control (CON) and sleep restriction (SR) for each night. CON = 8 h/night and SR = 4 h/night time in bed. Data are presented as mean ± SEM. n = 10. 
 
 CON1 CON2 CON3 CON4 SR1 SR2 SR3 SR4 
Glucose 
(AU) 
Total 
Early 
Late 
 
 
784 ± 64  
433 ± 29 
351 ± 39 
 
 
875 ± 65 
473 ± 35 
403 ± 33 
 
 
791 ± 72 
420 ± 32 
371 ± 42 
 
 
776 ± 66 
420 ± 29 
356 ± 42 
 
 
928 ± 81 
489 ± 34 
439 ± 51 
 
 
883 ± 62 
465 ± 26 
418 ± 39 
 
 
943 ± 49 
483 ± 21 
460 ± 31 
 
 
925 ± 65 
479 ± 26 
446 ± 43 
Insulin (AU) 
Total 
Early 
Late 
 
5181 ± 1223 
2381 ± 499 
2800 ± 739 
 
5573 ± 1144 
2866 ± 612 
2707 ± 547 
 
5418 ± 1059 
2839 ± 636 
2580 ± 496 
 
4717 ± 761 
2671 ± 530 
2046 ± 316 
 
6141 ± 1145 
2875 ± 539 
3266 ± 615 
 
6346 ± 1335 
3184 ± 867 
3162 ± 548 
 
 
6832 ± 1077 
3151 ± 496 
3680 ± 613 
 
 
7162 ± 1294 
3597 ± 753 
3565 ± 566 
Matsuda 15.6 ± 5.4 8.8 ± 1.6 8.8 ± 2.0 10.2 ± 2.0 7.6 ± 1.6 8.9 ± 2.2 7.17 ± 4.8 8.8 ± 2.8 
HOMA 1.1 ± 0.4 1.4 ± 0.4 1.4 ± 0.2 1.1 ± 0.2 1.1 ± 0.2 1.3 ± 0.3 1.0 ± 0.2 1.2 ± 0.2 
65 
 
 Discussion 
The primary aim of this chapter was to assess if the impairment in glucose 
regulation following sleep restriction was impacted by the number of nights of 
restriction. The findings demonstrate that sleep restriction alters glucose regulation, 
increasing the area under the curve in both glucose and insulin concentrations when 
compared to the control condition. However, contrary to the hypothesis, the results 
did not show evidence that this impairment was affected by the number of nights of 
sleep restriction. 
The increase in glucose AUC found following sleep restriction suggests altered 
glycaemic control. These findings are consistent with previous research (Donga et 
al., 2010; Nedeltcheva et al., 2009; Schmid et al., 2011; Spiegel et al., 1999). 
However, others have found no change in glucose profiles following sleep restriction 
(Bosy-Westphal et al., 2008; Wang et al., 2016). We have previously postulated that 
the varied findings in altered glucose profiles after sleep restriction was possibly due 
to differing methodologies relating to the severity of sleep restriction either in 
number of nights or hours of restriction each night (Sweeney et al., 2017). However, 
the evidence from this study does not support the hypothesis that cumulative sleep 
restriction would lead to larger impairments in glucose regulation. These results 
show that altered glucose profiles do not change in a linear manner. 
Circulating glucose is tightly regulated by the actions of insulin. Therefore, in some 
cases, it is not surprising to observe no change in glucose profiles after a particular 
intervention due to alterations in insulin concentrations. Changes to insulin profiles 
and hyperinsulinemia have been shown to be an early marker of metabolic disease, 
independent of glucose concentrations (Dankner et al., 2009; Weir & Bonner-Weir, 
2004). Indeed, an increased area under the curve for insulin in response to a 
standard glucose challenge would indicate reduced insulin sensitivity. The results of 
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the present study show increased insulin profiles during the OGTT following sleep 
restriction when compared to the control condition suggesting reduced insulin 
sensitivity. These results are consistent with previous work showing reduced insulin 
sensitivity following sleep restriction ranging from 1 to 14 nights (Broussard et al., 
2012; Buxton et al., 2010; Donga et al., 2010; Klingenberg et al., 2013; Nedeltcheva 
et al., 2009; Schmid et al., 2011; Wang et al., 2016). Whilst an effect of condition 
was observed, there was no evidence for a cumulative effect of sleep restriction on 
insulin profiles, similar to the glucose profiles observed in the study.  
The underlying mechanisms to explain the overall decrease in glucose regulation 
are unclear. Previous research has suggested peripheral insulin signalling may play 
a key role in the altered glucose metabolism following sleep loss (Broussard et al., 
2012; Rao et al., 2015). Other mechanisms which have been proposed include 
increased inflammation and production of cortisol, however findings for these have 
not been consistent (Irwin et al., 2006; Nedeltcheva et al., 2009; Spiegel et al., 
1999; Vgontzas et al., 2004). Taking into account the findings of the present study, it 
may be possible that any underlying mechanism could be active after the first night 
of sleep restriction with no further activation/impairments on subsequent nights.  
The study was not designed to elucidate the underlying mechanisms, which may be 
viewed as a limitation. Further limitations include the small sample size and use of 
only healthy, young adults. Findings should therefore be interpreted with caution 
when extrapolating to other populations such as those with existing metabolic 
disorders and other age categories. However, the relatively homogenous sample 
may also be considered a strength, as findings are unlikely to have been 
confounded by factors such as age and health status. Furthermore, the replication 
of dietary intake across conditions also ensures changes in diet did not influence 
findings.   
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Taken together, the findings of the current study suggest that sleep restriction 
influences insulin sensitivity but may not do so in a cumulative manner. This may 
have implications for future studies involving sleep restriction, as it does not appear 
that the number of nights of sleep restriction is the main factor in the extent of the 
impairment in insulin sensitivity.  
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Chapter 5 – The Effect of Acute Sprint Interval Exercise on 
Glycaemic Control Following Sleep Restriction 
 Introduction 
Sleep restriction can exert negative effects on glucose regulation and whole body 
insulin sensitivity (Knutson et al., 2007). A number of experimental studies have 
shown that sleep restriction results in impaired glucose control (Buxton et al., 2010; 
Donga et al., 2010; Rao et al., 2015; Reynolds et al., 2012; Spiegel et al., 1999). 
These findings are supported by findings in Chapter 4 of this thesis demonstrating 
that four nights of sleep restriction to 4 h each night impaired glycaemic control in 
healthy individuals. However, the findings did not demonstrate a cumulative effect of 
the number of nights of sleep restriction on the impairment in glucose regulation, 
suggesting that a single night of sleep restriction is sufficient to impair glucose 
regulation. This has also been previously shown by Donga and colleagues (2010), 
who demonstrated a 20% decrease in whole-body insulin sensitivity after a single 
night of 4 h sleep compared to a night of 8 h sleep.  
One of the most commonly proposed mechanisms underlying the impairment in 
insulin sensitivity following sleep loss is altered peripheral insulin signalling 
(Broussard et al., 2012; Rao et al., 2015; Sweeney et al., 2017). Rao et al. (2015) 
demonstrated a 25% reduction in whole-body insulin sensitivity and 29% reduction 
in peripheral insulin sensitivity, but no significant change in hepatic insulin sensitivity 
after five nights of sleep restriction in healthy individuals. Insulin signalling in 
adipocytes and skeletal muscle may be impaired following four and two nights of 
sleep restriction, respectively (Broussard et al., 2012; Sweeney et al., 2017).  
Additionally, increased levels of triglycerides are also indicative of metabolic 
impairment and may contribute to the impairment in insulin sensitivity after sleep 
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restriction. Lipid-induced insulin resistance is thought to occur in multiple ways. 
These include interfering with key components of the insulin signalling pathway in 
peripheral tissues such as PI3K and Akt phosphorylation (Yu et al., 2002), 
prohibiting glucose uptake via the Randle cycle, and inducing mitochondrial 
dysfunction through increased production of reactive oxygen species and therefore 
inhibiting phosphorylation of IRS-1 on the tyrosine residue (Martins et al., 2012). 
Research has demonstrated changes to the metabolic profile after sleep loss, 
favouring fatty acid transportation (Davies et al., 2014). Observational studies also 
show higher triglyceride concentrations in individuals with sleep durations less than 
7 hours per night compared to those sleeping between 7 and 8 hours per night 
(Bjorvatn et al., 2007). Conversely, experimental findings are scarce and 
inconsistent. Lipid profiles measured over the course of a day were unaltered after 
five nights of 4 h sleep in one study (O'Keeffe et al., 2013) but improved in another 
(Reynolds et al., 2012). It is still unclear how lipid metabolism is impacted during an 
oral glucose tolerance test after sleep restriction, when the impairment in insulin 
sensitivity is most prominent.  
Whilst research has investigated the mechanisms which contribute to the 
impairment in insulin sensitivity after sleep restriction, little is known about how to 
combat this impairment. Exercise is well known to improve insulin sensitivity 
(Borghouts & Keizer, 2000). An acute bout of exercise has the potential to 
upregulate insulin sensitivity for up to two days (Ortega et al., 2015). This effect is 
apparent with different exercise modalities, however high intensity exercise may be 
superior to continuous exercise for increasing insulin sensitivity (Ortega et al., 2015; 
Rynders et al., 2014). A single bout of sprint interval exercise has been shown to 
decrease glucose and insulin AUC and increase insulin sensitivity index by 142% 
during an IVGTT conducted 30 minutes post-exercise compared to rest (Ortega et 
al., 2015). Additionally, late phase insulin AUC has been shown to decrease by 26% 
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and minimal model derived insulin sensitivity increase by 85% following a single 
bout of high intensity exercise compared to no exercise in prediabetic adults 
(Rynders et al., 2014). However, while an improved postprandial response following 
exercise is well established, it is not clear if these improvements would be elicited in 
sleep restricted individuals.  
Emerging evidence suggests exercise may be a promising intervention to alleviate 
the impairment in glycaemic control following sleep loss. It has been speculated that 
exercise may target similar molecular mechanisms to those which contribute to the 
impairment in insulin sensitivity following sleep restriction, such as signalling 
molecules in skeletal muscle, and therefore be beneficial following sleep loss (Saner 
et al., 2018). Indeed, recent research showed that two weeks of high intensity 
exercise training prior to a single night of total sleep deprivation attenuated the 
impaired insulin response to an OGTT (De Souza et al., 2017). However, total sleep 
deprivation is arguably less likely to occur than partial sleep restriction, which often 
occurs due to increased work and lifestyle demands of modern society (Basner et 
al., 2014). Moreover, two weeks of exercise training may not be feasible for 
situations where unplanned sleep restriction occurs.  
Consequently, the primary aim of the current study was to examine if acute sprint 
interval exercise following a single night of sleep restriction could alleviate the effect 
of short sleep on insulin sensitivity. We hypothesised that in the sleep restriction and 
exercise condition, glucose regulation and insulin sensitivity would be improved 
compared to the sleep restriction and no exercise condition. The secondary aim of 
the study was to examine changes in triglyceride concentrations following sleep 
restriction to identify whether or not this contributed to the altered insulin sensitivity.  
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 Methods 
5.2.1 Participants 
Recruitment for the study was conducted by placing poster advertisements around 
Northumbria University campus and through word of mouth. Individuals who 
expressed an interest in participating were provided with the Participant Information 
Sheet (Appendix A2) and given at least 24 h to read the information sheet before 
deciding if they wanted to take part. 
Participants were healthy non-smoking males aged between 18 and 50 years old. 
Females were not included as the menstrual cycle can affect glucose regulation 
(Pulido & Salazar, 1999) and it would not have been feasible to control for 
menstrual cycle phase given the timescale of the study. Exclusion criteria were shift 
work, regular travel across time zones (classed as more than three times a year), 
travel across time zones in the past 4 weeks, any disorders which may influence 
glycaemic control (such as diabetes) or sleep (for example, obstructive sleep 
apnea), current or previous medication in the past year which may have impacted 
glucose metabolism or sleep, and a history of drug or alcohol abuse or eating 
disorders, following a specific diet such as intermittent fasting. Furthermore, 
individuals were excluded if they had alterated their sleep, diet, or physical activity 
pattern in the previous 3 months,  had a habitual bedtime before 2200 h or after 
0100 h, or a habitual wake time before 0600 h or after 0900 h.Individuals with poor 
sleep quality, classed as a Pittsburgh Sleep Quality Index (Buysse et al., 1989) 
score of above 5, or who were classed as extreme morning or evening types, 
assessed by the morningness-eveningness questionnaire (Horne & Ostberg, 1976), 
were also excluded from participating.  
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5.2.2 Study design 
The study utilised a randomised crossover design, which consisted of a 
familiarisation session and four 1-night experimental conditions. Experimental 
conditions were control (CON), sleep restriction (SR), control plus exercise (CE), 
and sleep restriction plus exercise (SRE). Throughout the study participants slept in 
the home environment. Randomisation was done using an online randomisation tool 
(www.randomization.com) and participants were assigned to conditions in 
chronological order as they signed up to the study. The study protocol was reviewed 
and approved through the Northumbria University Ethical Approval System (13557) 
and written informed consent (Appendix B2) was obtained from all individuals prior 
to participation. 
5.2.3 Study conditions 
Experimental conditions differed in either sleep duration or exercise status. During 
CON and CE time in bed was 8 h (2300 - 0700). During SR and SRE time in bed 
was 4 h (0300 - 0700). In CON and SR participants rested in the morning upon 
wakening, and in SR and SRE they were required to carry out a bout of exercise 1 
hour after wakening. All experimental visits were separated by at least 1 week to 
prevent carryover effects. Two nights of 8 h sleep has been shown to reverse the 
effects of five nights of sleep restriction on insulin concentrations (van Leeuwen et 
al., 2010). A maximum of 3 weeks was permitted between visits. Participants were 
not informed which condition they were assigned to until the day preceding the 
experimental night of control or sleep restriction.  
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5.2.4 Experimental Protocol 
5.2.4.1 Familiarisation 
At least one week prior to the first experimental visit participants attended the 
laboratory for screening and a familiarisation of the protocol. Upon arrival 
participants were briefed on the study protocol and given the opportunity to ask 
questions before completing an informed consent form. They were then asked to 
complete several screening questionnaires – a physical activity readiness 
questionnaire, the Pittsburgh Sleep Quality Index (Buysse et al., 1989), and a 
morningness-eveningness questionnaire (Horne & Ostberg, 1976). Following 
satisfactory completion of the screening questionnaires, they were issued with a 3-d 
food diary (Appendix C), actigraphy watch, and 7-d sleep diary (Appendix D). They 
were asked to start wearing the actigraphy watch and completing the sleep diary 1 
week prior to the first experimental condition.  
Body mass and stature were measured using balance scales (SECA) and a free-
standing stadiometer (SECA). BMI was then calculated as described in Chapter 3. 
Participants undertook an exercise familiarisation, which was a reduced version of 
the study exercise protocol. The familiarisation exercise bout consisted of a 5-
minute warm-up at 70 W on the cycle ergometer, followed by two all-out 30-second 
sprints against 7.5% of body mass. Sprints were separated by 4.5 minutes of active 
recovery at a self-selected pace. A 5-minute cool down was then completed. Verbal 
encouragement was given during the sprints to ensure participants gave maximum 
effort. During the familiarisation session, seat height was self-selected by 
participants, with guidance from the researcher. Seat height was recorded to allow 
replication during experimental trials.       
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5.2.4.2 Experimental trials 
An entraining period identical to that described in Chapter 4 was conducted prior to 
each experimental trial. Diet was provided for the day preceding each experimental 
trial and was replicated across conditions. Diet was individualised from food diaries 
as previously described in Chapter 3. Participants were instructed to eat only the 
foods provided and to avoid consumption of any caffeine or alcohol. Water was 
permitted ad libitum. Participants were also asked to refrain from exercise during 
this time. Wrist actigraphy was used throughout the study to ensure compliance. In 
addition, participants sent time-stamped text messages to the researcher between 
2300 and 0300 in SR and SRE conditions.  
After the night of control sleep or sleep restriction, participants arrived at the 
laboratory by public transport at 0800 each morning following a 10 h overnight fast. 
Upon arrival, participants either completed a bout of high intensity exercise (CE and 
SRE) or rested in a seated position for the equivalent duration (CON and SR). They 
were then given a 30 min recovery period in which they rested in a seated position. 
During the recovery period a cannula was inserted into the antecubital vein and a 
baseline sample was drawn at the end of the 30 min period. A 2 h oral glucose 
tolerance test was conducted, and blood samples were drawn at regular intervals. 
During the OGTT participants remained seated in the laboratory but were permitted 
to complete sedentary tasks such as watch films, read, or work. Participants were 
debriefed and thanked for their participation before leaving the laboratory at 
approximately 1130. 
5.2.4.3 Exercise 
The exercise protocol used in this study was based on previous research by Ortega 
et al (2015). Ortega and colleagues demonstrated a 142% increase in IVGGT-
derived insulin sensitivity measured 30 minutes following sprint interval exercise in 
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healthy, physically active males recruited from a university population, which mirrors 
the population used in the present study.  
All exercise was performed on a Monark Ergomedic 894E cycle ergometer (Monark, 
Sweden). Seat height was recorded and remained consistent across the two 
exercise experimental trials. All sprint interval exercise in the familiarisation and 
experimental trials was preceded with a 5-minute warm-up and cool down at 70 W.  
The sprint interval exercise consisted of four all-out 30 s sprints interspersed with 
4.5 minutes of active recovery. During the sprints resistance was set at 7.5% of 
body mass. During the active recovery period, participants cycled at a self-selected 
pace against a resistance of 1 kg, which was the lowest permitted by the ergometer. 
Cycle ergometers were connected to a computer equipped with Monark Anaerobic 
software (Monark) to conduct the sprints and record power output. Verbal 
encouragement was given throughout each sprint.  
5.2.4.4 Blood collection and processing  
Blood was collected at baseline (0), 15, 30, 45, 60, 90 and 120 minutes during the 
OGTT using the cannulation technique. Samples were collected and processed as 
described in Chapter 3.  
Serum glucose was measured using the Biosen automatic analyser (EKF 
Diagnostics). Insulin was determined using commercially available ELISA kits 
(Mercodia), which were conducted according to manufacturers instructions. All 
conditions and timepoints for a single participant were analysed on the same plate. 
Intra- and inter-assay CV were 4.9% and 18%. Serum triglycerides were measured 
using the Randox Daytona automated analyser (Randox Laboratories, Crumlin, 
UK).  
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5.2.5 Data analysis 
5.2.5.1 Sample size calculation 
Sample size was calculated using G*Power software version 3.1 (Faul et al., 2007). 
Previously published data (Rynders et al., 2014) showing a mean difference of 1.5 
mmol/L in 2-hour glucose values during an OGTT after high intensity exercise 
compared to control was used. 18 participants were required to achieve 90% power, 
therefore 20 participants were recruited to account for a potential dropout rate of 
10%. 
5.2.5.2 Statistical analysis 
Descriptive data are presented as mean ± SD and metabolic data as mean ± SEM. 
Area under the curve (AUC) for glucose, insulin and triglycerides was calculated 
using the trapezoidal rule. Glucose and insulin AUC were calculated for total (2 
hours), early phase (0-60 min) and late phase (60-120 min) during the OGTT. 
HOMA-IR (Matthews et al., 1985) and Matsuda Index (Matsuda & DeFronzo, 1999) 
were calculated as described in Chapter 3 to estimate insulin resistance and whole-
body insulin sensitivity.  
Data were analysed using SPSS Statistics version 22 (IBM). Shapiro-Wilk tests 
were used to check for normality and any data which violated the assumption of 
normality were transformed using a natural log transformation. Linear mixed 
modelling was used to compare glucose, insulin and triglyceride concentrations and 
AUC between conditions. Post-hoc tests were conducted on significant main effects 
using the Sidak method. P < 0.05 was used to indicate significance.  
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 Results 
5.3.1 Participant characteristics 
Nineteen males completed the study, with one participant withdrawing due to feeling 
unwell whilst having a cannula inserted. Participant characteristics are displayed in 
Table 5.1. 
Table 5.1. Participant characteristics. 
Age (y) 25 ± 8  
Stature (cm) 180 ± 7 
Body mass (kg) 81 ± 12 
BMI (kg/m2) 25 ± 3  
PSQI score 4 ± 1 
Morningness-eveningness 
score 
53 ± 9 
Data are mean ± SD. n = 19. PSQI score of 5 or below indicates good sleep quality. 
Morningness-eveningness score between 42-58 indicates intermediate, 41 or below 
indicates evening, and 59 or above indicates morning type. n = 19. 
 
5.3.2 Sleep 
Actigraphy-derived sleep variables are presented in Table 5.2. Total sleep time 
(TST) was different between CON and SR (mean difference 142 min [2.4 h]; P < 
0.001), CE and SR (mean difference 182 min [3.0 h]; P < 0.001), CE and SRE 
(mean difference 181 min [3.0 h]; P < 0.001) and CON and SRE (mean difference 
141 min [2.4 h]; P < 0.001). 
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Table 5.2. Sleep variables for each experimental condition. 
 CON CE SR SRE 
Bed time (hhmm) 2303 ± 0029 2306 ± 0023 0305 ± 0017 0255 ± 0017 
Wake time (hhmm) 0658 ± 0017 0659 ± 0011 0700 ± 0010 0657 ± 0023 
TIB (min) 472 ± 27 472 ± 22 236 ± 19 244 ± 15 
TST (min) 337 ± 95 377 ± 61 195 ± 43*† 196 ± 37*† 
Bed time, wake time, time in bed (TIB) and total sleep time (TST) in control (CON), control 
plus exercise (CE), sleep restriction (SR) and sleep restriction plus exercise (SRE) condition. 
Data are mean ± SD. * indicates difference from CON (P < 0.05). † indicates difference from 
CE (P < 0.05). n = 19. 
 
5.3.3 Exercise 
Peak power output (PPO) and work done during each of the 30-second sprints is 
outlined in Table 5.3. PPO did not differ between conditions (P = 0.644), but a 
difference was observed over time (P < 0.001), with PPO significantly higher in the 
first sprint compared to the third (mean difference 106 W; P = 0.009) and fourth 
(mean difference 118 W; P = 0.007), and higher in the second compared to the 
fourth (mean difference 60 W; P = 0.041). Total work done was similar between 
conditions (63666 ± 12029 J in CE and 65045 ± 11294 J in SRE; P = 0.340). 
 
Table 5.3. Peak power output and total work done during sprints. 
 PPO (W)  Total work (J) 
 CE SRE  CE  SRE 
1 857 ± 189 853 ± 187  18356 ± 2903  18355 ± 3471 
2 818 ± 177 804 ± 160  16551 ± 2921  16580 ± 3139 
3 762 ± 194 736 ± 172  15488 ± 2842  15424 ± 3237 
4 733 ± 179 746 ± 144  14686 ± 2408  15502 ± 2490 
Peak power output (PPO) and total work during 4 all-out 30 s sprints performed the morning 
after a night of 8 h (CE) or 4 h (SRE) time in bed. No significant differences were observed 
between conditions. Data are presented as mean ± SD. n = 19. 
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5.3.4 Glucose and insulin 
Glucose and insulin concentrations during the OGTT are displayed in Figure 5.1. 
Total, early and late phase AUC for glucose and insulin are shown in Figure 5.2.  
Glucose concentrations did not show evidence of an effect of condition (P = 0.216) 
or interaction effect (P = 0.146). However, there was a significant effect of time 
during the OGTT (P < 0.001). No significant difference between conditions were 
found for peak glucose (P = 0.158). There was no evidence of an effect of condition 
(P = 0.207) for total glucose AUC. Likewise, late phase and early phase glucose 
AUC did not show any significant differences between conditions (P = 0.264 and P 
= 0.122, respectively). 
Insulin concentrations demonstrated a main effect of condition (P = 0.019), time (P 
< 0.001), and an interaction effect (P = 0.014). Post-hoc analyses revealed 
significantly higher insulin concentrations in SR compared to CON (P = 0.022), with 
SR showing higher concentrations than CON at 30 min (40.04 ± 23.17 and 25.79 ± 
13.94 µIU/ml; P = 0.004). Insulin concentrations were higher in SR compared to 
SRE at 60 minutes (31.40 ± 4.42 and 21.03 ± 3.38 μIU/ml; P = 0.042), 90 minutes 
(19.47 ± 3.51 and 15.52 ± 4.94 μIU/ml; P = 0.002), and 120 minutes (14.12 ± 4.69 
and 5.99 ± 1.67 μIU/ml; P = 0.003). Total insulin AUC displayed a trend for an effect 
of condition (P = 0.075), with SR tending to be higher than CON (P = 0.064). Early 
and late phase insulin AUC also showed significant main effects of condition (P = 
0.010 and P < 0.001, respectively). The early phase insulin AUC was higher in SR 
than CON (1472 ± 186 and 2044 ± 1129; P = 0.048). Late phase displayed a lower 
AUC in SRE than SR (1267 ± 128 and 862 ± 135; P = 0.004).  
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Figure 5.1. Glucose (A) and insulin (B) concentrations during the OGTT after one night of 
control sleep and rest (CON), sleep restriction and rest (SR), control sleep and exercise 
(CE) and sleep restriction and exercise (SRE). P < 0.05 indicates significance. * indicates 
main effect of condition. ‡ indicates difference between CON and SR. † indicates difference 
between SR and SRE. n = 19. 
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Figure 5.2. Total (white bars), early (grey shaded bars) and late (black bars) phase AUC for 
glucose (A) and insulin (B) during oral glucose tolerance test following one night of 8 h time 
in bed (control – CON), 4 h time in bed (SR) 8 h time in bed plus a session of sprint interval 
exercise in the morning (CE), and 4 h time in bed plus a session of sprint interval exercise in 
the morning (SRE). Data are presented as mean ± SEM. Main effect of condition for early 
(0-60 min) and late (60-120 min) AUC. * indicates significant difference (P <0.05) compared 
to CON in early phase. † indicates significant difference (P <0.05) compared to SR in late 
phase. n = 19.  
 
HOMA-IR showed a main effect of condition (P = 0.019), with SR higher than CON 
(0.87 ± 0.23 and 1.64 ± 0.60; P = 0.029). Matsuda index was significantly different 
between conditions (P = 0.003), with SR displaying a lower index than CON (25.31 
± 4.77 and 12.11 ± 1.46; P = 0.020). 
5.3.5 Triglycerides 
Triglyceride concentrations during the OGTT (Figure 5.3) did not show evidence for 
a difference between conditions (P = 0.863) or interaction effect (P = 0.225). There 
was a significant effect of time (P < 0.001), with concentrations higher at 0, 30, and 
60 min compared to 120 min (P < 0.05), and 30 and 60 min compared to 90 min (P 
< 0.05). Similarly, AUC was comparable between conditions (94 ± 8 mmol/L for 
CON, 97 ±8 mmol/L for CE, 104 ± 9 mmol/L for SR and 113 ± 17 mmol/L for SRE; P 
= 0.732). 
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Figure 5.3. Triglyceride concentrations during the OGTT in control (CON – 8 h time in bed), 
control plus exercise (CE – 8 h time in bed), sleep restriction (SR – 4 h time in bed), and 
sleep restriction plus exercise (SRE – 4 h time in bed) conditions. No evidence of differences 
between conditions was found (P > 0.05). n=19. 
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 Discussion 
The current study aimed to determine if a single session of exercise could alleviate 
the impairment in insulin sensitivity that occurs following acute sleep restriction. The 
findings demonstrate that a single night of sleep restriction impaired insulin 
sensitivity, and that a single session of sprint interval exercise performed following 
sleep restriction may improve the late postprandial response.  
Consistent with the findings in Chapter 4, participants displayed reduced insulin 
sensitivity after sleep restriction, as indicated by increased insulin concentrations 
during the OGTT and a decreased Matsuda index in SR compared to CON. This is 
in agreement with previous research demonstrating that one night of sleep 
restriction reduces whole-body insulin sensitivity in healthy individuals (Donga et al., 
2010), as well as other studies which employed multiple nights of sleep restriction 
(Sweeney et al., 2017; Wang et al., 2016). Sleep restriction may impair whole body 
insulin sensitivity through alteration of peripheral insulin signalling, with five nights of 
sleep restriction to 4 hours per night reducing peripheral, but not hepatic, insulin 
sensitivity (Rao et al., 2015). Furthermore, sleep restriction has been shown to 
decrease Akt phosphorylation, which plays a key role in the insulin signalling 
pathway in peripheral tissues (Broussard et al., 2012).  
It was hypothesised that a bout of sprint interval exercise would attenuate the 
impairment in insulin sensitivity in sleep-restricted individuals. Whilst total insulin 
AUC was not significantly altered after the exercise bout, findings suggest that there 
was an alteration to the late post-prandial response. Insulin AUC was lower during 
the second hour of the OGTT when exercise was performed after sleep restriction 
compared to sleep restriction alone. However, there did not appear to be evidence 
of an improvement in insulin or glucose profiles after exercise in the early phase of 
the OGTT following exercise. These findings are in contrast to Ortega and 
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colleagues (2015) who demonstrated improved insulin and glucose 60 minutes 
following high intensity exercise. Methodological differences may explain this 
discrepancy, as an IVGTT was employed in that study, whereas we used an OGTT. 
Gastric emptying plays a role during the OGTT whereas this is bypassed when 
glucose is injected rather than ingested orally. Gastric emptying rate may be slowed 
by intermittent high intensity exercise (Leiper et al., 2001), likely due to a reduction 
in splanchnic blood flow which plays an important role in gastric emptying. This may 
delay the absorption of the glucose drink and therefore findings may not be 
comparable between an OGTT and IVGTT. Alternatively, it may be possible that 
sleep restriction alters the metabolic response to exercise.  
The findings of the present study reflect those by Rynders and colleagues (2014), 
who noted improvements in the late rather than total postprandial response after a 
bout of exercise. High intensity exercise is known to temporarily increase glucose 
due to gluconeogenesis, possibly for carbohydrate sparing and glycogen repletion 
(Marliss et al., 1992). Given that assessments were made only 30 minutes after 
cessation of exercise, the temporary alterations in glucose regulation which occur 
during exercise were still influencing our measurements. Insulin secretion in the 
early phase may impact the late-phase response by suppressing endogenous 
glucose production (Del Prato et al., 2002). Therefore, it is possible that increased 
early-phase insulin response after exercise due to gluconeogenesis may have 
played a role in the reduced late-phase response observed in SRE. Nonetheless, a 
reduced late-phase response during an OGTT may predict incident diabetes 
independent of early-phase response (Lorenzo et al., 2012), which suggests that 
although no change in total AUC was observed, the reduced late-phase response 
may be beneficial for metabolic health.  
A secondary aim of the current study was to determine whether any changes 
occurred in serum triglycerides after sleep restriction compared to control sleep, and 
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if exercise altered this. The findings did not show any evidence for altered 
triglyceride concentrations between conditions. Epidemiological studies suggest that 
short sleep may impair lipid metabolism, however few studies have addressed 
changes in triglycerides following experimental sleep restriction. Reynolds and 
colleagues (2012) demonstrated decreased triglyceride concentrations after sleep 
restriction, but speculated this change may have been influenced by the study 
design which provided a diet which may have differed from the participants’ habitual 
diet. As the diet provided in the current study was designed to match habitual diet it 
is unlikely the findings were influenced by a change in dietary intake. However, the 
findings of the current study mimic those of O’Keeffe et al. (O'Keeffe et al., 2013), 
who also did not find any evidence for a change in lipid profiles following sleep 
restriction in healthy individuals.  
Whilst the present study suggests there is potential for exercise to positively 
influence the post-prandial response to an OGTT in sleep-restricted individuals, the 
underlying mechanisms remain elusive. There did not appear to be any changes in 
triglycerides between rest and exercise, suggesting any alterations in glycaemic 
control were mediated by other mechanisms. Previous research has suggested that 
insulin action is improved after exercise through altered phosphorylation of 
components of the insulin signalling pathway in peripheral tissues (Wojtaszewski & 
Richter, 2006). As sleep restriction is thought to negatively affect peripheral insulin 
sensitivity (Broussard et al., 2012; Rao et al., 2015), it can be speculated that 
exercise improves insulin sensitivity in sleep-restricted individuals through alteration 
of insulin action in peripheral tissues.  
The present study has some limitations which should be noted. Firstly, the study 
population consisted only of healthy males, meaning it may not be feasible to 
extrapolate the findings to other populations such as females or those with existing 
metabolic abnormalities. Secondly, an OGTT does not enable measurement of 
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metabolic characteristics such glucose disposal and uptake, so gives limited 
information regarding the decrease in insulin sensitivity. 
In summary, sprint interval exercise may offer some potential to attenuate the 
impairments in insulin sensitivity following a single night of reduced sleep. This may 
have implications for individuals facing sleep curtailment, whether voluntarily or 
otherwise. To our knowledge, this is the first study to explore the effect of acute 
exercise on insulin sensitivity following sleep restriction, therefore further exploration 
is warranted. Future research may investigate whether exercise modality, intensity, 
duration, or timing influences the change in glucose regulation in sleep-restricted 
individuals. Furthermore, the effect of exercise and sleep duration on glycaemic 
control should be investigated in the chronic setting, examining whether habitual 
sleep duration and physical activity levels have similar effects on metabolism in the 
free-living environment. 
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Chapter 6 – Markers of glycaemic control in habitual short 
sleepers with high and low physical activity 
 Introduction 
Evidence demonstrates an association between sleep duration and metabolic 
health. Short sleepers have an increased risk of developing a metabolic disorder 
such as type 2 diabetes (Yaggi et al., 2006). Several experimental studies, including 
those in the previous two chapters, have examined the impact of acute sleep 
restriction on glucose metabolism using various methods, and repeatedly observed 
impaired metabolism after short sleep (Knutson et al., 2007). Controlled 
experimental studies are useful for determining initial findings or mechanisms, but 
due to their nature in design, they often lack ecological validity, and findings may not 
always transfer to the free-living environment where many external factors can 
influence measures.  
Cross-sectional studies have demonstrated associations between sleep duration 
and markers of glycaemic control (Lee et al., 2017; Nakajima et al., 2008; Ohkuma 
et al., 2013; Twedt et al., 2015). Other markers associated with glycaemic control 
such as adiponectin, cholesterol (total, HDL and LDL) and triglycerides have shown 
associations with sleep duration in some (Kaneita et al., 2008) but not all studies 
(Taheri et al., 2004; Williams et al., 2007). However, these studies have limitations 
which must be considered. Some included only diabetic participants (Ohkuma et al., 
2013; Twedt et al., 2015) where findings may not necessarily be comparable at the 
sub-clinical level. Furthermore, cross-sectional studies often employ subjective 
measures of sleep (Hancox & Landhuis, 2012; Kaneita et al., 2008; Nakajima et al., 
2008; Ohkuma et al., 2013), which can be useful in large-scale studies. However, 
individuals tend to overestimate their sleep duration by up to an hour compared to 
objective measures (Lauderdale et al., 2008). Assessment of physical activity, diet, 
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and/or body composition are also often measured by subjective means or methods 
known to be flawed such as BMI or 24-hour recall dietary questionnaires. The 
discrepancies in methodologies and assessment tools used may explain the 
inconsistent findings; hence, it remains unclear whether associations would exist 
when objective measures are used.  
Physical activity is positively associated with glycaemic control (Warburton et al., 
2006). Both cross-sectional and experimental trials have observed a positive impact 
of higher physical activity on markers of glycaemic control, including serum glucose, 
cholesterol, and triglycerides (Crichton & Alkerwi, 2015; Figueiró et al., 2019; Mann 
et al., 2014). Given that physical activity can improve markers of glycaemic control, 
it can be hypothesised that individuals who undertake regular physical activity may 
be less impacted by short sleep than those who are less physically active.  
Accordingly, the aim of this study was to determine if markers of glycaemic control 
differed between individuals with short habitual sleep durations and individuals 
achieving longer sleep durations. Furthermore, this study examined whether or not 
habitual physical activity levels among shorter sleepers influenced glycaemic 
control. It was hypothesised that markers of glycaemic control would be negatively 
altered in less physically active short sleepers, but that differences would not be 
evident between the more active short sleepers and those achieving longer sleep 
durations.  
 Methods 
6.2.1 Participants 
120 volunteers were recruited by poster advertisement around Northumbria 
University and the surrounding areas. Individuals were eligible for the study if they 
were aged 18 to 50 years, and of white European ethnicity. Only individuals of white 
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European ethnicity were included as metabolic markers and circadian genes may 
be influenced by ethnicity (Egan et al., 2017) and this would potentially confound 
findings. Exclusion criteria were shift work, regular travel across time zones (>3 
times each year) or travel across time zones in the past 4 weeks, any disorders or 
medication which may influence glycaemic control (for example PCOS, diabetes, 
metformin, etc.), a sleep disorder (assessed using the Sleep Disorders Symptom 
Checklist-17) (Klingman et al., 2017), extreme morning or evening chronotype 
(assessed by the MEQ) (Horne & Ostberg, 1976), alteration to physical activity, 
dietary or sleep behaviours in the previous 3 months, a history of drug or alcohol 
abuse or eating disorder, pregnant or up to 1 year post-partum, or a psychological 
or linguistic inability to give written informed consent. 
6.2.2 Study design 
This study involved two visits to the laboratory, separated by one week. During the 
first visit, information about the participant’s health behaviours was collected using 
questionnaires. The second visit consisted of numerous physiological 
measurements. Participants were issued with an actigraphy watch (GeneActiv, 
Activinsights) to wear, and 3-day food diary (Appendix C) and 7-day sleep diary 
(Appendix D) to complete between visits. The study protocol was approved through 
the Northumbria University Online Ethics System (ethics number 4259) and written 
informed consent (Appendix B3) was obtained prior to participation.  
6.2.3 Study Protocol 
The first study visit took place at a time and day suitable for participants. Upon 
arrival at the laboratory, participants completed informed consent and were then 
given several questionnaires to complete. These questionnaires were the Sleep 
Disorders Symptom Checklist (SDS-CL-17; (Klingman et al., 2017), a screening 
questionnaire, morningness-eveningness questionnaire (Horne & Ostberg, 1976), 
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and the Hospital Depression and Anxiety Scale (HADS) (Zigmond and Snaith, 
1983). 
At the end of the first visit participants were issued with an actigraphy watch 
(GENEActiv, Activinsights), 3-day food diary, and 7-day sleep diary. They were 
instructed to wear the watch continuously for seven days to measure sleep and 
physical activity. Additionally, they were asked to press the button on the actigraphy 
watch when they intended to go to sleep and upon wakening in the morning. This 
button press added a marker on the data, which assisted with analysis of sleep if 
required. The sleep diary was completed in conjunction with the actigraphy monitor 
to assist with sleep analysis as well as yield subjective bed and wake time. The 
second visit was conducted one week after the first visit, and consisted of 
measurement of physiological variables which included basic anthropometric 
variables, body composition and serum metabolic markers.  
6.2.3.1 Physical activity 
Wrist actigraphy was used to capture activity data between visits. As outlined in 
Chapter 3 and by others (Esliger et al., 2011; Powell et al., 2017), the GENEActiv 
wrist-worn accelerometer is a valid tool to measure physical activity in healthy 
adults. Participants wore the GENEActiv accelerometer (Activinsights) on their non-
dominant wrist from the laboratory visit on the first day until they arrived at the 
laboratory for the second visit. As the first and last day were incomplete days, five 
full days of activity data were collected for each participant. Data were collected 
using at 10 Hz and converted using 60 s epochs. Data were extracted and CSV files 
were imported into the GENEActiv everyday living macro for Microsoft Excel 
(https://open.geneactiv.org). Absolute and percent sedentary behaviour and light, 
moderate, and vigorous activity was determined for each full day of wear and 
averaged to give a daily value. Cut-off points for light, moderate, and vigorous 
activity were set at 483, 678 and 2264 g/min, as recommended by the manufacturer 
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and Esliger and colleagues (2011). Moderate and vigorous metabolic minutes per 
day (met.mins/day) were combined to obtain a measure of moderate-to-vigorous 
activity (MVPA).  
6.2.3.2 Dietary intake 
Dietary behaviours were obtained using 3-day food diaries. Participants were asked 
to complete the food diaries on two weekdays and one weekend day. They were 
asked to log the time of eating, what they ate, the cooking method, and the amount. 
Any liquids consumed, with the exception of water, were also recorded. Food diaries 
were analysed for energy, carbohydrate, fat, saturated fat, and protein intake using 
Microdiet dietary analysis software (version 4.4; Downlee Systems).  
6.2.3.3 Body composition 
Stature and body mass were measured using a Harpenden wall-mounted 
stadiometer (Seritex) and digital scales (SECA). Whole-body dual energy x-ray 
absorptiometry (DXA) scanning was used to determine body composition. All scans 
were conducted using the Hologic Horizon W DXA scanner (Hologic, 
Massachusetts, USA) by the same trained technician and analysed using Hologic 
APEX Software version 5.6.0.5. Recommendations set out by Nana and colleagues 
(2015) were followed to ensure consistency between scans. All participants wore 
loose, light clothing and any metal was removed. Participants lay in a supine 
position with hands in a mid-prone position and feet angled inwards. In cases where 
the arms did not fit inside the scanning area, reflexion scanning was utilised, with 
the left upper limb excluded from the original scan and automatically determined 
using the DXA analysis software by reflection of the right upper limb. Reflexion 
scanning is a useful alternative to whole-body scanning for broader individuals and 
provides comparable results (Moco et al., 2019). Scans were analysed 
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automatically by the software and verified manually by the same researcher for all 
participants.  
6.2.3.4 Sleep variables 
Wrist actigraphy (GeneActiv, Activinsights) was used for 1 week between visits to 
measure sleep variables in conjunction with physical activity. As previously 
described in Chapter 3, participants wore the actigraphs on their non-dominant wrist 
and were instructed to press the button to indicate intention to sleep and wake 
times. A 7-day sleep log was completed in conjunction with actigraphy. From the 
data, total sleep time (TST) was determined for each night of wear using the 
GeneActiv sleep macro for Microsoft Excel (https://open.geneactiv.org). The TST for 
all nights were combined and divided by the total number of nights to give an 
average nightly sleep duration. Any participants with less than 6 nights of wear were 
excluded from analysis.  
6.2.3.5 Blood sampling 
During the second visit a blood sample was obtained using the venepuncture 
technique to determine markers of glycaemic control including glucose, adiponectin, 
total cholesterol, HDL cholesterol, and triglycerides. Samples were processed then 
frozen as indicated in Chapter 3 until further analysis.  
6.2.4 Data Analysis 
A previous study (Krueger & Friedman, 2009) demonstrated approximately one third 
of adults have a sleep duration below 7 hours per night. Therefore, 120 participants 
were recruited for the current study to ensure the sample included a sufficient range 
of sleep durations.  
The sample was divided into sextiles according to sleep duration. The participants in 
the bottom two sextiles (i.e. 40 individuals with shortest sleep duration) and top 
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sextile (20 individuals with longest sleep duration) were included in analysis. The 40 
short sleepers were further divided into two groups according to MVPA 
met.mins/day. Therefore, three groups were included in analysis: less active short 
sleepers (LASS), more active short sleepers (MASS), and longer sleepers (LS). 
Blood samples were tested to determine serum glucose, adiponectin, triglycerides, 
total cholesterol and HDL cholesterol. Glucose was measured immediately after 
centrifugation using the Biosen automatic analyser (EKF Diagnostics). Adiponectin 
was measured using a commercially available ELISA kit (Abbexa, Cambridge, UK). 
Triglycerides were determined using an automated analyser (Randox Daytona, 
Randox Laboratories). Total and HDL cholesterol were measured by the Reflotron 
Plus analyser (Roche, Switzerland). LDL cholesterol was calculated from total 
cholesterol, HDL cholesterol and triglycerides using Friedewald’s formula 
(Friedewald et al., 1972): 
𝐿𝐷𝐿 = 𝑡𝑜𝑡𝑎𝑙 𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 (𝑚𝑚𝑜𝑙 𝐿⁄ ) − 𝐻𝐷𝐿 𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 (𝑚𝑚𝑜𝑙 𝐿⁄ )
−  
𝑡𝑟𝑖𝑔𝑙𝑦𝑐𝑒𝑟𝑖𝑑𝑒𝑠 (𝑚𝑚𝑜𝑙 𝐿⁄ )
2.19
 
Triglyceride to HDL ratio was calculated by dividing triglyceride concentration by 
HDL cholesterol concentration.  
6.2.4.1 Statistical analysis 
Data were analysed using SPSS statistical software version 22 (IBM). Shapiro-Wilk 
tests of normality were conducted and any variables which violated the assumption 
of normality were natural log-transformed. Participant characteristics were 
compared between groups using one-way ANOVAs for continuous variables and 
Chi-squared tests for categorical variables. One-way ANCOVAs were conducted to 
determine differences between sleep durations for adiponectin, total cholesterol, 
HDL cholesterol, LDL cholesterol, triglycerides (TG), TG-to-HDL ratio, and fasting 
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glucose. Any significant main effects were compared using the Sidak method . 
Analyses were adjusted for age, sex, lean mass, and energy intake.  
 
 Results 
6.3.1 Participant Characteristics 
Participant characteristics for each of the three groups are displayed in Table 6.1. 
MEQ score was 52 ± 5 in LS, 50 ± 9 in LASS, and 57 ± 12 in MASS. Anxiety and 
depression scores were 7 ± 3 and 3 ± 2 in LS, 6 ± 3 and 2 ± 2 in LASS, and 6 ± 3 
and 2 ± 3 in MASS, respectively. Groups differed by sex (P = 0.002), BMI (P = 
0.045), lean mass (P = 0.048), total sleep time (P < 0.001) and MVPA (P < 0.001) 
but did not show differences between age (P = 0.825), energy intake (P = 0.449), 
carbohydrate intake (P = 0.736), fat intake (P = 0.964), protein intake (P = 0.863), 
fat mass (P = 0.062), or visceral adipose tissue (P = 0.144). Post-hoc analyses did 
not show evidence for any differences between groups for BMI or lean mass. MVPA 
was higher in MASS than LASS and LS (P < 0.001 for both). Total sleep time was 
lower in both MASS and LASS than LS (P < 0.001 for both). 
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Table 6.1. Participant characteristics by group. 
 LASS MASS LS  
Age (y) 27 ± 7 28 ± 8 28 ± 8  
Sex (M:F) 16:4 8:12 6:14  
BMI (kg/m2) 26 ± 5 23 ± 4 24 ± 3  
Lean mass (%)  66 ± 6   66 ± 7  61 ± 7  
FM (%) 30 ± 7 30 ± 7 34 ± 6  
VAT (g) 416 ± 251 299 ± 163 335 ± 192  
Energy 
(MJ/kg/day) 
 0.12 ± 0.04  0.12 ± 0.03  0.12 ± 
0.04 
 
CHO (g/kg/day)  3.04 ± 0.97  3.21 ± 0.96  2.95 ± 
1.11  
 
Fat (g/kg/day)  1.16 ± 0.54  1.20 ± 0.36  1.19 ± 
0.43 
 
Protein (g/kg/day)  1.51 ± 0.53 1.43 ± 0.60  1.43 ± 
0.71 
 
TST (mins) 340 ± 34* 341 ± 33 461 ± 24**  
TST (h) 5.7 ± 0.6* 5.7 ± 0.6 7.7 ± 0.4**  
MVPA 
(met.mins/day) 
690 ± 212** 1337 ± 242* 663 ± 426  
Participant characteristics for less active short sleepers (LASS), more active short sleepers 
(MASS) and longer sleepers (LS). BMI = body mass index; FM = fat mass; VAT = visceral 
adipose tissue; CHO = carbohydrate; TST = total sleep time; MVPA = moderate-to-vigorous 
physical activity. P < 0.05 used for significance. * indicates difference from LS. ** indicates 
difference from MASS. Data are mean ± SD. n = 20 for each group.  
 
6.3.2 Metabolic markers 
Metabolic markers for each group are presented in Table 6.2. There was a 
significant difference in HDL cholesterol between groups (P = 0.024). Post-hoc 
analyses revealed HDL cholesterol was significantly lower in LASS compared to LS 
(P = 0.038) and MASS (P = 0.050), but no differences were observed between 
MASS and LS (P = 1.000). No differences were observed between groups for 
adiponectin (P = 0.315), triglycerides (P = 0.909), total cholesterol (P = 0.290), LDL 
cholesterol (P = 0.076), fasting glucose (P = 0.710), and TG to HDL ratio (P = 
0.553) (Table 6.2). 
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Table 6.2. Metabolic markers in each group. 
 LASS MASS LS 
HDL (mmol/L)† 1.12 ± 0.06 1.31 ± 0.06* 1.32 ± 0.05* 
Triglycerides 
(mmol/L) 
1.14 ± 0.10 1.13 ± 0.18 0.81 ± 0.06 
Total cholesterol 
(mmol/L)† 
4.14 ± 0.2 4.41 ± 0.2 4.5 ± 0.2 
LDL (mmol/L)† 2.35 ± 0.21 2.73 ± 0.20 2.73 ± 0.18 
TG:HDL 1.28 ± 0.16 1.03 ± 0.26 0.62 ± 0.06 
Glucose 
(mmol/L)† 
5.03 ± 0.14 5.15 ± 0.14 5.13 ± 0.13 
Adiponectin 
(µg/mL) 
10.13 ± 1.05 12.18 ± 1.18 13.71 ± 1.00 
Data are adjusted means (†) or geometric means ± SEM. LASS = less active short sleepers, 
MASS = more active short sleepers, and LS = longer sleepers. Adjusted for sex, BMI, 
energy intake, fat mass, and visceral adipose tissue mass. P = 0.05 used to indicate 
significance.* indicates significantly different from LASS. n = 20 for each group.  
 
 
 Discussion 
The current study aimed to examine if differences in habitual sleep duration and 
physical activity determined any differences in serum markers of glycaemic control. 
It was hypothesised that less physically active shorter sleepers would have altered 
markers of glycaemic control compared to longer sleepers, but that there would not 
be a difference between more active short sleepers and longer sleepers. The 
findings do not demonstrate any evidence of altered markers of glycaemic control 
between sleep durations and physical activity levels for most markers, with the 
exception of HDL cholesterol, which showed reduced levels of HDL cholesterol in 
the less physically active short sleepers compared to the more physically active 
short sleepers and longer sleepers.  
There was no evidence of a difference between groups for glucose, adiponectin, 
total cholesterol, LDL cholesterol, triglycerides or TG-to-HDL ratio. This is in 
contrast to some previous studies showing differences in these markers between 
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sleep durations (Kaneita et al., 2008) but in agreement with others (Anujuo et al., 
2015; Bjorvatn et al., 2007; Bos et al., 2019). Bjorvatn and colleagues (2007) initially 
showed significant relationships between short sleep duration and triglycerides and 
total cholesterol, however this association was mitigated when confounding factors 
were included. The findings of the present study did show HDL cholesterol was 
lower in short sleepers who were less active compared to short sleepers who were 
more active and longer sleepers. Research examining HDL cholesterol and sleep 
duration is limited, however a few studies have demonstrated positive associations 
between shorter sleep durations and lower HDL cholesterol (Kaneita et al., 2008; 
Lin et al., 2017; Potter et al., 2017). The findings of the present study suggest that 
physical activity may possibly improve HDL cholesterol in short sleepers.  
Previous research has demonstrated mixed findings with regards to whether or not 
habitual short sleep duration affects markers of glycaemic control. Anujuo et al. 
(2015) did not observe associations between sleep duration and glycaemic control. 
However, significant differences in markers of glycaemic control according to sleep 
duration were found in multiple studies including those by Whitaker et al. (2018) and 
Kaneita et al. (2008). It is unclear why there are differences between study findings, 
however, it could be speculated that the discrepancies are due to the confounding 
factors included in the analysis, and the method by which variables were measured. 
Studies employing self-reported tools are at risk of overestimation of sleep duration 
and physical activity (Dyrstad et al., 2014; Lauderdale et al., 2008b). Additionally, a 
number of previous studies did not adjust for dietary intake. Short sleep is known to 
be associated with altered macronutrient intake, including increased total fat intake 
(Grandner et al., 2010). Fat intake shows positive associations with HbA1c (Harding 
et al., 2001), and therefore dietary intake should be considered in studies examining 
sleep duration and glycaemic control. Furthermore, body composition is known to 
be a factor associated with risk of developing type 2 diabetes (Yeung et al., 2019) 
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and should be adjusted for when analysing such data. The current study used 
objective measures to control for multiple confounding factors known to be 
associated with glycaemic control, such as DXA scanning for body composition and 
actigraphy for physical activity and sleep. The findings did not demonstrate 
differences between shorter and longer sleepers for any markers with the exception 
of HDL cholesterol, suggesting that confounding factors such as body composition, 
dietary intake, and physical activity may mediate the positive relationship between 
sleep duration and glycaemic control that was observed in previous studies.  
An alternative explanation for the discrepancies in study findings could be related to 
sleep duration thresholds. Previous research that has observed differences in 
markers of glycaemic control examined individuals sleeping less than five hours 
compared to individuals sleeping 7 to 8 hours (Kaneita et al., 2008; Whitaker et al., 
2018). However, in the current study, the short sleep duration groups slept between 
5 and 6 hours, which was compared to 7 - 8 hours. It could be speculated that there 
is a threshold habitual sleep duration below which there are metabolic 
consequences, and that the short sleep durations in the present study were not 
short enough to observe these effects. In agreement with this, a previous study did 
not demonstrate significantly increased odds of developing metabolic syndrome 
when comparing a group with an average sleep duration of 5.88 hours to a group 
who had an average sleep duration of 7.26 hours (Potter et al., 2017), reflecting the 
durations in the current study. 
The present study design has multiple strengths. Firstly, it was conducted in the 
free-living environment, and therefore has higher ecological validity than controlled 
laboratory-based studies. Whilst controlled laboratory studies are useful for 
determining preliminary findings and understanding mechanisms, the results may 
not always transfer to the free-living environment in which the environment 
influences lifestyle factors such as diet, physical activity and sleep. Secondly, 
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objective measures were used where possible, such as DXA scanning for body 
composition and actigraphy for sleep and physical activity. These measures remove 
the potential for underestimation and overestimation, which is often associated with 
self-reported measures (Dyrstad et al., 2014; Lauderdale et al., 2008b). In contrast, 
the study did not include more active longer sleepers. Therefore, it is unclear if the 
differences in markers of glycaemic control between sleep durations would be more 
pronounced if more active longer sleepers were included. Individuals who are 
generally more physically active tend to have improved markers of glycaemic 
control including cholesterol and triglycerides (Monda et al., 2009), and 
consequently, it would have been useful to examine any differences between more 
active longer sleepers and shorter sleepers. Furthermore, the sample size is small, 
and data were captured at only one timepoint. Thus, it is not possible to determine 
how markers would have changed over time if short sleep was continued for several 
months or years. 
In summary, the findings of the present study suggest that overall markers of 
glycaemic control do not appear to be different between longer and shorter sleepers 
when confounding variables are accounted for, but that there may be a difference in 
HDL cholesterol between longer and shorter sleepers which is mitigated when 
habitual physical activity is higher. 
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Chapter 7 - General Discussion 
 Overview 
Short sleep durations are common amongst adults in the United Kingdom, with 
almost three-quarters sleeping less than 7 hours each night (The Sleep Council, 
2017). In parallel with the increase in short sleep durations is the rise in the 
prevalence of type 2 diabetes (Sharma et al., 2016). Observational studies have 
demonstrated associations between short sleep durations and increased risk of 
developing type 2 diabetes (Gangwisch et al., 2007; Yaggi et al., 2006); and 
experimental studies have established impaired insulin sensitivity after sleep 
restriction (Zhu et al., 2019). However, little research has focussed on solutions to 
combat these metabolic consequences of sleep restriction. Furthermore, research 
often overlooks other lifestyle factors that link poor sleep to impaired glucose 
control. 
The research in this thesis has examined the interaction between short sleep, 
exercise, and glycaemic control in healthy individuals. Specifically, the primary aims 
were three-fold: i) to understand the impaired glycaemic response to glucose intake 
over consecutive nights of sleep restriction (Chapter 4); ii) to investigate if exercise 
has the potential to alleviate the sleep restriction induced impairment in insulin 
sensitivity (Chapter 5); iii) to determine if these factors act in a similar manner when 
transferred to the free-living environment (Chapter 6). A secondary aim was to 
investigate if changes in lipid profiles were involved in mediating the impairment in 
insulin sensitivity arising from sleep restriction in controlled (Chapter 5) and free-
living settings (Chapter 6). Consistent with these aims, the main findings in this 
thesis were that: i) there did not seem to be a cumulative effect of the number of 
nights of sleep restriction on the impairment in glucose regulation; ii) acute exercise 
may be beneficial for the late postprandial response after acute short sleep; iii) 
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when confounding factors are accounted for, there does not appear to be an impact 
of habitual short sleep on markers of glycaemic control. There was also no evidence 
of changes in lipid metabolism after acute sleep restriction, suggesting alternate 
mechanisms may be responsible for these changes. Collectively, these findings 
indicate that exercise may have the potential for beneficial metabolic health in short 
sleepers in acute settings, but further study is required under chronic conditions.  
 
 Summary of chapters and main findings 
Whilst there is an abundance of studies examining sleep restriction and glycaemic 
control (Zhu et al., 2019), it remained unclear if the impairment in glucose control 
was exacerbated with each consecutive night of sleep restriction. Due to the 
differing methodologies employed for inducing sleep loss and measuring glucose 
control, directly comparing existing studies is challenging. Determining the manner 
in which insulin sensitivity is impaired is of importance to inform future sleep studies 
that will examine potential mechanisms or studies that employ interventions to 
mitigate the metabolic consequences of sleep restriction. Chapter 4 aimed to 
address this gap in the literature and establish a foundation for the subsequent 
study which was presented in Chapter 5. A 4-night sleep restriction protocol was 
used with oral glucose tolerance tests conducted each morning to determine 
differences in serum glucose and insulin profiles. Consistent with previous research 
outlined in Chapter 2, four nights of sleep restriction to four hours per night 
significantly impaired insulin sensitivity. However, the findings indicated that the 
impairment in glycaemic control was similar across the four nights. This suggests 
that one night of sleep restriction to 4 hours could induce a metabolic impairment 
with no further decline following subsequent nights. This important novel finding 
informs future studies that employ sleep restriction protocols to induce metabolic 
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changes. Implementing a single night of sleep restriction may provide minimum 
burden to participants while still achieving intended outcomes.  
Chapter 5 utilised the findings from Chapter 4 to explore if exercise could alleviate 
impaired glucose regulation after sleep restriction. In addition, this chapter also 
examined if changes in serum lipids contributed to this impairment. Recent evidence 
has shown that two weeks of exercise training can subsequently improve the insulin 
response to total sleep deprivation (De Souza et al., 2017). Accordingly, it was 
hypothesised that an acute bout of exercise would have similar outcomes following 
partial sleep restriction. After a single night of sleep restriction to four hours and 
either sprint interval exercise or no exercise, serum markers of glycaemic control 
were measured in response to an OGTT. As expected, sleep restriction increased 
the insulin response to glucose intake. Exercise after sleep restriction did not alter 
the total insulin AUC, but there was a reduction in late-phase insulin AUC when 
compared to sleep restriction alone. Late-phase AUC is an important aspect of 
postprandial metabolism. An improvement in late-phase AUC can be indicative of a 
reduced risk of developing type 2 diabetes (Hayashi et al., 2013; Lorenzo et al., 
2012). A later peak or more prolonged increase in insulin concentrations suggest an 
increased beta-cell insulin secretory response due to diminished insulin sensitivity 
(Hayashi et al., 2013). Findings did not demonstrate any significant changes in 
triglycerides after sleep restriction or exercise, indicating that a change in 
triglycerides is unlikely to be a major contributor to the changes in glucose 
regulation after acute sleep restriction. 
Short-term intervention studies, using controlled measures, are very useful to 
determine physiological responses. However, it is important to explore how well 
these findings transfer to the free-living environment when behaviours are 
uncontrolled and influenced by many external factors. Chapter 6 aimed to 
investigate differences in glycaemic control between individuals of different habitual 
103 
 
sleep durations as well as those with differing physical activity levels in a free-living 
setting. Multiple measures were used to obtain an overview of the major factors that 
can influence glycaemic control, including diet and body composition. Groups were 
formed according to habitual sleep duration and short sleepers were further split 
according to habitual physical activity levels. The results revealed a lack of 
significant differences between groups for markers of glycaemic control. These 
findings agree with some previous work indicating that habitual short sleep duration 
may not be primarily responsible for the increased risk of metabolic disorders. 
However, HDL cholesterol concentrations were lower in less active short sleepers 
compared to longer and more active short sleepers, suggesting that physical activity 
potentially rescues the decrease in HDL cholesterol during habitual short sleep.  
 
 Reduced sleep quantity and impaired glycaemic control 
Chapters 4 and 5 add to the current body of literature by highlighting changes in 
glycaemic control after a single night of sleep restriction to four hours. Whilst this 
has been previously shown (Donga et al., 2010), this was not systematically 
addressed over multiple nights of restriction. The exact mechanisms which lead to 
this impairment are yet to be elucidated. Arguably, the most strongly suggested 
mechanism is alterations in peripheral tissue insulin sensitivity. Rao and colleagues 
(2015) demonstrated changes in peripheral, but not hepatic, insulin sensitivity after 
five nights of four hours sleep in healthy individuals. This change was accompanied 
by increased non-esterified fatty acids (NEFAs), suggesting that a change in lipid 
metabolism may have played a role in altering peripheral insulin sensitivity. 
Furthermore, we and others have previously shown potential changes in the insulin 
signalling pathway in peripheral tissues after sleep restriction (Broussard et al., 
2012; Sweeney et al., 2017). Akt activity and phosphorylation in skeletal muscle and 
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adipocytes were reduced after partial sleep restriction to two nights of 50% of 
habitual duration and four nights of 4.5 hours sleep per night, respectively, in 
healthy males.  
Altered lipid metabolism, including increased NEFA and triglyceride concentrations, 
can negatively impact peripheral insulin signalling (Saltiel & Kahn, 2001), and it 
could therefore be suggested from previous literature that an alteration in lipid 
metabolism induces changes in peripheral insulin sensitivity after sleep loss. In 
Chapter 5, triglycerides were measured to assess altered lipid metabolism as a 
potential mechanism and no significant changes in triglycerides between conditions 
were observed. However, the possibility that changes in lipid metabolism were 
contributing to the reduced insulin sensitivity cannot be ruled out. Rao and 
colleagues (2015) demonstrated decreased triglycerides in combination with 
increased NEFAs, and proposed that this combination may have been due to 
preference for gluconeogenesis rather than de novo lipogenesis during sleep loss. 
Therefore, it is possible that detecting changes may require simultaneous 
measurement of triglycerides and NEFAs.  
Habitual short sleep is often also associated with impaired metabolism (Iftikhar et 
al., 2015). Proposed mechanisms include altered appetite hormones and timing of 
food intake, changes in body composition, and underlying sleep disorders (Balkau 
et al., 2010; Moller-Levet et al., 2013; Schmid et al., 2015; Taheri et al., 2004). The 
study presented in Chapter 6, however, demonstrated contrasting findings, 
displaying no differences in glycaemic control between individuals sleeping 5-6 
hours each night and those sleeping 7-8 hours per night. There are several potential 
explanations for the differences between study findings, one being that confounding 
factors may mediate such differences. For example, in some studies, significant 
relationships were observed initially but were reduced or completely mitigated when 
confounding factors, such as sex and BMI, were included in analysis (Ayas et al., 
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2003; Bjorvatn et al., 2007). An alternative explanation may be due to the nature of 
the study design (i.e. an observational study). With such studies, it is difficult to 
establish cause and effect, and may indeed be a reverse causality issue. Insulin 
resistance may lead to disrupted sleep or even short sleep duration. Evidence 
shows that insulin resistance is associated with an increased risk of developing 
sleep disorders such as obstructive sleep apnea (Balkau et al., 2010), which is often 
characterised by disrupted and short sleep.  
 
 Exercise, physical activity and metabolic function in sleep 
restricted individuals 
The role of exercise and physical activity within sleep and metabolism is an 
underexplored area that is only just beginning to be developed. The findings in 
Chapter 5 have added to the body of literature, illustrating for the first time that 
sprint interval exercise can improve late-phase postprandial insulin response after 
sleep restriction to four hours. However, Chapter 6 revealed no differences in 
biomarkers of glycaemic control between more and less physically active individuals 
sleeping 5-6 hours.  
Acute exercise is known to improve glycaemic control through insulin dependent 
and independent mechanisms (Wojtaszewski & Richter, 2006), particularly in the 
peripheral tissues. Esbjörnsson-Liljedahl et al. (2002) have shown that sprint 
interval exercise on a cycle ergometer reduces muscle glycogen content by more 
than 50%. As a result, glucose uptake into skeletal muscle is increased, with an 
estimated 40% of an oral glucose bolus used for this purpose (Hickner et al., 1997; 
Kelley et al., 1988). Using a similar protocol to Esbjörnsson-Liljedahl and 
colleagues, Chapter 5 has demonstrated changes in the late-phase postprandial 
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insulin response after exercise, which has also been observed by others (Rynders 
et al., 2014). However, total AUC for insulin was not altered which may be due to 
the timepoint at which the OGTT was conducted. Exercise inflicts a temporary 
increase in glucose concentrations, which may be caused by increased 
gluconeogenesis and increased catecholamines. These temporary changes appear 
to last around thirty minutes after a session of high intensity exercise (Rynders et 
al., 2014). Thus, it is likely that any possible improvements in insulin sensitivity did 
not become apparent until longer after cessation of exercise and the collection of 
glycaemic markers.  
Chronic physical activity is also well established to have positive effects on 
cardiometabolic markers (Grgic et al., 2018). More specifically, moderate to 
vigorous physical activity is associated with decreased risk of type 2 diabetes 
incidence (Sternfeld et al., 2019). Given the association between sleep duration and 
risk of developing type 2 diabetes, Chapter 6 aimed to investigate the role of MVPA 
in individuals with short sleep duration. Findings from the chapter did not 
demonstrate an effect of sleep duration or physical activity on biomarkers of 
glycaemic control. While it is difficult to determine why this is the case, it could be 
speculated that since no differences were observed between groups of different 
sleep duration, the role of physical activity to attenuate any impairment in glycaemic 
control would be minimal. Furthermore, the physical activity levels of each group 
were much greater than the minimum recommended level (less active group ~690 
MET.min/day vs. recommended activity ~86 MET.min/day) (Kyu et al., 2016). Given 
such differences, it is unlikely that increases in physical activity will yield large 
benefits in glycaemic control. Kyu et al. (2016) have detailed a dose response curve 
for physical activity and diabetes risk in a recent meta-analysis. Results from the 
study indicate that major benefits occurred at around 571 MET.min/day with 
diminishing benefits from greater levels of physical activity. Increases in those with 
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high physical activity levels (from 1285 MET.min/day to 1714 MET.min/day) reduced 
the risk of diabetes by only 0.6%.  
Findings from Chapter 6 have revealed reduced HDL cholesterol in the less active 
short sleepers compared to longer sleepers. In addition, physical activity in the short 
sleepers improves HDL cholesterol. Few studies have investigated physical activity, 
sleep and cholesterol. However, studies reallocating sleep time with moderate-to-
vigorous physical activity show possible benefits on metabolic biomarkers (Grgic et 
al., 2018). Replacing thirty minutes of sleep each day with MVPA showed more 
favourable HDL cholesterol, triglycerides, glucose, insulin, and insulin sensitivity 
(Buman et al., 2014). Similarly, Chastin et al., (2015) showed that whilst sleep is 
beneficial for obesity and blood pressure, it may have negative consequences for 
metabolic biomarkers if sleep is favoured over MVPA.  
Taken together, these findings suggest that exercise may exhibit beneficial effects 
on glycaemic control in sleep restricted individuals in the acute setting but that the 
effect of chronic physical activity and short sleep duration on glycaemic control is 
less clear, and therefore warrants further study.  
 Limitations 
Whilst specific limitations have been highlighted in each chapter, there are some 
limitations which are common between studies. Firstly, the studies in this thesis 
were designed to focus on healthy individuals. The findings therefore cannot be 
extrapolated to individuals with existing metabolic disorders such as type 2 
diabetes. Additionally, the samples used were relatively homogenous in that the 
majority of participants were aged 18 to 50 years old. Although similar findings 
between sleep duration and glycaemic control have been observed in younger and 
older age groups, results have been mixed and other factors may begin to 
contribute to a decline in glycaemic control in ageing individuals (i.e. those over 60 
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years old (Imbeault et al., 2003; Shimokata et al., 1991). All participants in the 
studies presented in this thesis were nocturnal sleepers and did not have any sleep 
disorders. In populations where sleep is misaligned with the natural circadian 
rhythms, such as shift workers, insulin sensitivity may be influenced by factors other 
than sleep duration. For example, circadian misalignment in shift workers has been 
demonstrated to disrupt insulin sensitivity independent of sleep duration (Leproult et 
al., 2014). The findings in this thesis should therefore be interpreted with caution 
when referring to populations other than those used in the three studies presented.  
In the studies presented in Chapters 4 and 5, glycaemic control was measured 
using an OGTT, and insulin sensitivity was estimated using the Matsuda index and 
HOMA. Whilst it has been demonstrated that these surrogate measures of insulin 
sensitivity relate well to insulin sensitivity measures obtained from the 
hyperinsulinemic-euglycaemic clamp method, it is not possible to obtain detailed 
information about glucose uptake and effectiveness from an OGTT. Therefore, the 
exact nature of the impairment in glucose regulation which occurred in these studies 
is unclear. However, it may be argued that the OGTT is ecologically superior to a 
method such as the hyperinsulinemic-euglycaemic clamp due to oral ingestion of 
the glucose rather than an intravenous infusion. Furthermore, in these chapters 
many aspects of lifestyle which are known to influence glycaemic control were 
controlled and replicated across conditions. Whilst a controlled design is useful for 
examination of novel concepts, it should be acknowledged that this does not fully 
reflect a free-living setting in which food intake and physical activity are likely to 
differ.  
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 Conclusion and future research directions  
The main aim of this thesis was to explore the link between short sleep, glycaemic 
control, and physical activity. The studies presented in this thesis have confirmed 
previous research demonstrating an impairment in glycaemic control after acute 
sleep restriction, highlighting the importance of sleep in addition to diet and physical 
activity for modulating insulin sensitivity. However, when transferred to the chronic 
setting, findings were contradictory, showing no evidence of differences in markers 
of glycaemic control, except for HDL cholesterol. This adds to the mixed findings in 
the current body of literature, suggesting further work in this area is required to 
elucidate the role sleep plays in long term metabolic health. This thesis provides 
preliminary data which suggests a potential benefit of exercise in attenuating the 
negative metabolic consequences of short sleep in an acute, controlled setting.  
From a practical perspective, it can be suggested that sufficient sleep should be 
included as part of a healthy lifestyle to prevent declines in metabolic health. In 
those individuals who experience acute sleep restriction, it may be advantageous to 
conduct a bout of sprint interval exercise following the night of short sleep to 
counteract the impairment in insulin sensitivity which occurs after sleep loss.  
However, as the research examining this topic is just beginning to emerge, there are 
many unanswered questions which provide scope for future research. These 
include investigating the effect of different exercise modalities, timings, and 
durations after sleep restriction, and examining the time-course of improved insulin 
sensitivity following an exercise bout in sleep-restricted individuals. Whilst 
improvements in glycaemic control have been observed with sprint interval exercise, 
resistance exercise may be superior to sprint interval exercise for reducing insulin 
AUC and improving insulin sensitivity (Tong et al., 2017). Furthermore, the 
impairment in glucose regulation after insulin sensitivity may be due to 
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compromised insulin signalling within skeletal muscle (Sweeney et al., 2017). Acute 
resistance exercise can enhance glucose uptake in skeletal muscle and research 
has shown increased phosphorylation of components of the insulin signalling 
pathway in skeletal muscle for up to 26 hours following cessation of exercise (Breen 
et al., 2011). Hence, resistance exercise may provide superior effects on insulin 
sensitivity after sleep restriction compared to sprint interval exercise, and thus is an 
area which warrants further study.  
It would also be of interest to examine the time course of impaired glycaemic control 
following sleep restriction, and to determine if underlying mechanisms differ 
according to the severity of sleep duration, either in number of nights or duration of 
restriction each night. Future research could therefore use different sleep restriction 
protocols and simultaneously measure variables which are proposed to contribute to 
the impairment in glucose regulation after sleep restriction, such as insulin signalling 
in skeletal muscle and adipose tissue, systemic inflammation, and circadian gene 
expression. This would enable interventions to be targeted towards a specific 
mechanism or mechanisms.  
Future research may also focus on the link between sleep, physical activity, and 
glycaemic control in the chronic setting. Longer term studies using objective 
measures such as actigraphy to measure sleep and physical activity are warranted, 
as well as tracking how changes in sleep duration and physical activity over a 
prolonged period impacts glycaemic control. Studies such as these could employ 
more robust measures of glycaemic control such as an OGTT or continuous 
glucose monitoring, rather than obtaining a single sample as was done in the study 
presented in Chapter 6. This would enable more detailed information to be collected 
about glycaemic control status.  
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To summarise, this thesis has provided novel findings which show that i) there does 
not appear to be a linear increase in the impairment of glycaemic control with an 
increasing number of nights of sleep restriction, ii) acute sprint interval exercise may 
be beneficial for improving the late postprandial response to an OGTT after sleep 
restriction, and iii) the link between habitual sleep duration and glycaemic control 
may be influenced by confounding factors, suggesting that a multi-factorial 
approach should be taken to achieve optimal metabolic health. Future research can 
build upon these findings to address the gaps in the literature which will advance 
understanding in the field of sleep, exercise and glycaemic control.  
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Appendices 
Appendix A1- Participant Information Sheet (Chapter 4) 
 
Study Title: Sleep restriction and impaired glucose 
regulation – a dose-response study 
Investigator: Emma Sweeney 
 
 
Participant Information Sheet 
 
You are being invited to take part in this research study.  Before you decide it is 
important for you to read this leaflet so you understand why the study is being 
carried out and what it will involve. 
 
Reading this leaflet, discussing it with others or asking any questions you might 
have will help you decide whether or not you would like to take part. 
 
 
What is the Purpose of the Study 
 
This study aims to determine how partial sleep restriction impacts blood glucose 
control, insulin sensitivity and inflammation within the body. 
 
Studies have shown that lack of sleep can have negative effects on metabolic 
function, particularly the control of blood glucose levels. However, it is unknown 
whether the effects worsen if sleep loss increases or if the effect is the same 
regardless of how much sleep is lost. Why blood glucose control is affected by sleep 
restriction is also unknown, but increased inflammation may be one possibility. This 
study will therefore aim to investigate blood glucose control and levels of 
inflammation in the body after each night of sleep restriction. We will also 
investigate whether sleep structure (amount of deep sleep, how long it takes to fall 
asleep, etc.) changes in response to sleep loss. 
 
Why have I been invited? 
 
You have been invited to participate in this study because you: 
✓ Are a healthy individual aged between 18 and 40 years old 
✓ Have a normal sleep pattern (7-9 hr sleep per night) 
✓ Do not smoke 
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Due to the nature of the study you cannot take part if you suffer from a 
neurological disorder, psychiatric disorder, metabolic disorder (e.g. impaired 
glucose tolerance or diabetes), inflammatory disorder (e.g. inflammatory bowel 
disease), sleep disorder or blood clotting disorder (e.g. hemophilia). If you are 
taking medication which impacts metabolism (e.g. metformin or other blood 
glucose control medication) or inflammation (e.g. immunosuppressants) you will 
also be unable to participate. You will also not be able to take part if you are a shift 
worker, have travelled over time zones in the past 4 weeks or have recently been 
involved in drug or alcohol abuse, as these may affect your circadian rhythm which 
will influence study results. If you have an allergy to dextrose (a type of sugar) you 
cannot take part as this will be used in the oral glucose tolerance test. 
 
Do I have to take part? 
 
No. Taking part in this study is completely voluntary and it is your decision whether 
or not you wish to take part. If you decide to take part you may withdraw from the 
study at any time without questioning. Participation is voluntary so no judgement 
will be made should you decide you do not wish to take part either before or during 
the study. 
 
What will happen if I take part? 
 
This study will involve a 2-week preliminary phase and 2 experimental phases, during 
which sleep will be restricted to 4 or 8 hours per night. The preliminary phase will 
involve a one night stay in the sleep laboratory to measure your sleep structure, and 
each experimental phase will involve a four night stay in the sleep laboratory. 
Experimental visits will be separated by a period of at least 3 weeks. During your stay 
in the sleep laboratory you will be allowed to leave once testing has finished (around 
10am) each day, but must return to the sleep laboratory at 7pm each night for your 
overnight stay. During the times you are not in the sleep laboratory you will not be 
allowed to do any physical activity, nap or consume any foods except those provided 
by the researchers. If you are sleep restricted please also avoid driving as your 
reaction times may be slower than usual. 
 
Preliminary Phase 
During the 2 week preliminary phase you will be issued with an actigraphy watch 
which you must wear on your wrist at all times and a sleep diary to complete every 
morning for the two weeks. You will also be given a 3 day food diary to complete in 
week one which will allow us to individualise your diet to your likes and dislikes 
during your stays in the laboratory. Females will also be required to complete a 
menstrual cycle questionnaire so that both experimental trials can be conducted 
during the same phase of the menstrual cycle. During the preliminary phase you will 
be asked to have around 7 to 9 hours of sleep each night, and to keep a consistent 
wake time in the mornings. In the middle of the 2-week preliminary phase you will 
stay over in the sleep laboratory for one night, where your sleep will be measured 
(explained below). This will give us an indication of your sleep structure and identify 
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any possible sleep problems. This preliminary phase will be repeated prior to the 
second experimental phase. 
 
Experimental Phase 
Each experimental phase will involve 4 nights in the sleep laboratory. In the 24 hr 
prior to attending you will be asked to avoid any vigorous exercise or caffeine 
consumption. You will arrive at the sleep laboratory in the evening before the first 
night of experimental sleep. 
Each morning an oral glucose tolerance test (OGTT – procedure explained below) will 
be carried out. During the OGTT blood samples will be obtained at regular intervals. 
The procedures for these are also outlined below.  
You will then be allowed to leave the sleep laboratory and return at 7pm. Each night 
you will sleep for either 4 or 8 hours depending on the condition you have been 
assigned to. As your bed time will be delayed in the sleep restriction condition you 
may watch television, do work, read, etc. during this time. On the first and third night 
in each condition sleep structure will be measured. You will also be asked to complete 
appetite scales before and after each meal every day. After the OGTT on the final 
morning you will be instructed to have a recovery sleep if you have been sleep 
restricted.  
 
Oral Glucose Tolerance Test 
For the OGTT you will be given a drink containing 82.5 g dextrose (a type of sugar) 
mixed with 300 ml of water, which you will be asked to consume within 5 minutes. 
Following this, blood samples will be collected at regular intervals, as outlined below. 
 
Blood sampling 
Blood samples will be obtained via the cannulation technique. A cannula will be 
inserted into the antecubital vein in the arm to allow regular blood samples to be 
drawn. Blood samples will be drawn at baseline (0), 15, 30, 45, 60, 90 and 120 min 
following consumption of the dextrose drink.  
 
Measurement of sleep structure 
Measurement of sleep structure involves the attachment of electrodes to the head 
in order to gain measures such as total sleep time, time spent in each stage of sleep 
and sleep efficiency. This is a painless process. All electrodes will be attached by a 
trained researcher before you go to sleep and you will then be left to sleep 
uninterrupted until the morning. Electrodes will then be removed upon wakening. 
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The Sleep Laboratory 
 
 
The sleep laboratory, pictured above, is fully equipped with a bedroom, en-suite 
bathroom, kitchen, and lounge. During your stay you will not be permitted to leave 
but may use the facilities within the sleep laboratory and may also bring your 
laptop/tablet/etc. There will be a staff member around at all times should you have 
any questions or problems during your stay. You should have also been given an 
information sheet for overnight stays in the sleep laboratory – please read that in 
conjunction with this information sheet before deciding if you would like to 
participate as it contains more detail on what your stay would entail. 
 
Does the study involve any discomfort or embarrassment? 
 
This study involves collection of blood samples using the cannulation technique. 
There may be slight discomfort whilst the cannula is inserted however any 
discomfort experienced should be mild and only last a short period of time. Whilst 
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the cannula is left in for the duration of the OGTT discomfort should be minimal, 
often not being felt at all. A risk assessment has been carried out for the collection 
of blood samples. Please note that should any abnormalities be found during sleep 
or from blood samples you will be advised to inform your general practitioner of 
these findings. No psychological embarrassment will be involved in this study. 
What are the possible benefits of taking part? 
 
By taking part in this study you will be contributing to research to develop insight 
into the way sleep duration can impact metabolic health. This research may have 
implications for individuals at risk of developing metabolic disorders and those who 
regularly curtail their sleep. 
 
Will I be reimbursed for participating in the study? 
 
Due to the large time commitment involved, you will be issued with £160 of 
Love2Shop gift cards for participating in the study. These can be spent at a large 
number of leading retailers. A full list of retailers can be found online 
(https://www.highstreetvouchers.com/gift/where-to-spend-love2shop-cards) 
 
Will my taking part in this study be kept confidential and anonymous? 
 
Yes. You will be assigned a unique reference number for the study which means you 
will remain anonymous. All data will be anonymized. When the data is used it will 
be collated with that of the other participants and will in no way be linked back to 
you. Only the researchers will have access to the individual data sheets. Data sheets 
will be stored separately from consent forms. 
How will my data be stored? 
 
All data which is in paper form will be stored in a locked filing cabinet within the 
Faculty of Health & Life Sciences at Northumbria University. Electronic data will be 
stored on a password protected computer. Data will be stored in accordance with 
University guidelines and the Data Protection Act (1998) will be followed. 
 
How will the results of this study be used? 
 
On completion of the study results will be collated with those of the other 
participants and will in no way be linked back to you. Findings may be published in 
scientific papers or presented at conferences. If you would like a copy of the 
summary of findings you may contact the researcher at the email address given 
below and you will be issued a copy once the study has ended. Please note that 
individual data will not be issued and collated findings will not be available 
immediately after completion of the study. 
 
Who is Organizing and Funding the Study? 
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This study has been organised by researchers within the Department of Sport, 
Exercise and Rehabilitation at Northumbria University. The principal investigator is 
Emma Sweeney (doctoral researcher). No funding has been sought from external 
sources. 
 
Who has reviewed this study? 
 
This study has been reviewed and approved by the Faculty of Health and Life 
Sciences Research Ethics Committee at Northumbria University.  
Should you require any information about the ethical aspects of this study please 
contact: 
Dr Mick Wilkinson 
Northumberland Building 
Northumbria University 
Newcastle upon Tyne 
NE1 8ST 
Email: mic.wilkinson@northumbria.ac.uk 
 
 
 
 
 
Contact for further information: 
 
Emma Sweeney (principal researcher) – emma.sweeney@northumbria.ac.uk 
 
Name of another person who can provide independent information or advice 
about the project: 
Mick Wilkinson – mic.wilkinson@northumbria.ac.uk 
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Appendix A2 – Participant Information Sheet (Chapter 5) 
Faculty of Health & Life Sciences 
PARTICIPANT INFORMATION  
TITLE OF PROJECT: The effect of exercise on glucose regulation following acute sleep 
restriction 
 
Participant ID:   
 
Principal Investigator: Emma Sweeney (PhD researcher) 
Investigator contact details:     Email: emma.sweeney@northumbria.ac.uk  
 
1. What is the purpose of the project? 
Sleep duration has been shown to impact health, with insufficient sleep being associated with a 
higher risk of developing metabolic disorders such as diabetes. Sleep restriction can impair blood 
glucose control even in healthy individuals. However, it remains unknown whether exercise, 
which has positive effect on glucose metabolism, can help the impairment in blood glucose 
regulation after sleep restriction. 
 
2. Why have I been selected to take part? 
You have indicated that you are: 
• interested in taking part in the study 
• male 
• healthy 
• aged 18-50 years (inclusive)  
• non-smoker 
Additionally, please read the next section which outlines the exclusion criteria. 
 
3. What are the exclusion criteria (i.e. are there any reasons why I should not take part)?  
Participants complying with at least one of the following criteria will not be eligible:  
 
• Participants diagnosed with at least one of the following will not be eligible:  
- diabetes (type I or type II), or any other disorder likely to affect 
metabolism  
- blood clotting disorder 
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- sleep disorder (such as obstructive sleep apnea)  
• Taking any medication known to affect metabolism or sleep 
• Working in shift schedules (ex: nurse, baker, etc.)  
• Regular travel across time zones (>3 times a year) or travel across time zones in 
the past 4 weeks 
• A bedtime before 22:00 or after 01:00, or a wake time before 06:00 or after 09:00 
• A history of alcohol or drug abuse  
• Eating disorders: anorexia and bulimia or unstable dietary pattern;  
• A psychological or linguistic inability to sign the informed consent;  
 
If you are unsure about your eligibility then please contact the research team and we 
can discuss any issues or ambiguity. 
 
We cannot list every individual medical condition and medication in the exclusion criteria; 
if you have any health issues or are taking any medications (prescribed or over the 
counter) you are encouraged to check with the research team that these do not exclude 
you from the study before you attend the lab. These criteria are study specific, so whilst 
one study may allow certain medications, another may not. 
 
4. What will I have to do? 
The study will involve a prescreening/exercise testing session and 4 experimental trials 
which each require one visit to the laboratory, at least 1 week apart. There will be a 
maximum of 2 weeks between visits. A summary of the experimental visits is presented 
in the diagram below. 
Prescreening/Exercise familiarisation – 1 hour 
During the first visit you will have the opportunity to ask any questions you may have 
about the study before completing a written consent form if you are happy to take part. 
You will then be asked to complete several questionnaires related to your sleep habits 
and given a 3 day food diary (2 weekdays and 1 weekend day) to complete before the first 
experimental trial. Following this, you will complete an exercise session to become 
familiarised with the type of exercise which will be used in the experimental trials. For the 
familiarisation exercise, you will complete a 5 minute warm up, followed by two maximum 
effort 30 second sprints on the cycle ergometer, followed by a 5 min cool down. 
Experimental trials 
There are 4 experimental trials – a control trial, a control plus exercise trial, a sleep 
restriction trial, and a sleep restriction plus exercise trial. You will complete all 4 trials in 
a random order and will not be told which trial you are on until the day prior to the night 
of sleep restriction or control sleep.  
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Prior to each trial you will have a 1 week entraining period, which involves keeping a 
consistent sleep wake schedule for 7 days. During this period you will be asked to wear an 
actigraphy watch which will track your sleep and complete a sleep diary. 
Following the entraining period you will have either a night of 8 hour sleep (control and 
control plus exercise conditions) or 4 hour sleep (sleep restriction and sleep restriction 
plus exercise conditions). On the day prior to the 4 or 8 h sleep you will be required to 
keep a consistent diet across the 4 conditions. We will provide you with a diet for this day 
based on your habitual intake as determined from your food diary. You must also avoid 
alcohol, caffeine, and exercise on this day. 
In the 4 h sleep conditions, in addition to wearing the actigraphy watch, you will be 
required to send text messages to the researcher every hour between 11pm and 3am to 
ensure you are awake. You may also receive a phonecall from the researcher for this 
purpose.   
Upon wakening after your night of 4 or 8 hour sleep, you will come to the laboratory in a 
rested, fasted state. This means you will be asked to avoid all food and drink except water 
for 10 hours prior to arrival at the laboratory. When making your way to the laboratory 
please use transport where possible, unless you live within the immediate vicinity of the 
university. This is because any physical activity may influence the measures in the study. 
If you are sleep restricted please do not drive as you may have increased tiredness. 
You will then either rest or complete a high intensity cycling exercise protocol. The 
exercise protocol in the experimental conditions will be similar to the familiarisation, 
except that four maximum effort 30 second sprints will be completed rather than two. 
Sprints will be separated by 4.5 minutes of unloaded recovery. Warm up and cool down 
will remain the same. 
Following the rest or exercise, you will be given a 30 min recovery period. An oral glucose 
tolerance test (OGTT) will then be conducted. The oral glucose tolerance test involves 
insertion of a cannula into the antecubital vein in your arm. A fasted blood sample will be 
drawn from the cannula, then you will be given a glucose drink to consume. Following 
consumption of the glucose drink, blood samples will be drawn at regular intervals for 120 
min. During the 2 hours you must remain in the laboratory however you may do 
work/read/watch a film between blood samples. 
You will also be asked to collect urine samples at several points during each experimental 
visit. The timepoints for urine samples are show on the diagram below and outlined in 
section 7. These will be the second urination of the day on the day prior to each testing 
day and each testing day. You will also be asked to provide spot samples when you arrive 
at the laboratory, before the OGTT, and at the end of the OGTT. 
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All experimental visits will follow this similar protocol, but differ in the length of sleep or 
whether you are exercising or resting in the morning. 
Figure 1. Timeline of activities for experimental trials (visits 2,3,4 and 5). Red arrows indicate blood samples. 
Green arrows indicate urine samples. Sleep on experimental night will be from 11pm-7am in control conditions 
and 3am-7am in sleep restriction conditions. 8-8.30am will be rest in the two rest conditions and exercise in 
the two exercise conditions (rest shown as an example of timings). 
 
 
5. Will my participation involve any discomfort or embarrassment? 
This study involves collection of blood samples using the cannulation technique. There 
may be slight discomfort whilst the cannula is inserted, however any discomfort 
experienced should be mild and only last a short period of time. Minor bruising may also 
occur following cannulation. A risk assessment has been carried out for the collection of 
blood samples and the samples will be collected by trained researcher following 
standard operating procedures. Please note that should any abnormalities be found 
from the blood sample you will be advised to inform your general practitioner of these 
findings.  
The nature of the exercise sessions in this study are designed to be difficult. You may 
therefore find the exercise challenging. 
As you will be sleep restricted in 2 of the visits, we advise that you do not drive or carry 
out any tasks which require a high level of alertness on these days. You should have an 
extended sleep the night following sleep restriction to ensure you are recovered.  
No psychological embarrassment will be involved in this study. 
 
6. Will my participation result in any benefits to me? 
By taking part in this study you will be contributing to research to develop insight into 
the way sleep and exercise can impact metabolic health. Whilst there will be no direct 
benefit to you, the study results are intended to extend knowledge on the relationship 
between sleep, exercise, and metabolic health which may benefit others in the future. 
 
7. Will I have to provide any bodily samples (i.e. blood, saliva)?   
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Blood samples will be obtained by the cannulation technique during the OGTTs in visits 
2, 3, 4 and 5. All samples will be obtained by a trained researcher. 10ml will be obtained 
for each sample and an additional 5 ml at the beginning and end of the OGTT, so 80 ml 
will be collected in total for each visit. 
You will also provide urine samples. You will collect these yourself from the second 
urination of the day on the day prior to each testing day and each testing day. You will 
also be asked to provide spot samples when you arrive at the laboratory, before the 
OGTT, and at the end of the OGTT. 
 
 
9. Who will have access to the information that I provide? 
Only the principal investigator (Miss Emma Sweeney) and the research team will have 
access to the information that you provide. Any data that leaves the site will only be 
identifiable by an identification number and it will not be possible for anybody outside of 
the investigational site to identify you. 
 
 
8. How will confidentiality be assured? 
You will be assigned a unique reference number for the study which means you will remain 
anonymous. All data will be anonymized. When the data is used it will be collated with 
that of the other participants and will in no way be linked back to you. Only the researchers 
will have access to the individual data sheets. Data sheets will be stored separately from 
consent forms. 
All data which is in paper form will be stored in a locked filing cabinet within the Faculty 
of Health & Life Sciences at Northumbria University. Electronic data will be stored on a 
password protected computer. Data will be stored in accordance with University 
guidelines and the Data Protection Act (1998) will be followed. Data will be stored for 5 
years after completion of the study. 
10. What categories of personal data will be collected and processed in this study? 
We will collect contact details, date of birth, ethnicity and blood/urine markers of 
glycaemic control. 
11. What is the legal basis for processing personal data? 
The legal basis for processing the personal data required for the purposes of this study is 
that the research is being conducted in the public interest, necessary for scientific research 
purposes. 
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12. How will my information be used in the future? 
On completion of the study results will be collated with those of the other participants 
and will in no way be linked back to you. Findings may be published in scientific papers, 
presented at conferences, and used to form part of a thesis. 
 
13. Has this investigation received appropriate ethical clearance? 
Yes, this study has received ethical approval from the Faculty of Health and Life Sciences 
Ethics committee. If you require confirmation  of this please contact the Chair of this 
Committee, stating the title of the research project and the name of the principal 
investigator: 
Mick Wilkinson, Chair of Faculty of Health and Life Sciences Ethics Committee, 
Northumberland Building, Northumbria University, Newcastle upon Tyne, NE1 8ST 
 
14. Will I receive any financial rewards / travel expenses for taking part? 
No.  
 
15. How can I withdraw from the project? 
Participation in this study is completely voluntary. If you wish to withdraw at any point 
you can do so by contacting the principal researcher (Emma Sweeney) at the contact 
details given in section 17. Should you decide to withdraw no judgement will be made and 
you do not have to state your reason for withdrawal if you do not wish to do so. 
 
16. What are my rights as a participant in this study? 
You have the right of access to a copy of the information comprised in your personal data 
(to do so, submit a Subject Access Request). You have a right, in certain circumstances, to 
have inaccurate personal data rectified, and a right to object to decisions being taken by 
automated means. If you are dissatisfied with the University’s processing of personal data, 
you have the right to complain to the Information Commissioner’s Office.  
 
17. If I require further information who should I contact and how? 
If you need more information you should contact the principal investigator - Emma 
Sweeney: 
Email: emma.sweeney@northumbria.ac.uk 
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Tel: 0191 243 7018 
Name and contact of Data Protection Officer at Northumbria University: Duncan James 
(dp.officer@northumbria.ac.uk) 
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Appendix A3 – Participant Information Sheet (Chapter 6) 
Faculty of Health & Life Sciences 
PARTICIPANT INFORMATION  
TITLE OF PROJECT: Sleep duration and glycaemic control 
 
Participant ID:   
 
Principal Investigator: Emma Sweeney (PhD researcher) 
Investigator contact details:     Email: emma.sweeney@northumbria.ac.uk  
 
1. What is the purpose of the project? 
Sleep duration has been shown to impact health, with insufficient sleep being associated with a 
higher risk of developing metabolic disorders such as diabetes. However many studies which have 
investigated this have not taken into account the physical activity status, dietary intake, or body 
composition of the participants. All of these lifestyle factors may influence glucose control. 
Therefore, the aim of this study is to examine the relationship between sleep duration and 
glycaemic control whilst taking into account lifestyle factors which may modify this relationship. 
Additionally, part B of this study (optional – see section 4 for more information) will investigate if 
there is a difference in metabolite profile between shorter and longer sleepers. Identifying 
differences in metabolite profile will allow us to see which metabolic pathways are altered by 
sleep duration, which may help to explain why short sleepers have been shown to be at greater 
risk of developing chronic diseases such as type 2 diabetes. 
 
2. Why have I been selected to take part? 
You have indicated that you are: 
• interested in taking part in the study 
• healthy 
• aged 18-50 years (inclusive)  
Additionally, please read the next section which outlines the exclusion criteria. 
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3. What are the exclusion criteria (i.e. are there any reasons why I should not take part)?  
Participants complying with at least one of the following criteria will not be eligible:  
 
• Participants diagnosed with at least one of the following will not be eligible:  
- diabetes (type I or type II), or any other disorder likely to affect 
metabolism (eg. PCOS) 
- blood clotting disorder 
- sleep disorder (such as obstructive sleep apnea)  
- any other pathology which, according to investigator’s judgment, is likely 
to affect the study parameters 
• Taking any medication known to affect metabolism or sleep 
• Ethnicity which is not white, European descent (due to differences in circadian 
genes). 
• Working in shift schedules (ex: nurse, baker, etc.)  
• Regular travel across time zones (>3 times a year) 
• A bedtime before 22:00 or after 01:00, or a wake time before 06:00 or after 09:00 
• Change in smoking, physical activity, sleep or dietary habits in the past 3 months 
• A history of alcohol or drug abuse  
• Eating disorders: anorexia and bulimia or unstable dietary pattern;  
• Pregnancy in progress (or suspected)  
• A psychological or linguistic inability to sign the informed consent;  
 
If you are unsure about your eligibility then please contact the research team and we 
can discuss any issues or ambiguity. 
 
We cannot list every individual medical condition and medication in the exclusion criteria; 
if you have any health issues or are taking any medications (prescribed or over the 
counter) you are encouraged to check with the research team that these do not exclude 
you from the study before you attend the lab. These criteria are study specific, so whilst 
one study may allow certain medications, another may not. 
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4. What will I have to do? 
You will be required to attend the laboratory on 2 occasions:  
Visit 1 (approx. half an hour) 
On arrival you will be met by the researcher who will go over the study protocol and give 
you the opportunity to ask any questions you may have. Providing you are still happy to 
participate you will be given an informed consent form to complete and the researcher 
will confirm your eligibility. Once eligibility has been confirmed you will be given several 
questionnaires which will ask about your sleep and lifestyle habits. At the end of this visit 
you will be provided with a food and physical activity diary, sleep diary, and actigraphy 
watch. You will be given instructions on how to complete/wear these until your next visit.  
Part B: There is an optional second part to this project (part B). If you agree to participate 
in the second part, you will also be given a tube to collect a urine sample prior to the 
second visit. Please note that if you wish to participate in part B, it does not necessarily 
mean that your blood and urine sample will be used for this part of the study. The reason 
for this is that we are only using 60 participants for part B, and these participants will be 
the 30 people who sleep for the shortest amount of time and the 30 people who sleep for 
the longest amount of time. Therefore if you have provided samples for this part of the 
study and do not fall into these categories your data will not be analysed for metabolite 
profile. 
Visit 2 (approx. half an hour) 
This visit will take place 7 days after visit 1. Please arrive in a fasted state (no food or drink 
except water for 10 h prior) and bring your completed food and sleep diaries to this visit 
along with your actigraphy watch. You will be required to rest in a chair for 5 minutes then 
blood pressure will be measured. You will then have a DXA scan, which is an accurate 
method of measuring body composition. Following the DXA scan you will be required to 
provide a single blood sample which will be obtained from the antecubital vein in your 
arm by a trained researcher.   
 
Throughout participation (between visits 1 and 2) 
You will be given a 7-day sleep diary and 3-day food, physical activity and light exposure 
diary to complete and an actigraphy watch to wear between visits. You will be requested 
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not to change y o u r  h a b i t s  (dietary, sleeping and smoking habits, usual physical 
activity, etc.) during participation; However, if any changes occur, it will have to be 
reported to the investigator. On the morning of your second visit you will be required to 
collect a urine sample from your second void of the day and bring this with you to the 
laboratory. 
 
DXA scan 
A DXA scan is considered a gold-standard method of measuring body composition. You 
will be asked to lie still on the scanner table for approximately 7 minutes whilst the scan 
is carried out. For the DXA scan you will be required to wear comfortable clothing which 
doesn’t contain any metal, and remove any jewellery. To allow for an accurate reading, 
you need to be hydrated so please ensure you drink plenty of water before arriving at 
the laboratory.  
DXA scans emit a small dose of radiation – each whole-body scan is equivalent to less than 
2 days UK background radiation. You will therefore be required to complete a DXA 
screening form prior to the scan. 
 
5. Will my participation involve any discomfort or embarrassment? 
This study involves collection of blood samples using the venepuncture technique. There 
may be slight discomfort whilst the needle is inserted however any discomfort 
experienced should be mild and only last a short period of time. A risk assessment has 
been carried out for the collection of blood samples and the sample will be collected in a 
sterile environment. Please note that should any abnormalities be found from the blood 
sample you will be advised to inform your general practitioner of these findings. No 
psychological embarrassment will be involved in this study. 
 
6. Will my participation result in any benefits to me? 
By taking part in this study you will be contributing to research to develop insight into 
the way sleep can impact metabolic health. Whilst there will be no direct benefit to you, 
the study results are intended to extend knowledge on the relationship between sleep 
and metabolic health which may benefit others in the future. 
 
7. Will I have to provide any bodily samples (i.e. blood, saliva)?   
 
You will be required to provide a single blood sample on visit 2. This will be obtained 
using the venepuncture technique, which involves a needle being inserted into the 
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antecubital vein in your arm. Should any abnormality be found from the blood sample 
you will be advised to visit your GP. 
Should you agree to participate in Part B, a urine sample (second void of the day) is also 
required on the morning of your second visit. You will collect this using the equipment 
provided by the researchers and bring it with you to the laboratory. As outlined above, 
only those 30 participants who sleep for the shortest amount of time and those 30 
participants who sleep for the longest amount of time will have their data analysed for 
part B. Therefore even if you opt in to this part of the study your data will not be used 
for metabolite profile analysis if you do not fall into either of these categories. 
 
 
 
 
 
9. Who will have access to the information that I provide? 
Only the principal investigator (Miss Emma Sweeney) and the research team will have 
access to the information that you provide. However, any data that leaves the site will 
only be identifiable by an identification number and it will not be possible for anybody 
outside of the investigational site to identify you. 
 
8. How will confidentiality be assured? 
You will be assigned a unique reference number for the study which means you will remain 
anonymous. All data will be anonymized. When the data is used it will be collated with 
that of the other participants and will in no way be linked back to you. Only the researchers 
will have access to the individual data sheets. Data sheets will be stored separately from 
consent forms. 
All data which is in paper form will be stored in a locked filing cabinet within the Faculty 
of Health & Life Sciences at Northumbria University. Electronic data will be stored on a 
password protected computer. Data will be stored in accordance with University 
guidelines and the Data Protection Act (1998) will be followed. Data will be stored for 5 
years after completion of the study. 
10. What categories of personal data will be collected and processed in this study? 
We will collect contact details, date of birth, ethnicity, blood markers of glycaemic control 
and metabolite profile (Part B only). 
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12. How will my information be used in the future? 
On completion of the study results will be collated with those of the other participants 
and will in no way be linked back to you. Findings may be published in scientific papers or 
presented at conferences.  
 
13. Has this investigation received appropriate ethical clearance? 
Yes, this study has received ethical approval from the Faculty of Health and Life Sciences 
Ethics committee. If you require confirmation  of this please contact the Chair of this 
Committee, stating the title of the research project and the name of the principal 
investigator: 
Chair of Faculty of Health and Life Sciences Ethics Committee, Northumberland Building, 
Northumbria University, Newcastle upon Tyne, NE1 8ST 
 
14. Will I receive any financial rewards / travel expenses for taking part? 
No.  
 
15. How can I withdraw from the project? 
Participation in this study is completely voluntary. If you wish to withdraw at any point 
you can do so by contacting the principal researcher (Emma Sweeney) at the contact 
details given at the top of this information sheet. Should you decide to withdraw no 
judgement will be made and you do not have to state your reason for withdrawal if you 
do not wish to do so. 
 
16. What are my rights as a participant in this study? 
11. What is the legal basis for processing personal data? 
The legal basis for processing the personal data required for the purposes of this study is 
that the research is being conducted in the public interest, necessary for scientific research 
purposes. 
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You have the right of access to a copy of the information comprised in your personal data 
(to do so, submit a Subject Access Request). You have a right, in certain circumstances, to 
have inaccurate personal data rectified, and a right to object to decisions being taken by 
automated means. If you are dissatisfied with the University’s processing of personal data, 
you have the right to complain to the Information Commissioner’s Office.  
 
17. If I require further information who should I contact and how? 
If you need more information you should contact the principal investigator - Emma 
Sweeney: 
Email: emma.sweeney@northumbria.ac.uk 
Tel: 0191 243 7018 
Name and contact of Data Protection Officer at Northumbria University: Duncan James 
(dp.officer@northumbria.ac.uk) 
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Appendix B1 – Informed consent form (Chapter 4) 
INFORMED CONSENT FORM 
 
 
Project Title: Sleep restriction and impaired glucose metabolism – a dose-response study 
 
Principal Investigator: Emma Sweeney (doctoral resesarcher) 
 
 
               please tick or initial  
  where applicable 
I have carefully read and understood the Participant Information Sheet.  
 
I have had an opportunity to ask questions and discuss this study and I have received 
satisfactory answers. 
 
 
I understand I am free to withdraw from the study at any time, without having to give a 
reason for withdrawing, and without prejudice. 
 
 
I agree to take part in this study.  
 
 
REMOVAL AND STORAGE OF TISSUE 
I agree that the following tissue or other bodily material may be taken and used for the 
study:  
 
Tissue/Bodily material Purpose Removal Method 
Blood 
 
Glucose, insulin, 
inflammatory markers 
Cannulation 
 
I understand that if the material is required for use in any other way than that explained to 
me, then my consent to this will be specifically sought. I understand that I will not receive 
specific feedback from any assessment conducted on my samples, but should any kind of 
abnormality be discovered then the investigator will contact me.  
 
I understand that the University may store this tissue in a Licensed Tissue Bank 
only for the duration of the study, it will then be destroyed. 
 
Method of disposal:    
Clinical Waste             ✓  
Other                             
If other please specify........................................................... 
 
 
 
 
 
 
Signature of participant.......................................................    Date.....……………….. 
 
(NAME IN BLOCK LETTERS)....................................................………………………. 
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Signature of researcher.......................................................    Date.....……………….. 
 
(NAME IN BLOCK LETTERS)....................................................………………………. 
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Appendix B2 – Informed consent form (Chapter 5) 
INFORMED CONSENT FORM 
 
 
Project Title: The effect of exercise on glucose regulation following acute sleep restriction  
 
Principal Investigator: Emma Sweeney (doctoral researcher) 
 
 
               please tick or initial  
  where applicable 
I have carefully read and understood the Participant Information Sheet.  
 
I have had an opportunity to ask questions and discuss this study and I have received 
satisfactory answers. 
 
 
I understand I am free to withdraw from the study at any time, without having to give a 
reason for withdrawing, and without prejudice. 
 
 
I agree to take part in this study.  
 
 
REMOVAL AND STORAGE OF TISSUE 
I agree that the following tissue or other bodily material may be taken and used for the 
study:  
 
Tissue/Bodily material Purpose Removal Method 
Blood 
 
Markers of glycaemic 
control and metabolite 
profile 
Cannulation 
Urine Metabolite profile Participant collection 
 
I understand that if the material is required for use in any other way than that explained 
to me, then my consent to this will be specifically sought. I understand that I will not 
receive specific feedback from any assessment conducted on my samples, but should 
any kind of abnormality be discovered then the investigator will contact me.  
 
I understand that the University may store this tissue in a Licensed Tissue Bank 
only for the duration of the study, it will then be destroyed. 
 
Method of disposal:    
Clinical Waste             ✓  
Other                             
If other please specify........................................................... 
 
 
 
 
 
 
Signature of participant.......................................................    Date.....……………….. 
 
(NAME IN BLOCK LETTERS)....................................................………………………. 
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Signature of researcher.......................................................    Date.....……………….. 
 
(NAME IN BLOCK LETTERS)....................................................………………………. 
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Appendix B3 – Informed consent form (Chapter 6) 
INFORMED CONSENT FORM 
 
 
Project Title: Sleep duration and glycaemic control 
 
Principal Investigator: Emma Sweeney (doctoral researcher) 
 
 
               please tick or initial  
  where applicable 
I have carefully read and understood the Participant Information Sheet.  
 
I have had an opportunity to ask questions and discuss this study and I have received 
satisfactory answers. 
 
 
I understand I am free to withdraw from the study at any time, without having to give a 
reason for withdrawing, and without prejudice. 
 
 
I agree to take part in this study.  
 
 
REMOVAL AND STORAGE OF TISSUE 
I agree that the following tissue or other bodily material may be taken and used for 
the study:  
 
Tissue/Bodily material Purpose Removal Method 
Blood 
 
Markers of glycaemic 
control  
Venepuncture 
 
I understand that if the material is required for use in any other way than that 
explained to me, then my consent to this will be specifically sought. I understand that 
I will not receive specific feedback from any assessment conducted on my samples, 
but should any kind of abnormality be discovered then the investigator will contact 
me.  
 
I understand that the University may store this tissue in a Licensed Tissue 
Bank only for the duration of the study, it will then be destroyed. 
 
Method of disposal:    
Clinical Waste             ✓  
Other                             
If other please specify........................................................... 
 
 
 
 
 
 
Signature of participant.......................................................    Date.....……………….. 
 
(NAME IN BLOCK LETTERS)....................................................………………………. 
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Signature of researcher.......................................................    Date.....……………….. 
 
(NAME IN BLOCK LETTERS)....................................................………………………. 
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Appendix C – Food log 
 Diet Log 
 
 
 
 
 
Name: 
 
 
Date: 
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Nutritional Questionnaire 
Do you have any food allergies or intolerances? 
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
________________________________ 
 
What type of milk do you normally use? 
__________________________________________________________________________
________ 
 
What type of bread do you normally eat? 
__________________________________________________________________________
________ 
 
What type of spread do you normally use? 
__________________________________________________________________________ 
 
Do you regularly drink tea or coffee and if so, how often and what with? 
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________ 
 
Do you take any supplements including vitamins and minerals? 
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________ 
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Guidance notes 
The aim of this booklet is to allow the investigator to attain an understanding of your daily 
dietary intake.  For 3 days, you will need to record EVERYTHING you eat and drink. 
 
Diet Logs 
One page is allocated for each day’s nutritional intake. Please provide detailed information 
when describing food and drink intake.  
- Provide precise weights of foods / volumes of fluids. 
- Record the cooking method (eg. fried, boiled) 
- Record the ‘brand’ of food and fluid consumed (e.g. Tesco, Uncle Ben’s etc).  
 
 It is extremely important to be completely honest when recording your food and drink 
intake. 
 
Examples are provided in the grey boxes in the table provided overleaf.  
 
Contact 
If you unsure how to complete this booklet and require further information at any time, 
please contact: 
Emma Sweeney 
Email: emma.sweeney@northumbria.ac.uk  
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DAY 1:   Date:  _____________________ 
TIME FOOD / BRAND COOKING 
METHOD 
QUANTITY 
Example 
7.00 am 
 
 
 
Weetabix 
Semi-skimmed milk 
Tea with 2 sugars 
 
 
 
 
 
2 
200 ml 
1 cup 
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DAY 2:    Date:  ________________        
TIME FOOD / BRAND 
COOKING 
METHOD 
QUANTITY 
Example 
7:15 am 
 
 
Brown toast with flora margerine 
Tea with 2 sugars 
 
 
 
2 slices 
1 cup 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
143 
 
DAY 3:   Date:  ____________________ 
TIME FOOD / BRAND 
COOKING 
METHOD 
QUANTITY 
Example 
8:30 am 
 
 
 
Walls sausages 
Eggs (medium) 
Tea with 2 sugars 
 
Grilled 
Scrambled 
 
 
2 
3 
1 cup 
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Appendix D – Sleep log 
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Appendix E – Publication arising from study presented in Chapter 
5 
Accepted author manuscript version from International Journal of Sport 
Nutrition and Exercise Metabolism, 2019, 
https://doi.org/10.1123/ijsnem.2019-0235 © Human Kinetics, Inc.  
 
Impaired Insulin Profiles Following a Single Night of Sleep 
Restriction: The Impact of Acute Sprint Interval Exercise 
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Abstract 
Experimental sleep restriction has demonstrated reduced insulin sensitivity in 
healthy individuals. Exercise is well-known to be beneficial for metabolic health. A 
single bout of exercise has the capacity to increase insulin sensitivity for up to two 
days. Therefore, the current study aimed to determine if sprint interval exercise could 
attenuate the impairment in insulin sensitivity after one night of sleep restriction in 
healthy males. Nineteen males were recruited for this randomised crossover study 
which consisted of four conditions – control (CON), sleep restriction (SR), control 
plus exercise (CE), and sleep restriction plus exercise (SRE). Time in bed was 8 h 
(2300 – 0700) in the control conditions and 4 h (0300 – 0700) in the sleep restriction 
conditions. Conditions were separated by a 1 wk entraining period. Participants slept 
at home and compliance was assessed using wrist actigraphy. Following the night of 
experimental sleep, participants either conducted sprint interval exercise or rested for 
the equivalent duration. An oral glucose tolerance test was then conducted. Blood 
samples were obtained at regular intervals for measurement of glucose and insulin. 
Insulin concentrations were higher in SR than CON (P = 0.022). Late-phase insulin 
AUC was significantly lower in SRE than SR (862 ± 589 and 1267 ± 558; P = 
0.004). Glucose AUC was not different between conditions (P = 0.207). These 
findings suggest that exercise improves the late post-prandial response following a 
single night of sleep restriction.  
Key Words: Glucose metabolism, sleep loss, high intensity exercise  
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Introduction 
Short sleep durations are becoming increasingly common, with almost 75% of adults 
in Great Britain sleeping outside the recommended 7-9 hours each night 
(Hirshkowitz et al., 2015). Chronic short sleep is associated with increased risk of 
developing many diseases, including type 2 diabetes (Yaggi et al., 2006). 
Experimental studies demonstrate impaired glucose control following sleep 
restriction (Knutson et al., 2007), with a single night of restriction reducing whole-
body insulin sensitivity by 20% (Donga et al., 2010). 
The proposed mechanisms underlying impaired glucose regulation following sleep 
restriction include altered peripheral insulin sensitivity (Broussard et al., 2012; Rao 
et al., 2015) and changes to the metabolic profile, favouring fatty acid transportation 
(Davies et al., 2014) which may interfere with insulin signalling. However, while the 
detrimental effects of sleep restriction are clear, few studies have focussed on 
strategies to counter the impairment.  
Exercise may have the potential to alter these proposed underlying mechanisms 
(Saner et al., 2018). A single bout of exercise positively impacts glucose regulation 
for up to 24 hours (Koopman et al., 2005). This improvement in glucose regulation is 
apparent with various types of exercise (Breen et al., 2011; Gillen et al., 2012); 
although high intensity exercise may to be superior to moderate intensity exercise for 
improving insulin sensitivity (Rynders et al., 2014; Ortega et al., 2015). Sprint 
interval exercise has been shown to produce improvements in insulin area under the 
curve (AUC) and the insulin sensitivity index when measured 30 min post cessation 
of the exercise bout in healthy males (Ortega et al., 2015). Whether or not 
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improvements such as these would occur in sleep-restricted individuals remains 
unknown. 
Exercise appears to be a promising intervention to alleviate the impairment in insulin 
sensitivity following total sleep deprivation. Two weeks of high intensity exercise 
training has been shown to attenuate the insulin response to an oral glucose tolerance 
test after one night of total sleep deprivation (de Souza et al., 2017). However, it 
remains unclear if a single bout of exercise performed after partial sleep restriction 
can produce similar outcomes.  
Consequently, this study aimed to investigate the effect of a single bout of sprint 
interval exercise on whole-body insulin sensitivity, following a single night of sleep 
restriction. We hypothesised that insulin sensitivity would be reduced following 
sleep restriction, and that this effect would be attenuated when exercise was 
performed.  
 
Methods 
Participants 
Nineteen healthy males (mean ± SD; age 25 ± 8 y; body mass 81.4 ± 12.0 kg; stature 
180 ± 7 cm) participated in this study. Exclusion criteria included shift workers, 
regular travel across time zones (>3 times a year) or in the past 4 weeks, presence of 
any disorders which may influence glycaemic control (such as diabetes) or sleep 
(such as obstructive sleep apnea), current or previous medication in the past year 
which may have impacted on glucose metabolism or sleep, alteration of sleep, 
dietary, or physical activity patterns in the previous 3 months, a history of drug or 
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alcohol abuse or eating disorders, following a specific diet which may influence the 
results, such as intermittent fasting, a habitual bedtime before 2200 or after 0100, or 
a habitual wake time before 0600 or after 0900. Individuals were also excluded if 
they had a contraindication to exercise, poor sleep quality (defined as a Pittsburgh 
Sleep Quality Index [PSQI] (Buysse et al., 1989) score of above 5), or were classed 
as extreme morning or evening types, assessed by the morningness-eveningness 
questionnaire [MEQ] (Horne & Ostberg, 1976). The study protocol was approved 
through the Northumbria University Ethical Approval system. All participants 
provided written informed consent prior to participation.  
Study Design 
This randomised crossover trial consisted of a familiarisation visit and four one-night 
experimental trials. The experimental conditions were control (CON), control plus 
exercise (CE), sleep restriction (SR) and sleep restriction plus exercise (SRE). Each 
condition involved a single night of either 8 h time in bed from 2300 to 0700 (CON 
and CE) or 4 h time in bed from 0300 to 0700 (SR and SRE). Four hours sleep has 
been shown to reduce insulin sensitivity in previous research (Donga et al., 2010). 
The morning following the control or restricted sleep, participants either rested 
(CON and SR) or undertook a bout of sprint interval exercise (CE and SRE). All 
experimental conditions were separated by at least 1 week to prevent carryover 
effects (van Leeuwen et al., 2010), but no more than 3 weeks.  
Throughout the study participants slept at home. Experimental trials were preceded 
by a one-week entraining period, in which participants were asked to keep a 
consistent bed and wake time. Wrist actigraphy (GeneActiv, Activinsights Ltd, UK) 
was used in conjunction with time-stamped text messages to ensure compliance. 
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Participants sent hourly messages to the researcher between 2300 and 0300 in SR 
and SRE conditions. Participants were informed which condition they were on the 
day before each laboratory visit.  
Diet was provided for the day preceding each experimental trial and was replicated 
across conditions. Diet was individualised from food diaries issued during the 
familiarisation session and total energy, carbohydrates, fat, and protein were kept 
within 10% of habitual intake. Participants were instructed to eat only the foods 
provided and to avoid consumption of any caffeine or alcohol, however were 
permitted to drink water ad libitum. Participants were also asked to refrain from 
exercise and napping during this time.  
Study protocol 
Familiarisation 
One week prior to the first experimental visit participants attended the laboratory for 
a screening and familiarisation visit. Upon arrival participants were briefed on the 
study protocol and given the opportunity to ask questions before completing written 
informed consent. They completed several screening questionnaires – a physical 
activity readiness questionnaire, the PSQI (Buysse et al., 1989), and the MEQ 
(Horne & Ostberg, 1976). Following satisfactory completion of the screening 
questionnaires, they were issued with a 3-day food diary, actigraphy watch, and 7-
day sleep diary.  
Body mass and stature were measured using balance scales (SECA, UK) and a free-
standing stadiometer (SECA, UK). Stature was measured to the nearest 0.1 cm and 
body mass to the nearest 0.1 kg.  
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Participants then underwent an exercise familiarisation, which was a reduced version 
of the study exercise protocol. The familiarisation exercise bout consisted of a 5-
minute warm-up at 70 W on a cycle ergometer (Monark, Sweden), followed by two 
all-out 30-second sprints against 7.5% of their body mass. Sprints were separated by 
4.5 minutes of active recovery at a self-selected pace. A 5-minute cool down was 
then completed.  
Experimental trials 
Participants went to bed at 2300 or 0300, depending on the condition. After getting 
up at 0700, participants arrived at the laboratory by public transport in a rested state 
at 0800, following a 10-hour overnight fast. Upon arrival, participants either 
completed a bout of sprint interval exercise (CE and SRE) or rested in a seated 
position for the equivalent duration (CON and SR). In all conditions participants 
were given a 30-minute recovery period, resting in a seated position. After the 
recovery period a 2-hour oral glucose tolerance test (OGTT) was conducted, and 
blood samples were drawn at regular intervals. The OGTT consisted of 82.5 g 
dextrose (MyProtein, UK) mixed with 300 ml water, consumed within 5 minutes. 
During the OGTT participants remained seated in the laboratory but were permitted 
to complete sedentary tasks. Participants left the laboratory at approximately 1130. 
Exercise 
The exercise protocol used in this study was based on previous research by Ortega et 
al (2015) who demonstrated a 142% increase in IVGTT-derived insulin sensitivity 
measured 30 minutes following sprint interval exercise in healthy males. All exercise 
was performed on a cycle ergometer (Monark Ergomedic 894E, Sweden), preceded 
and proceeded with a 5-minute warm-up and cool-down at 70 W.  
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The sprint interval exercise consisted of four all-out 30-second sprints against 7.5% 
of body mass, interspersed with 4.5 min of recovery. During the active recovery 
period, participants cycled at a self-selected pace against a resistance of 1 kg, which 
was the lowest permitted by the ergometer. Verbal encouragement was given 
throughout each sprint by the same researcher.  
Blood collection and processing  
Blood was collected at baseline (0), 15, 30, 45, 60, 90 and 120 minutes during the 
OGTT using the cannulation technique. For each sample, 8 ml was drawn into a 
syringe and transferred to a 10 ml serum vacutainer (Becton Dickinson, Sweden). 
Vacutainers were inverted to ensure thorough mixing. The samples were left to clot 
at room temperature for 30 minutes before being centrifuged at 3500 rpm at 4°C for 
15 minutes. Serum was aliquoted into microtubes. A small amount of serum from 
each sample was taken up into a capillary tube and placed in microtubes containing 1 
ml hemolysing solution (EKF Diagnostics, UK) for determination of glucose 
concentration. The remaining serum was frozen at -80°C until further analysis. 
Serum glucose was measured using the Biosen C-line automatic glucose analyser 
(EKF Diagnostics, Germany). Serum insulin was measured using commercially 
available ELISA kits (Mercodia, Sweden), conducted according to manufacturers 
instructions. Intra- and inter-assay coefficients of variation were 6% and 14%, 
respectively. 
Data analysis 
Sample size calculation 
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Sample size was calculated using G*Power version 3.1.9.2 (Faul et al., 2007). Based 
on previous work showing a difference of 26.9 mg/dL in 2-hour glucose values 
during an OGTT between control and exercise conditions (Rynders et al., 2014), 18 
participants were required to achieve 90% power. 
Statistical analysis 
Data are presented as mean ± SD. Area under the curve (AUC) for glucose and 
insulin were calculated using the trapezoidal rule. AUC was calculated for total (2 
hours), early-phase (0-60 minutes) and late-phase (60-120 minutes) during the 
OGTT. HOMA-IR (Matthews et al., 1985) and Matsuda Index (Matsuda & 
DeFronzo, 1999) were calculated to estimate insulin resistance and whole-body 
insulin sensitivity. 
Data were analysed using SPSS Statistics version 22 (IBM, UK). Shapiro-Wilk tests 
were used to check for normality and any data which violated the assumption of 
normality were transformed using a natural logarithm transformation. Linear mixed 
modelling was used to compare glucose and insulin between conditions. P < 0.05 
was used to indicate significance.  
Results 
Sleep 
Average time to bed, wake time, time in bed (TIB), and total sleep time (TST) in 
each condition are presented in Table 1. Differences in TST were observed between 
CON and SR (mean difference 142 min; P < 0.001), CE and SRE (mean difference 
182 min; P < 0.001), CE and SRE (mean difference 181 min; P < 0.001) and CON 
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and SRE (mean difference 141 min; P < 0.001). No differences were observed 
between CON and CE (P = 0.581) or SR and SRE (P = 1.000).   
 
Exercise 
Peak power output (PPO) during each of the 30-second sprints is outlined in Table 2. 
PPO did not differ between conditions (P = 0.644), but a difference was observed 
over time (P < 0.001), with PPO significantly higher in the first sprint compared to 
the third (mean difference 106 W; P = 0.009) and fourth (mean difference 118 W; P 
= 0.007), and higher in the second compared to the fourth (mean difference 60 W; P 
= 0.041). Total work done was similar between conditions (63666 ± 12029 J in CE 
and 65045 ± 11294 J in SRE; P = 0.340). 
 
Glucose and insulin 
Glucose and insulin concentrations during the OGTT are displayed in Figure 1. 
Total, early- and late-phase AUC for glucose and insulin are shown in Figure 2.  
Glucose concentrations did not show evidence of an effect of condition (P = 0.216) 
or interaction effect (P = 0.146). However, there was a significant effect of time 
during the OGTT (P < 0.001). No significant difference between conditions was 
found for peak glucose (P = 0.158). There was no evidence of an effect of condition 
(P = 0.207) for total glucose AUC. Likewise, late- and early-phase glucose AUC did 
not show any significant differences between conditions (P = 0.264 and P = 0.122, 
respectively). 
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Insulin concentrations demonstrated an overall difference between conditions (P = 
0.019), time points (P < 0.001), and an interaction between conditions and time 
points (P = 0.014). Post-hoc analyses on these overall differences revealed 
significantly higher insulin concentrations in SR compared to CON (P = 0.022), with 
SR showing higher concentrations than CON at 30 min (40.04 ± 23.17 and 25.79 ± 
13.94 µIU/ml; P = 0.004). Insulin concentrations were higher in SR compared to 
SRE at 60 minutes (31.40 ± 13.99 and 21.03 ± 10.67 μIU/ml; P = 0.042), 90 minutes 
(19.47 ± 11.11 and 15.52 ± 15.63 μIU/ml; P = 0.002), and 120 minutes (14.12 ± 
14.84 and 5.99 ± 5.27 μIU/ml; P = 0.003). Total insulin AUC displayed a trend for 
an effect of condition (P = 0.075), with SR tending to be higher than CON (P = 
0.064). Early- and late-phase insulin AUC also showed significant main effects of 
condition (P = 0.010 and P < 0.001, respectively). The early-phase insulin AUC was 
higher in SR than CON (1472 ± 811 and 2044 ± 1129; P = 0.048). Late-phase 
displayed a lower AUC in SRE than SR (1267 ± 558 and 862 ± 589; P = 0.004).  
 
HOMA-IR showed a main effect of condition (P = 0.019), with SR higher than CON 
(0.87 ± 0.99 and 1.64 ± 2.60; P = 0.029). Matsuda index was significantly different 
between conditions (P = 0.003), with SR displaying a lower index than CON (25.31 
± 20.80 and 12.11 ± 6.38; P = 0.020). 
 
Discussion 
The present study demonstrated that one night of sleep restriction impaired insulin 
sensitivity, and that performing sprint interval exercise after sleep restriction may 
improve the late post-prandial response. 
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Participants displayed reduced insulin sensitivity after sleep restriction, indicated by 
increased insulin concentrations during the OGTT and decreased Matsuda index in 
SR compared to CON. This is consistent with previous research that has 
demonstrated reduced whole-body insulin sensitivity after a single night (Donga et 
al., 2010), and multiple nights of sleep restriction (Sweeney et al., 2017; Wang et al., 
2016). Sleep restriction may impair whole-body insulin sensitivity through alteration 
of peripheral insulin signalling, with five nights of sleep restriction reducing 
peripheral, but not hepatic, insulin sensitivity (Rao et al., 2015). Furthermore, sleep 
restriction reduces Akt phosphorylation, which plays a key role in the insulin 
signalling pathway in peripheral tissues (Broussard et al., 2012).  
We hypothesised that a bout of sprint interval exercise would attenuate the 
impairment in insulin sensitivity in sleep-restricted individuals. Whilst total insulin 
AUC was not significantly altered after the exercise bout, our findings suggest that 
there was an alteration to the late post-prandial response when comparing the sleep 
restricted conditions. However, we did not observe an improvement in insulin or 
glucose profiles after exercise in the early-phase of the OGTT. Our findings are in 
contrast to Ortega and colleagues (2015) who demonstrated improved insulin and 
glucose 60 minutes following high intensity exercise. Methodological differences 
may explain this discrepancy, as an IVGTT was employed by Ortega and colleagues, 
whereas we used an OGTT. Gastric emptying plays a role during the OGTT whereas 
this is bypassed when glucose is injected rather than ingested orally. Gastric 
emptying rate may be slowed by intermittent high intensity exercise (Leiper et al., 
2001), delaying the absorption of the glucose drink and therefore findings may not 
be comparable between an OGTT and IVGTT. Alternatively, it may be possible that 
sleep restriction alters the metabolic response to exercise.  
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Our findings reflect those by Rynders and colleagues (2014), who noted 
improvements in the late rather than total postprandial response after a bout of 
exercise. High intensity exercise is known to temporarily increase glucose due to 
gluconeogenesis and possible carbohydrate sparing for glycogen repletion (Marliss 
et al., 1992). It may be possible that as glucose regulation was measured 30 minutes 
after cessation of exercise, the temporary alterations in glucose regulation which 
occur during exercise were still influencing our measurements. Additionally, 
although not statistically significant, it appears that insulin concentrations in the 
early-phase of the OGTT were increased after exercise compared to rest in the 
current study. An increase in early-phase insulin secretion may influence late-phase 
responses, potentially through suppression of endogenous glucose production (Del 
Prato et al., 2002). This early-phase response may therefore contribute to the lower 
late-phase insulin AUC which was observed in SRE compared to SR. The late-phase 
of the OGTT has been shown to predict incident diabetes independent of the early-
phase (Lorenzo et al., 2012), suggesting that despite no overall change, a decrease in 
late-phase insulin AUC may be beneficial.  
Whilst the present study suggests there is potential for exercise to positively 
influence the post-prandial response to an OGTT in sleep-restricted individuals, it 
was not designed to identify the possible mechanisms. Previous research has 
suggested that insulin action is improved after exercise through altered 
phosphorylation of components of the insulin signalling pathway in peripheral 
tissues (Wojtaszewski & Richter, 2006). As sleep restriction is thought to negatively 
impact peripheral insulin sensitivity (Broussard et al., 2012; Rao et al., 2015), it can 
be speculated that exercise improves insulin sensitivity in sleep-restricted individuals 
through alteration of insulin action in peripheral tissues.  
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The present study has some limitations which should be noted. Firstly, the study 
population consisted only of healthy males, meaning it may not be feasible to 
extrapolate the findings to other populations including females and individuals with 
metabolic abnormalities. Secondly, an OGTT does not enable measurement of 
metabolic characteristics such glucose disposal and uptake, so gives limited 
information regarding the decrease in insulin sensitivity. 
In summary, sprint interval exercise may offer some potential to attenuate the 
impairments in insulin sensitivity following a single night of reduced sleep. This 
may have implications for individuals facing sleep curtailment. To our knowledge, 
this is the first study to explore the effect of acute exercise on insulin sensitivity 
following sleep restriction. Therefore, future research may investigate whether 
exercise modality, intensity, duration, or timing influences the change in glucose 
regulation in sleep-restricted individuals. It would also be beneficial to investigate 
the time course of improved glucose regulation to determine whether the benefit of 
exercise persists for multiple hours as is the case in non-sleep-restricted individuals.   
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 Table 1. Sleep variables for each experimental condition. 
 CON CE SR SRE 
Bed time (hhmm) 2303 2306 0305 0255 
Wake time (hhmm) 0658 0659 0700 0657 
TIB (min) 472 ± 27 472 ± 22 236 ± 19 244 ± 15 
TST (min) 337 ± 95 377 ± 61 195 ± 43*† 196 ± 37*† 
Bed time, wake time, time in bed (TIB) and total sleep time (TST) in control (CON), 
control plus exercise (CE), sleep restriction (SR) and sleep restriction plus exercise 
(SRE) condition. Data are mean ± SD. * indicates difference from CON (P < 0.05). † 
indicates difference from CE (P < 0.05). 
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Table 2. Peak power output and total work done during sprints. 
 PPO (W)  Total work (J) 
 CE SRE   CE  SRE  
1 857 ± 189 853 ± 187  18356 ± 2903  18355 ± 3471 
2 818 ± 177 804 ± 160  16551 ± 2921  16580 ± 3139 
3 762 ± 194 736 ± 172  15488 ± 2842  15424 ± 3237 
4 733 ± 179 746 ± 144  14686 ± 2408  15502 ± 2490 
Peak power output (PPO) and total work during 4 all-out 30 s sprints performed the 
morning after a night of 8 h (CE) or 4 h (SRE) time in bed. No significant 
differences were observed between conditions. Data are presented as mean ± SD. 
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Figure 2. Glucose (A) and insulin (B) concentrations during the OGTT. P < 0.05 
indicates significance. * indicates main effect of condition, with SR higher than 
CON. ‡ indicates difference between CON and SR. † indicates difference between 
SR and SRE. 
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Figure 3. Total (white bars), early (grey shaded bars) and late (black bars) phase 
AUC for glucose (A) and insulin (B). Data are presented as mean ± SEM. Main 
effect of condition for early and late AUC. * indicates significant difference (P 
<0.05) compared to CON in early phase. † indicates significant difference (P <0.05) 
compared to SR in late phase.  
 
 
  
167 
 
List of References 
 
Abdul-Ghani, M., Matsuda, M., Balas, B., & DeFronzo, R. A. (2007). Muscle and 
Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance 
Test. Diabetes care, 30(1), 89.  
Adeva-Andany, M. M., González-Lucán, M., Donapetry-García, C., Fernández-
Fernández, C., & Ameneiros-Rodríguez, E. (2016). Glycogen metabolism in 
humans. BBA Clinical, 5, 85-100. 
doi:https://doi.org/10.1016/j.bbacli.2016.02.001 
Akerstedt, T., & Gillberg, M. (1990). Subjective and objective sleepiness in the 
active individual. Int J Neurosci, 52(1-2), 29-37. 
doi:10.3109/00207459008994241 
American Diabetes Association. (2006). Diagnosis and Classification of Diabetes 
Mellitus. Diabetes care, 29(Journal Article), s43-s48.  
American Diabetes Association. (2009). Standards of medical care in diabetes--
2009. Diabetes care, 32 Suppl 1(Suppl 1), S13-S61. doi:10.2337/dc09-S013 
Ancoli-Israel, S., Cole, R., Alessi, C., Chambers, M., Moorcroft, W., & Pollak, C. P. 
(2003). The role of actigraphy in the study of sleep and circadian rhythms. 
Sleep, 26(3), 342-392. doi:10.1093/sleep/26.3.342 
Anothaisintawee, T., Reutrakul, S., Van Cauter, E., & Thakkinstian, A. (2016). Sleep 
disturbances compared to traditional risk factors for diabetes development: 
Systematic review and meta-analysis. Sleep Med Rev, 30, 11-24. 
doi:10.1016/j.smrv.2015.10.002 
Anujuo, K., Stronks, K., Snijder, M. B., Jean-Louis, G., Rutters, F., van den Born, B. 
J., Peters, R. J., & Agyemang, C. (2015). Relationship between short sleep 
duration and cardiovascular risk factors in a multi-ethnic cohort - the helius 
study. Sleep Med, 16(12), 1482-1488. doi:10.1016/j.sleep.2015.08.014 
Artha, I. M. J. R., Bhargah, A., Dharmawan, N. K., Pande, U. W., Triyana, K. A., 
Mahariski, P. A., Yuwono, J., Bhargah, V., Prabawa, I. P. Y., Manuaba, I. B. 
A. P., & Rina, I. K. (2019). High level of individual lipid profile and lipid ratio 
as a predictive marker of poor glycemic control in type-2 diabetes mellitus. 
Vascular health and risk management, 15, 149-157. 
doi:10.2147/VHRM.S209830 
Artigues, M., Abellà, J., & Colominas, S. (2017). Analytical Parameters of an 
Amperometric Glucose Biosensor for Fast Analysis in Food Samples. 
Sensors (Basel, Switzerland), 17(11), 2620. doi:10.3390/s17112620 
Ayas, N. T., White, D. P., Al-Delaimy, W., Manson, J. E., Stampfer, M. J., Speizer, 
F. E., Patel, S., & Hu, F. B. (2003). A Prospective Study of Self-Reported 
Sleep Duration and Incident Diabetes in Women. Diabetes care, 26(2), 380.  
Bakrania, K., Edwardson, C. L., Khunti, K., Henson, J., Stamatakis, E., Hamer, M., 
Davies, M. J., & Yates, T. (2017). Associations of objectively measured 
168 
 
moderate-to-vigorous-intensity physical activity and sedentary time with all-
cause mortality in a population of adults at high risk of type 2 diabetes 
mellitus. Prev Med Rep, 5, 285-288. doi:10.1016/j.pmedr.2017.01.013 
Balkau, B., Mhamdi, L., Oppert, J.-M., Nolan, J., Golay, A., Porcellati, F., Laakso, 
M., & Ferrannini, E. (2008). Physical Activity and Insulin Sensitivity. 
Diabetes, 57(10), 2613. doi:10.2337/db07-1605 
Balkau, B., Vol, S., Loko, S., Andriamboavonjy, T., Lantieri, O., Gusto, G., Meslier, 
N., Racineux, J. L., & Tichet, J. (2010). High baseline insulin levels 
associated with 6-year incident observed sleep apnea. Diabetes care, 33(5), 
1044-1049. doi:10.2337/dc09-1901 
Banks, S., & Dinges, D. F. (2007). Behavioral and physiological consequences of 
sleep restriction. J Clin Sleep Med, 3(5), 519-528.  
Baron, K. G., Reid, K. J., & Zee, P. C. (2013). Exercise to improve sleep in 
insomnia: exploration of the bidirectional effects. J Clin Sleep Med, 9(8), 
819-824. doi:10.5664/jcsm.2930 
Basner, M., Spaeth, A. M., & Dinges, D. F. (2014). Sociodemographic 
characteristics and waking activities and their role in the timing and duration 
of sleep. Sleep, 37(12), 1889-1906. doi:10.5665/sleep.4238 
Basner, M., & Dinges, D. F. (2018). Sleep duration in the United States 2003-2016: 
first signs of success in the fight against sleep deficiency?. Sleep, 41(4), 
10.1093/sleep/zsy012. doi:10.1093/sleep/zsy012 
Bergman, R. N., Ider, Y. Z., Bowden, C. R., & Cobelli, C. (1979). Quantitative 
estimation of insulin sensitivity. Am J Physiol, 236(6), E667-677. 
doi:10.1152/ajpendo.1979.236.6.E667 
Bin, Y. S., Marshall, N. S., & Glozier, N. (2013). Sleeping at the limits: the changing 
prevalence of short and long sleep durations in 10 countries. American 
journal of epidemiology, 177(8), 826–833. doi:10.1093/aje/kws308 
Bird, S. R., & Hawley, J. A. (2017). Update on the effects of physical activity on 
insulin sensitivity in humans. BMJ Open Sport Exerc Med, 2(1), e000143-
e000143. doi:10.1136/bmjsem-2016-000143 
Bjornstad, P., & Eckel, R. H. (2018). Pathogenesis of Lipid Disorders in Insulin 
Resistance: a Brief Review. Curr Diab Rep, 18(12), 127. 
doi:10.1007/s11892-018-1101-6 
Bjorvatn, B., Sagen, I. M., Oyane, N., Waage, S., Fetveit, A., Pallesen, S., & Ursin, 
R. (2007). The association between sleep duration, body mass index and 
metabolic measures in the Hordaland Health Study. J Sleep Res, 16(1), 66-
76. doi:10.1111/j.1365-2869.2007.00569.x 
Boniol, M., Dragomir, M., Autier, P., & Boyle, P. (2017). Physical activity and change 
in fasting glucose and HbA1c: a quantitative meta-analysis of randomized 
trials. Acta Diabetol, 54(11), 983-991. doi:10.1007/s00592-017-1037-3 
169 
 
Borbely, A. A., Daan, S., Wirz-Justice, A., & Deboer, T. (2016). The two-process 
model of sleep regulation: a reappraisal. J Sleep Res, 25(2), 131-143. 
doi:10.1111/jsr.12371 
Borghouts, L. B., & Keizer, H. A. (2000). Exercise and Insulin Sensitivity: A Review. 
Int J Sports Med, 21(01), 1-12. doi:10.1055/s-2000-8847 
Bos, M. M., Noordam, R., van den Berg, R., de Mutsert, R., Rosendaal, F. R., 
Blauw, G. J., Rensen, P. C. N., Biermasz, N. R., & van Heemst, D. (2019). 
Associations of sleep duration and quality with serum and hepatic lipids: The 
Netherlands Epidemiology of Obesity Study. Journal of sleep research, 
28(4), e12776. doi:10.1111/jsr.12776 
Bosy-Westphal, A., Hinrichs, S., Jauch-Chara, K., Hitze, B., Later, W., Wilms, B., 
Settler, U., Peters, A., Kiosz, D., & MÃ¼ller, M. J. (2008). Influence of Partial 
Sleep Deprivation on Energy Balance and Insulin Sensitivity in Healthy 
Women. Obesity Facts, 1(5), 266-273.  
Bower, J. K., Meadows, R. J., Foster, M. C., Foraker, R. E., & Shoben, A. B. (2017). 
The Association of Percent Body Fat and Lean Mass With HbA1c in US 
Adults. Journal of the Endocrine Society, 1(6), 600-608. doi:10.1210/js.2017-
00046 
Boyce, R., Williams, S., & Adamantidis, A. (2017). REM sleep and memory. Curr 
Opin Neurobiol, 44, 167-177. doi:10.1016/j.conb.2017.05.001 
Boyle, P. J., Scott, J. C., Krentz, A. J., Nagy, R. J., Comstock, E., & Hoffman, C. 
(1994). Diminished brain glucose metabolism is a significant determinant for 
falling rates of systemic glucose utilization during sleep in normal humans. 
Journal of Clinical Investigation, 93(2), 529-535.  
Breen, L., Philp, A., Shaw, C. S., Jeukendrup, A. E., Baar, K., & Tipton, K. D. 
(2011). Beneficial Effects of Resistance Exercise on Glycemic Control Are 
Not Further Improved by Protein Ingestion. PLoS ONE, 6(6), e20613. 
doi:10.1371/journal.pone.0020613 
Broussard, J. L., Ehrmann, D. A., Van Cauter, E., Tasali, E., & Brady, M. J. (2012). 
Impaired Insulin Signaling in Human Adipocytes After Experimental Sleep 
RestrictionA Randomized, Crossover Study. Annals of Internal Medicine, 
157(8), 549-557.  
Broussard, J. L., Kilkus, J. M., Delebecque, F., Abraham, V., Day, A., Whitmore, H. 
R., & Tasali, E. (2016). Elevated ghrelin predicts food intake during 
experimental sleep restriction. Obesity, 24(1), 132-138. 
doi:10.1002/oby.21321 
Buman, M. P., Winkler, E. A., Kurka, J. M., Hekler, E. B., Baldwin, C. M., Owen, N., 
Ainsworth, B. E., Healy, G. N., & Gardiner, P. A. (2014). Reallocating time to 
sleep, sedentary behaviors, or active behaviors: associations with 
cardiovascular disease risk biomarkers, NHANES 2005-2006. Am J 
Epidemiol, 179(3), 323-334. doi:10.1093/aje/kwt292 
Buxton, O. M., Pavlova, M., Reid, E. W., Wang, W., Simonson, D. C., & Adler, G. K. 
(2010). Sleep restriction for 1 week reduces insulin sensitivity in healthy 
men. Diabetes, 59(9), 2126-2133. doi:10.2337/db09-0699 [doi] 
170 
 
Buysse, D. J., Reynolds, C. F., 3rd, Monk, T. H., Berman, S. R., & Kupfer, D. J. 
(1989). The Pittsburgh Sleep Quality Index: a new instrument for psychiatric 
practice and research. Psychiatry research, 28(2), 193-213. doi:0165-
1781(89)90047-4 [pii] 
Carney, C. E., Buysse, D. J., Ancoli-Israel, S., Edinger, J. D., Krystal, A. D., 
Lichstein, K. L., & Morin, C. M. (2012). The consensus sleep diary: 
standardizing prospective sleep self-monitoring. Sleep, 35(2), 287-302. 
doi:10.5665/sleep.1642 
Carskadon, M. A., & Dement, W. C. (2011). Normal human sleep: An overview. In 
M. H. Kryger, T. Roth, & W. C. Dement (Eds.), Principles and practice of 
sleep medicine (Vol. 5th, pp. 13-23). St. Louis: Elvsevier Saunders. 
Cedernaes, J., Osler, M. E., Voisin, S., Broman, J. E., Vogel, H., Dickson, S. L., 
Zierath, J. R., Schioth, H. B., & Benedict, C. (2015). Acute Sleep Loss 
Induces Tissue-Specific Epigenetic and Transcriptional Alterations to 
Circadian Clock Genes in Men. J Clin Endocrinol Metab, 100(9), E1255-
1261. doi:10.1210/jc.2015-2284 
Chastin, S. F., Palarea-Albaladejo, J., Dontje, M. L., & Skelton, D. A. (2015). 
Combined Effects of Time Spent in Physical Activity, Sedentary Behaviors 
and Sleep on Obesity and Cardio-Metabolic Health Markers: A Novel 
Compositional Data Analysis Approach. PLoS ONE, 10(10), e0139984. 
doi:10.1371/journal.pone.0139984 
Cnop, M., Havel, P. J., Utzschneider, K. M., Carr, D. B., Sinha, M. K., Boyko, E. J., 
Retzlaff, B. M., Knopp, R. H., Brunzell, J. D., & Kahn, S. E. (2003). 
Relationship of adiponectin to body fat distribution, insulin sensitivity and 
plasma lipoproteins: evidence for independent roles of age and sex. 
Diabetologia, 46(4), 459-469. doi:10.1007/s00125-003-1074-z 
Crichton, G. E., & Alkerwi, A. a. (2015). Physical activity, sedentary behavior time 
and lipid levels in the Observation of Cardiovascular Risk Factors in 
Luxembourg study. Lipids in Health and Disease, 14(1), 87. 
doi:10.1186/s12944-015-0085-3 
Dankner, R., Chetrit, A., Shanik, M. H., Raz, I., & Roth, J. (2009). Basal-state 
hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 
diabetes over a 24-year follow-up: a preliminary report. Diabetes Care, 
32(8), 1464-1466. doi:10.2337/dc09-0153 
Dashti, H. S., Scheer, F. A., Jacques, P. F., Lamon-Fava, S., & Ordovas, J. M. 
(2015). Short sleep duration and dietary intake: epidemiologic evidence, 
mechanisms, and health implications. Adv Nutr, 6(6), 648-659. 
doi:10.3945/an.115.008623 
Davies, S. K., Ang, J. E., Revell, V. L., Holmes, B., Mann, A., Robertson, F. P., Cui, 
N., Middleton, B., Ackermann, K., Kayser, M., Thumser, A. E., Raynaud, F. 
I., & Skene, D. J. (2014). Effect of sleep deprivation on the human 
metabolome. Proceedings of the National Academy of Sciences, 111(29), 
10761. doi:10.1073/pnas.1402663111 
171 
 
De Souza, L. Benedito-Silva, A. A., Pires, M. L. N., Poyares, D., Tufik, S., & Calil, H. 
M. (2003). Further validation of actigraphy for sleep studies. Sleep, 26(1). 
81-85.  
De Souza, J. F. T., Dattilo, M., De Mello, M. T., Tufik, S., & Antunes, H. K. M. 
(2017). High-intensity interval training attenuates insulin resistance induced 
by sleep deprivation in healthy males. Frontiers in physiology, 8. 
doi:10.3389/fphys.2017.00992 
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979). Glucose clamp technique: a 
method for quantifying insulin secretion and resistance. The American 
Journal of Physiology, 237(3), E214-223.  
DeFronzo, R. A., & Tripathy, D. (2009). Skeletal muscle insulin resistance is the 
primary defect in type 2 diabetes. Diabetes care, 32 Suppl 2(Journal Article), 
S157-163. doi:10.2337/dc09-S302 [doi] 
Del Prato, S., Marchetti, P., & Bonadonna, R. C. (2002). Phasic insulin release and 
metabolic regulation in type 2 diabetes. Diabetes, 51 Suppl 1, S109-116. 
doi:10.2337/diabetes.51.2007.s109 
Diez, J. J., & Iglesias, P. (2003). The role of the novel adipocyte-derived hormone 
adiponectin in human disease. Eur J Endocrinol, 148(3), 293-300. 
doi:10.1530/eje.0.1480293 
Dijk, D.-J. (2009). Regulation and functional correlates of slow wave sleep. J Clin 
Sleep Med, 5(2 Suppl), S6-S15.  
Donga, E., van Dijk, M., van Dijk, J. G., Biermasz, N. R., Lammers, G. J., van 
Kralingen, K. W., Corssmit, E. P., & Romijn, J. A. (2010). A single night of 
partial sleep deprivation induces insulin resistance in multiple metabolic 
pathways in healthy subjects. The Journal of clinical endocrinology and 
metabolism, 95(6), 2963-2968. doi:10.1210/jc.2009-2430 [doi] 
Dyrstad, S. M., Hansen, B. H., Holme, I. M., & Anderssen, S. A. (2014). Comparison 
of self-reported versus accelerometer-measured physical activity. Med Sci 
Sports Exerc, 46(1), 99-106. doi:10.1249/MSS.0b013e3182a0595f 
Eckel, Robert H., Depner, Christopher M., Perreault, L., Markwald, Rachel R., 
Smith, Mark R., McHill, Andrew W., Higgins, J., Melanson, Edward L., & 
Wright, Kenneth P. (2015). Morning Circadian Misalignment during Short 
Sleep Duration Impacts Insulin Sensitivity. Current Biology, 25(22), 3004-
3010. doi:https://doi.org/10.1016/j.cub.2015.10.011 
Edelman, D., Olsen, M. K., Dudley, T. K., Harris, A. C., & Oddone, E. Z. (2004). 
Utility of hemoglobin A1c in predicting diabetes risk. J Gen Intern Med, 
19(12), 1175-1180. doi:10.1111/j.1525-1497.2004.40178.x 
Egan, K.J., Knutson, K.L., Pereira, A.C., & von Schantz, M. (2017). The role of race 
and ethnicity in sleep, circadian rhythms and cardiovascular health. Sleep 
Medicine Reviews, 33, 70-78. doi:10.1016/j.smrv.2016.05.004 
Ekelund, U., Palla, L., Brage, S., Franks, P. W., Peters, T., Balkau, B., Diaz, M. J., 
Huerta, J. M., Agnoli, C., Arriola, L., Ardanaz, E., Boeing, H., Clavel-
Chapelon, F., Crowe, F., Fagherazzi, G., Groop, L., Fons Johnsen, N., 
172 
 
Kaaks, R., Khaw, K. T., Key, T. J., de Lauzon-Guillain, B., May, A., 
Monninkhof, E., Navarro, C., Nilsson, P., Nautrup Ostergaard, J., Norat, T., 
Overvad, K., Palli, D., Panico, S., Redondo, M. L., Ricceri, F., Rolandsson, 
O., Romaguera, D., Romieu, I., Sanchez Perez, M. J., Slimani, N., 
Spijkerman, A., Teucher, B., Tjonneland, A., Travier, N., Tumino, R., Vos, 
W., Vigl, M., Sharp, S., Langeberg, C., Forouhi, N., Riboli, E., Feskens, E., & 
Wareham, N. J. (2012). Physical activity reduces the risk of incident type 2 
diabetes in general and in abdominally lean and obese men and women: the 
EPIC-InterAct Study. Diabetologia, 55(7), 1944-1952. doi:10.1007/s00125-
012-2532-2 
Elmenhorst, E. M., Elmenhorst, D., Luks, N., Maass, H., Vejvoda, M., & Samel, A. 
(2008). Partial sleep deprivation: impact on the architecture and quality of 
sleep. Sleep Med, 9(8), 840-850. doi:10.1016/j.sleep.2007.07.021 
Esbjornsson-Liljedahl, M., Bodin, K., & Jansson, E. (2002). Smaller muscle ATP 
reduction in women than in men by repeated bouts of sprint exercise. J Appl 
Physiol (1985), 93(3), 1075-1083. doi:10.1152/japplphysiol.00732.1999 
Esliger, D. W., Rowlands, A. V., Hurst, T. L., Catt, M., Murray, P., & Eston, R. G. 
(2011). Validation of the GENEA Accelerometer. Medicine & Science in 
Sports & Exercise, 43(6), 1085-1093. doi:10.1249/MSS.0b013e31820513be 
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible 
statistical power analysis program for the social, behavioral, and biomedical 
sciences. Behavior Research Methods, 39(2), 175-191. 
doi:10.3758/BF03193146 
Fernandez-Real, J. M., Botas-Cervero, P., Lopez-Bermano, A., Casamitjana, R., 
Funahashi, T., Delgado, E., Kihara, S., & Ricart, W. (2004). Adiponectin is 
independently associated with glycosylated haemoglobin. Eur J Endocrinol, 
150(2), 201-205. doi:10.1530/eje.0.1500201 
Figueiró, T. H., Arins, G. C. B., Santos, C. E. S. D., Cembranel, F., Medeiros, P. A. 
d., d'Orsi, E., & Rech, C. R. (2019). Association of objectively measured 
sedentary behavior and physical activity with cardiometabolic risk markers in 
older adults. PLoS ONE, 14(1), e0210861-e0210861. 
doi:10.1371/journal.pone.0210861 
Ford, E. S., Cunningham, T. J., & Croft, J. B. (2015). Trends in Self-Reported Sleep 
Duration among US Adults from 1985 to 2012. Sleep, 38(5), 829–832. 
doi:10.5665/sleep.4684 
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972). Estimation of the 
concentration of low-density lipoprotein cholesterol in plasma, without use of 
the preparative ultracentrifuge. Clin Chem, 18(6), 499-502.  
Full, K. M., Kerr, J., Grandner, M. A., Malhotra, A., Moran, K., Godoble, S., 
Natarajan, L., & Soler, X. (2018). Validation of a physical activity 
accelerometer device worn on the hip and wrist against polysomnography. 
Sleep health, 4(2), 209-216. doi:10.1016/j.sleh.2017.12.007 
Fuller, P. M., Gooley, J. J., & Saper, C. B. (2006). Neurobiology of the sleep-wake 
cycle: sleep architecture, circadian regulation, and regulatory feedback. J 
Biol Rhythms, 21(6), 482-493. doi:10.1177/0748730406294627 
173 
 
Gais, S., Molle, M., Helms, K., & Born, J. (2002). Learning-dependent increases in 
sleep spindle density. J Neurosci, 22(15), 6830-6834. doi:20026697 
Gangwisch, J. E. (2009). Epidemiological evidence for the links between sleep, 
circadian rhythms and metabolism. Obes Rev, 10 Suppl 2, 37-45. 
doi:10.1111/j.1467-789X.2009.00663.x 
Gangwisch, J. E., Heymsfield, S. B., Boden-Albala, B., Buijs, R. M., Kreier, F., 
Pickering, T. G., Rundle, A. G., Zammit, G. K., & Malaspina, D. (2007). 
Sleep Duration as a Risk Factor for Diabetes Incidence in a Large US 
Sample. Sleep, 30(12), 1667-1673.  
Gay, J. L., Buchner, D. M., & Schmidt, M. D. (2016). Dose-response association of 
physical activity with HbA1c: Intensity and bout length. Prev Med, 86, 58-63. 
doi:10.1016/j.ypmed.2016.01.008 
Gerich, J. E. (1993). Control of glycaemia. Baillieres Clin Endocrinol Metab, 7(3), 
551-586. doi:10.1016/s0950-351x(05)80207-1 
Gerich, J. E. (2000). Physiology of glucose homeostasis. Diabetes Obes Metab, 
2(6), 345-350. doi:10.1046/j.1463-1326.2000.00085.x 
Goodyear, L. J., & Kahn, B. B. (1998). Exercise, glucose transport, and insulin 
sensitivity. Annu Rev Med, 49, 235-261. doi:10.1146/annurev.med.49.1.235 
Gordon, B. A., Fraser, S. F., Bird, S. R., & Benson, A. C. (2011). Reproducibility of 
multiple repeated oral glucose tolerance tests. Diabetes Research and 
Clinical Practice, 94(3), e78-e82. 
doi:https://doi.org/10.1016/j.diabres.2011.08.025 
Greiwe, J. S., Holloszy, J. O., & Semenkovich, C. F. (2000). Exercise induces 
lipoprotein lipase and GLUT-4 protein in muscle independent of adrenergic-
receptor signaling. J Appl Physiol (1985), 89(1), 176-181. 
doi:10.1152/jappl.2000.89.1.176 
Grgic, J., Dumuid, D., Bengoechea, E. G., Shrestha, N., Bauman, A., Olds, T., & 
Pedisic, Z. (2018). Health outcomes associated with reallocations of time 
between sleep, sedentary behaviour, and physical activity: a systematic 
scoping review of isotemporal substitution studies. International Journal of 
Behavioral Nutrition and Physical Activity, 15(1), 69. doi:10.1186/s12966-
018-0691-3 
Gubelmann, C., Heinzer, R., Haba-Rubio, J., Vollenweider, P., & Marques-Vidal, P. 
(2018). Physical activity is associated with higher sleep efficiency in the 
general population: the CoLaus study. Sleep, 41(7). 
doi:10.1093/sleep/zsy070 
Haack, M., Sanchez, E., & Mullington, J. M. (2007). Elevated inflammatory markers 
in response to prolonged sleep restriction are associated with increased pain 
experience in healthy volunteers. Sleep, 30(9), 1145-1152. 
doi:10.1093/sleep/30.9.1145 
Hafner, M., Stepanek, M., Taylor, J., Troxel, W. M., & van Stolk, C. (2017). Why 
Sleep Matters-The Economic Costs of Insufficient Sleep: A Cross-Country 
Comparative Analysis. Rand Health Q, 6(4), 11.  
174 
 
Hall, K., & Guo, J. (2017). Obesity Energetics: Body Weight Regulation and the 
Effects of Diet Composition. Gastroenterology, 152(7), 1718-1727. 
doi:10.1053/j.gastro.2017.01.052 
Hancox, R. J., & Landhuis, C. E. (2012). Association between sleep duration and 
haemoglobin A1c in young adults. J Epidemiol Community Health, 66(10), 
957-961. doi:10.1136/jech-2011-200217 
Harding, A.-H., Sargeant, L. A., Welch, A., Oakes, S., Luben, R. N., Bingham, S., 
Day, N. E., Khaw, K.-T., & Wareham, N. J. (2001). Fat Consumption and 
HbA&lt;sub&gt;1c&lt;/sub&gt; Levels. Diabetes care, 24(11), 1911. 
doi:10.2337/diacare.24.11.1911 
Hawley, J. A., & Lessard, S. J. (2008). Exercise training-induced improvements in 
insulin action. Acta Physiol (Oxf), 192(1), 127-135. doi:10.1111/j.1748-
1716.2007.01783.x 
Hayashi, T., Boyko, E. J., Sato, K. K., McNeely, M. J., Leonetti, D. L., Kahn, S. E., & 
Fujimoto, W. Y. (2013). Patterns of insulin concentration during the OGTT 
predict the risk of type 2 diabetes in Japanese Americans. Diabetes care, 
36(5), 1229-1235. doi:10.2337/dc12-0246 
Hickner, R. C., Fisher, J. S., Hansen, P. A., Racette, S. B., Mier, C. M., Turner, M. 
J., & Holloszy, J. O. (1997). Muscle glycogen accumulation after endurance 
exercise in trained and untrained individuals. J Appl Physiol (1985), 83(3), 
897-903. doi:10.1152/jappl.1997.83.3.897 
Hirshkowitz, M., Whiton, K., Albert, S. M., Alessi, C., Bruni, O., DonCarlos, L., 
Hazen, N., Herman, J., Katz, E. S., Kheirandish-Gozal, L., Neubauer, D. N., 
O'Donnell, A. E., Ohayon, M., Peever, J., Rawding, R., Sachdeva, R. C., 
Setters, B., Vitiello, M. V., Ware, J. C., & Adams Hillard, P. J. (2015). 
National Sleep Foundation's sleep time duration recommendations: 
methodology and results summary. Sleep Health, 1(1), 40-43. 
doi:10.1016/j.sleh.2014.12.010 
Horne, J. A., & Ostberg, O. (1976). A self-assessment questionnaire to determine 
morningness-eveningness in human circadian rhythms. International journal 
of chronobiology, 4(2), 97-110.  
Iftikhar, I. H., Donley, M. A., Mindel, J., Pleister, A., Soriano, S., & Magalang, U. J. 
(2015). Sleep Duration and Metabolic Syndrome. An Updated Dose-Risk 
Metaanalysis. Annals of the American Thoracic Society, 12(9), 1364-1372. 
doi:10.1513/AnnalsATS.201504-190OC 
Imbeault, P., Prins, J. B., Stolic, M., Russell, A. W., O'Moore-Sullivan, T., Despres, 
J. P., Bouchard, C., & Tremblay, A. (2003). Aging per se does not influence 
glucose homeostasis: in vivo and in vitro evidence. Diabetes care, 26(2), 
480-484. doi:10.2337/diacare.26.2.480 
Irwin, M., Thompson, J., Miller, C., Gillin, J. C., & Ziegler, M. (1999). Effects of sleep 
and sleep deprivation on catecholamine and interleukin-2 levels in humans: 
clinical implications. J Clin Endocrinol Metab, 84(6), 1979-1985. 
doi:10.1210/jcem.84.6.5788 
175 
 
Irwin, M. R., Wang, M., Campomayor, C. O., Collado-Hidalgo, A., & Cole, S. (2006). 
Sleep deprivation and activation of morning levels of cellular and genomic 
markers of inflammation. Archives of Internal Medicine, 166(16), 1756-1762. 
doi:166/16/1756 [pii] 
Irwin, M. R., Wang, M., Ribeiro, D., Cho, H. J., Olmstead, R., Breen, E. C., 
Martinez-Maza, O., & Cole, S. (2008). Sleep Loss Activates Cellular 
Inflammatory Signaling. Neurostimulatory and Neuroablative Treatments for 
Depression, 64(6), 538-540. 
doi:http://dx.doi.org/10.1016/j.biopsych.2008.05.004 
Johnson, N. A., Sachinwalla, T., Walton, D. W., Smith, K., Armstrong, A., 
Thompson, M. W., & George, J. (2009). Aerobic exercise training reduces 
hepatic and visceral lipids in obese individuals without weight loss. 
Hepatology, 50(4), 1105-1112. doi:10.1002/hep.23129 
Kaneita, Y., Uchiyama, M., Yoshiike, N., & Ohida, T. (2008). Associations of usual 
sleep duration with serum lipid and lipoprotein levels. Sleep, 31(5), 645-652. 
doi:10.1093/sleep/31.5.645 
Kelley, D., Mitrakou, A., Marsh, H., Schwenk, F., Benn, J., Sonnenberg, G., 
Arcangeli, M., Aoki, T., Sorensen, J., Berger, M., & et al. (1988). Skeletal 
muscle glycolysis, oxidation, and storage of an oral glucose load. J Clin 
Invest, 81(5), 1563-1571. doi:10.1172/jci113489 
Klem, G. H., Luders, H. O., Jasper, H. H., & Elger, C. (1999). The ten-twenty 
electrode system of the International Federation. The International 
Federation of Clinical Neurophysiology. Electroencephalogr Clin 
Neurophysiol Suppl, 52, 3-6.  
Klingenberg, L., Chaput, J. P., Holmbäck, U., Visby, T., Jennum, P., Nikolic, M., 
Astrup, A., & Sjödin, A. (2013). Acute Sleep Restriction Reduces Insulin 
Sensitivity in Adolescent Boys. Sleep, 36(7), 1085-1090.  
Klingman, K. J., Jungquist, C. R., & Perlis, M. L. (2017). Introducing the Sleep 
Disorders Symptom Checklist-25: A Primary Care Friendly and 
Comprehensive Screener for Sleep Disorders. Sleep Med Res, 8(1), 17-25. 
doi:10.17241/smr.2017.00010 
Knutson, K. L., Spiegel, K., Penev, P., & Van Cauter, E. (2007). The metabolic 
consequences of sleep deprivation. Sleep Medicine Reviews, 11(3), 163-
178. doi:http://dx.doi.org/10.1016/j.smrv.2007.01.002 
Knutson, K. L., Van Cauter, E., Rathouz, P. J., DeLeire, T., & Lauderdale, D. S. 
(2010). Trends in the prevalence of short sleepers in the USA: 1975-
2006. Sleep, 33(1), 37–45. doi:10.1093/sleep/33.1.37 
Kovacevic, A., Mavros, Y., Heisz, J. J., & Fiatarone Singh, M. A. (2018). The effect 
of resistance exercise on sleep: A systematic review of randomized 
controlled trials. Sleep Med Rev, 39, 52-68. doi:10.1016/j.smrv.2017.07.002 
Kredlow, M. A., Capozzoli, M. C., Hearon, B. A., Calkins, A. W., & Otto, M. W. 
(2015). The effects of physical activity on sleep: a meta-analytic review. J 
Behav Med, 38(3), 427-449. doi:10.1007/s10865-015-9617-6 
176 
 
Krueger, P. M., & Friedman, E. M. (2009). Sleep duration in the United States: a 
cross-sectional population-based study. Am J Epidemiol, 169(9), 1052-1063. 
doi:10.1093/aje/kwp023 
Kyu, H. H., Bachman, V. F., Alexander, L. T., Mumford, J. E., Afshin, A., Estep, K., 
Veerman, J. L., Delwiche, K., Iannarone, M. L., Moyer, M. L., Cercy, K., Vos, 
T., Murray, C. J., & Forouzanfar, M. H. (2016). Physical activity and risk of 
breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic 
stroke events: systematic review and dose-response meta-analysis for the 
Global Burden of Disease Study 2013. Bmj, 354, i3857. 
doi:10.1136/bmj.i3857 
Landolt, H. P. (2008). Sleep homeostasis: a role for adenosine in humans? Biochem 
Pharmacol, 75(11), 2070-2079. doi:10.1016/j.bcp.2008.02.024 
Lauderdale, D. S., Knutson, K. L., Yan, L. L., Liu, K., & Rathouz, P. J. (2008a). Self-
reported and measured sleep duration: how similar are they? Epidemiology, 
19(6), 838-845. doi:10.1097/EDE.0b013e318187a7b0 
Lauderdale, D. S., Knutson, K. L., Yan, L. L., Liu, K., & Rathouz, P. J. (2008b). 
Sleep duration: how well do self-reports reflect objective measures? The 
CARDIA Sleep Study. Epidemiology, 19(6), 838-845. 
doi:10.1097/EDE.0b013e318187a7b0 
Laws, A., & Reaven, G. M. (1992). Evidence for an independent relationship 
between insulin resistance and fasting plasma HDL-cholesterol, triglyceride 
and insulin concentrations. J Intern Med, 231(1), 25-30. doi:10.1111/j.1365-
2796.1992.tb00494.x 
Lee, S. W. H., Ng, K. Y., & Chin, W. K. (2017). The impact of sleep amount and 
sleep quality on glycemic control in type 2 diabetes: A systematic review and 
meta-analysis. Sleep Med Rev, 31, 91-101. doi:10.1016/j.smrv.2016.02.001 
Leiper, J. B., Broad, N. P., & Maughan, R. J. (2001). Effect of intermittent high-
intensity exercise on gastric emptying in man. Med Sci Sports Exerc, 33(8), 
1270-1278. doi:10.1097/00005768-200108000-00005 
Leproult, R., Copinschi, G., Buxton, O., & Van Cauter, E. (1997). Sleep loss results 
in an elevation of cortisol levels the next evening. Sleep, 20(10), 865-870.  
Leproult, R., Holmbäck, U., & Van Cauter, E. (2014). Circadian misalignment 
augments markers of insulin resistance and inflammation, independently of 
sleep loss. Diabetes, 63(6), 1860–1869. https://doi.org/10.2337/db13-1546 
Lewis, P., Korf, H. W., Kuffer, L., Gross, J. V., & Erren, T. C. (2018). Exercise time 
cues (zeitgebers) for human circadian systems can foster health and 
improve performance: a systematic review. BMJ Open Sport Exerc Med, 
4(1), e000443. doi:10.1136/bmjsem-2018-000443 
Li, S., Shin, H. J., Ding, E. L., & van Dam, R. M. (2009). Adiponectin Levels and 
Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA, 
302(2), 179-188. doi:10.1001/jama.2009.976 
Lin, P. M. D., Chang, K.-T., Lin, Y.-A., Tzeng, I. S., Chuang, H.-H., & Chen, J.-Y. 
(2017). Association between self-reported sleep duration and serum lipid 
177 
 
profile in a middle-aged and elderly population in Taiwan: a community-
based, cross-sectional study. BMJ Open, 7(10), e015964-e015964. 
doi:10.1136/bmjopen-2017-015964 
Lindseth, G., Lindseth, P., & Thompson, M. (2013). Nutritional effects on sleep. 
West J Nurs Res, 35(4), 497-513. doi:10.1177/0193945911416379 
Little, R. R., & Rohlfing, C. L. (2013). The long and winding road to optimal HbA1c 
measurement. Clinica chimica acta; international journal of clinical 
chemistry, 418, 63–71. doi:10.1016/j.cca.2012.12.026 
Lorenzo, C., Williams, K., & Haffner, S. M. (2012). Insulin secretion based on the 
late oral glucose tolerance test period and incident diabetes: the San 
Antonio Heart Study. Diabetic medicine : a journal of the British Diabetic 
Association, 29(8), e151-e158. doi:10.1111/j.1464-5491.2012.03660.x 
Luckhaupt, S. E., Tak, S., & Calvert, G. M. (2010). The prevalence of short sleep 
duration by industry and occupation in the National Health Interview Survey. 
Sleep, 33(2), 149-159. doi:10.1093/sleep/33.2.149 
Luyster, F. S., Strollo, P. J., Zee, P. C., Walsh, J. K., on behalf of the Boards of 
Directors of the American Academy of Sleep, M., & the Sleep, R. S. (2012). 
Sleep: A Health Imperative. Sleep, 35(6), 727-734. doi:10.5665/sleep.1846 
Mann, S., Beedie, C., & Jimenez, A. (2014). Differential effects of aerobic exercise, 
resistance training and combined exercise modalities on cholesterol and the 
lipid profile: review, synthesis and recommendations. Sports medicine 
(Auckland, N.Z.), 44(2), 211-221. doi:10.1007/s40279-013-0110-5 
Marino, M., Li, Y., Rueschman, M. N., Winkelman, J. W., Ellenbogen, J. M., Solet, J. 
M., Dulin, H., Berkman, L. F., & Buxton, O. M. (2013). Measuring Sleep: 
Accuracy, Sensitivity, and Specificity of Wrist Actigraphy Compared to 
Polysomnography. Sleep, 36(11), 1747-1755. doi:10.5665/sleep.3142 
Markwald, R. R., Melanson, E. L., Smith, M. R., Higgins, J., Perreault, L., Eckel, R. 
H., & Wright, K. P., Jr. (2013). Impact of insufficient sleep on total daily 
energy expenditure, food intake, and weight gain. Proc Natl Acad Sci U S A, 
110(14), 5695-5700. doi:10.1073/pnas.1216951110 
Marliss, E. B., Simantirakis, E., Miles, P. D., Hunt, R., Gougeon, R., Purdon, C., 
Halter, J. B., & Vranic, M. (1992). Glucose turnover and its regulation during 
intense exercise and recovery in normal male subjects. Clin Invest Med, 
15(5), 406-419.  
Martins, A. R., Nachbar, R. T., Gorjao, R., Vinolo, M. A., Festuccia, W. T., 
Lambertucci, R. H., Cury-Boaventura, M. F., Silveira, L. R., Curi, R., & 
Hirabara, S. M. (2012). Mechanisms underlying skeletal muscle insulin 
resistance induced by fatty acids: importance of the mitochondrial function. 
Lipids in Health and Disease, 11(1), 30. doi:10.1186/1476-511X-11-30 
Matsuda, M., & DeFronzo, R. A. (1999). Insulin sensitivity indices obtained from oral 
glucose tolerance testing: comparison with the euglycemic insulin clamp. 
Diabetes care, 22(9), 1462.  
178 
 
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & 
Turner, R. C. (1985). Homeostasis model assessment: insulin resistance 
and beta-cell function from fasting plasma glucose and insulin 
concentrations in man. Diabetologia, 28(7), 412-419.  
McLaughlin, T., Abbasi, F., Cheal, K., Chu, J., Lamendola, C., & Reaven, G. (2003). 
Use of metabolic markers to identify overweight individuals who are insulin 
resistant. Ann Intern Med, 139(10), 802-809. doi:10.7326/0003-4819-139-
10-200311180-00007 
Meier-Ewert, H. K., Ridker, P. M., Rifai, N., Regan, M. M., Price, N. J., Dinges, D. 
F., & Mullington, J. M. (2004). Effect of sleep loss on C-Reactive protein, an 
inflammatory marker of cardiovascular risk. Journal of the American College 
of Cardiology, 43(4), 678-683. doi:10.1016/j.jacc.2003.07.050 
Meyer, C., Pimenta, W., Woerle, H. J., Van Haeften, T., Szoke, E., Mitrakou, A., & 
Gerich, J. (2006). Different mechanisms for impaired fasting glucose and 
impaired postprandial glucose tolerance in humans. Diabetes care, 29(8), 
1909-1914. doi:10.2337/dc06-0438 
Moco, A. V., Matias, C. N., Santos, D. A., Rocha, P. M., Minderico, C. S., Cyrino, E. 
S., Sardinha, L. B., & Silva, A. M. (2019). Usefulness of Reflection Scanning 
in Determining Whole-Body Composition in Broadly Built Individuals Using 
Dual-Energy X-ray Absorptiometry. J Clin Densitom, 22(3), 429-436. 
doi:10.1016/j.jocd.2018.03.007 
Moller-Levet, C. S., Archer, S. N., Bucca, G., Laing, E. E., Slak, A., Kabiljo, R., Lo, 
J. C., Santhi, N., von Schantz, M., Smith, C. P., & Dijk, D. J. (2013). Effects 
of insufficient sleep on circadian rhythmicity and expression amplitude of the 
human blood transcriptome. Proc Natl Acad Sci U S A, 110(12), E1132-
1141. doi:10.1073/pnas.1217154110 
Monda, K. L., Ballantyne, C. M., & North, K. E. (2009). Longitudinal impact of 
physical activity on lipid profiles in middle-aged adults: the Atherosclerosis 
Risk in Communities Study. Journal of lipid research, 50(8), 1685-1691. 
doi:10.1194/jlr.P900029-JLR200 
Mullington, J. M., Simpson, N. S., Meier-Ewert, H., & Haack, M. (2010). Sleep Loss 
and Inflammation. Best practice & research.Clinical endocrinology & 
metabolism, 24(5), 775-784. doi:10.1016/j.beem.2010.08.014 
Muniyappa, R., Lee, S., Chen, H., & Quon, M. J. (2008). Current approaches for 
assessing insulin sensitivity and resistance in vivo: advantages, limitations, 
and appropriate usage. American journal of physiology.Endocrinology and 
metabolism, 294(1), E15-26. doi:00645.2007 [pii] 
Nakajima, H., Kaneita, Y., Yokoyama, E., Harano, S., Tamaki, T., Ibuka, E., 
Kaneko, A., Takahashi, I., Umeda, T., Nakaji, S., & Ohida, T. (2008). 
Association between sleep duration and hemoglobin A1c level. Sleep Med, 
9(7), 745-752. doi:10.1016/j.sleep.2007.07.017 
Nakajima, K., Suwa, K., & Toyama, K. (2017). Age-dependent changes in the 
association between sleep duration and impaired glucose metabolism. World 
J Diabetes, 8(8), 397-406. doi:10.4239/wjd.v8.i8.397 
179 
 
Nana, A., Slater, G. J., Stewart, A. D., & Burke, L. M. (2015). Methodology Review: 
Using Dual-Energy X-Ray Absorptiometry (DXA) for the Assessment of Body 
Composition in Athletes and Active People. International Journal of Sport 
Nutrition and Exercise Metabolism, 25(2), 198-215. 
doi:10.1123/ijsnem.2013-0228 
Nathan, D. M., Turgeon, H., & Regan, S. (2007). Relationship between glycated 
haemoglobin levels and mean glucose levels over time. Diabetologia, 
50(11), 2239-2244. doi:10.1007/s00125-007-0803-0 
Ndahimana, D., & Kim, E.-K. (2017). Measurement Methods for Physical Activity 
and Energy Expenditure: a Review. Clinical nutrition research, 6(2), 68-80. 
doi:10.7762/cnr.2017.6.2.68 
Nedeltcheva, A. V., Kessler, L., Imperial, J., & Penev, P. D. (2009). Exposure to 
recurrent sleep restriction in the setting of high caloric intake and physical 
inactivity results in increased insulin resistance and reduced glucose 
tolerance. The Journal of clinical endocrinology and metabolism, 94(9), 
3242-3250. doi:10.1210/jc.2009-0483 [doi] 
O'Keeffe, M., Roberts, A. L., Kelleman, M., Roychoudhury, A., & St-Onge, M. P. 
(2013). No effects of short-term sleep restriction, in a controlled feeding 
setting, on lipid profiles in normal-weight adults. J Sleep Res, 22(6), 717-
720. doi:10.1111/jsr.12060 
Ohkuma, T., Fujii, H., Iwase, M., Kikuchi, Y., Ogata, S., Idewaki, Y., Ide, H., Doi, Y., 
Hirakawa, Y., Nakamura, U., & Kitazono, T. (2013). Impact of Sleep Duration 
on Obesity and the Glycemic Level in Patients With Type 2 Diabetes. 
Diabetes care, 36(3), 611. doi:10.2337/dc12-0904 
Ortega, R.M., Pérez-Rodrigo, C., & López-Sobaler, A.M. (2015). Dietary 
assessment methods: dietary records. Nutr Hosp, 31(3), 38-45. 
doi:10.3305/nh.2015.31.sip3.8749  
Ortega, J. F., Fernandez-Elias, V. E., Hamouti, N., Pallares, J. G., & Mora-
Rodriguez, R. (2015). Higher insulin-sensitizing response after sprint interval 
compared to continuous exercise. Int J Sports Med, 36(3), 209-214. 
doi:10.1055/s-0034-1389942 
Otten, J., Ahrén, B., & Olsson, T. (2014). Surrogate measures of insulin sensitivity 
vs the hyperinsulinaemic–euglycaemic clamp: a meta-analysis. Diabetologia, 
57(9), 1781-1788. doi:10.1007/s00125-014-3285-x 
Pan, X., & Hussain, M. M. (2007). Diurnal regulation of microsomal triglyceride 
transfer protein and plasma lipid levels. J Biol Chem, 282(34), 24707-24719. 
doi:10.1074/jbc.M701305200 
Phillips, F., Chen, C. N., Crisp, A. H., Koval, J., McGuinness, B., Kalucy, R. S., 
Kalucy, E. C., & Lacey, J. H. (1975). Isocaloric diet changes and 
electroencephalographic sleep. Lancet, 2(7938), 723-725. 
doi:10.1016/s0140-6736(75)90718-7 
Plat, L., Leproult, R., L'Hermite-Baleriaux, M., Fery, F., Mockel, J., Polonsky, K. S., 
& Van Cauter, E. (1999). Metabolic effects of short-term elevations of 
180 
 
plasma cortisol are more pronounced in the evening than in the morning. J 
Clin Endocrinol Metab, 84(9), 3082-3092. doi:10.1210/jcem.84.9.5978 
Porter, J. M., & Horne, J. A. (1981). Bed-time food supplements and sleep: effects 
of different carbohydrate levels. Electroencephalogr Clin Neurophysiol, 
51(4), 426-433. doi:10.1016/0013-4694(81)90106-1 
Potter, G. D. M., Cade, J. E., & Hardie, L. J. (2017). Longer sleep is associated with 
lower BMI and favorable metabolic profiles in UK adults: Findings from the 
National Diet and Nutrition Survey. PLoS ONE, 12(7), e0182195. 
doi:10.1371/journal.pone.0182195 
Powell, C., Carson, B. P., Dowd, K. P., & Donnelly, A. E. (2017). Simultaneous 
validation of five activity monitors for use in adult populations. Scand J Med 
Sci Sports, 27(12), 1881-1892. doi:10.1111/sms.12813 
Pulido, J. M. E., & Salazar, M. A. (1999). Changes in Insulin Sensitivity, Secretion 
and Glucose Effectiveness During Menstrual Cycle. Archives of Medical 
Research, 30(1), 19-22. doi:https://doi.org/10.1016/S0188-0128(98)00008-6 
Qin, L., Knol, M. J., Corpeleijn, E., & Stolk, R. P. (2010). Does physical activity 
modify the risk of obesity for type 2 diabetes: a review of epidemiological 
data. European journal of epidemiology, 25(1), 5-12. doi:10.1007/s10654-
009-9395-y 
Rao, M. N., Neylan, T. C., Grunfeld, C., Mulligan, K., Schambelan, M., & Schwarz, 
J.-M. (2015). Subchronic Sleep Restriction Causes Tissue-Specific Insulin 
Resistance. The Journal of clinical endocrinology and metabolism, 100(4), 
1664-1671. doi:10.1210/jc.2014-3911 
Reybrouck, T., Ghesquiere, J., Weymans, M., & Amery, A. (1986). Ventilatory 
threshold measurement to evaluate maximal endurance performance. Int J 
Sports Med, 7(1), 26-29. doi:10.1055/s-2008-1025730 
Reynolds, A. C., Dorrian, J., Liu, P. Y., Van Dongen, H. P., Wittert, G. A., Harmer, L. 
J., & Banks, S. (2012). Impact of five nights of sleep restriction on glucose 
metabolism, leptin and testosterone in young adult men. PLoS ONE, 7(7), 
e41218. doi:10.1371/journal.pone.0041218 [doi] 
Roder, P. V., Wu, B., Liu, Y., & Han, W. (2016). Pancreatic regulation of glucose 
homeostasis. Exp Mol Med, 48, e219. doi:10.1038/emm.2016.6 
Rynders, C. A., Weltman, J. Y., Jiang, B., Breton, M., Patrie, J., Barrett, E. J., & 
Weltman, A. (2014). Effects of exercise intensity on postprandial 
improvement in glucose disposal and insulin sensitivity in prediabetic adults. 
J Clin Endocrinol Metab, 99(1), 220-228. doi:10.1210/jc.2013-2687 
Rynders, C. A., Weltman, J. Y., Malin, S. K., Jiang, B., Breton, M., Barrett, E. J., & 
Weltman, A. (2016). Comparing Simple Insulin Sensitivity Indices to the Oral 
Minimal Model Postexercise. Med Sci Sports Exerc, 48(1), 66-72. 
doi:10.1249/mss.0000000000000728 
Sadeh, A., Sharkey, K. M., & Carskadon, M. A. (1994). Activity-based sleep-wake 
identification: an empirical test of methodological issues. Sleep, 17(3), 201-
207.  
181 
 
Saleh, D., & Janssen, I. (2014). Interrelationships among sedentary time, sleep 
duration, and the metabolic syndrome in adults. BMC public health, 14, 666-
666. doi:10.1186/1471-2458-14-666 
Saltiel, A. R., & Kahn, C. R. (2001). Insulin signalling and the regulation of glucose 
and lipid metabolism. Nature, 414(6865), 799-806. doi:10.1038/414799a 
Saner, N. J., Bishop, D. J., & Bartlett, J. D. (2018). Is exercise a viable therapeutic 
intervention to mitigate mitochondrial dysfunction and insulin resistance 
induced by sleep loss? Sleep Med Rev, 37, 60-68. 
doi:10.1016/j.smrv.2017.01.001 
Santaguida, P. L., Balion, C., Hunt, D., Morrison, K., Gerstein, H., Raina, P., 
Booker, L., & Yazdi, H. (2005). Diagnosis, prognosis, and treatment of 
impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol 
Assess (Summ)(128), 1-11.  
Schmid, S. M., Hallschmid, M., Jauch-Chara, K., Wilms, B., Lehnert, H., Born, J., & 
Schultes, B. (2011). Disturbed glucoregulatory response to food intake after 
moderate sleep restriction. Sleep, 34(3), 371-377.  
Schmid, S. M., Hallschmid, M., & Schultes, B. (2015). The metabolic burden of 
sleep loss. Lancet Diabetes Endocrinol, 3(1), 52-62. doi:10.1016/s2213-
8587(14)70012-9 
Schmid, S. M., Jauch-Chara, K., Hallschmid, M., & Schultes, B. (2009). Mild sleep 
restriction acutely reduces plasma glucagon levels in healthy men. The 
Journal of clinical endocrinology and metabolism, 94(12), 5169-5173. 
doi:10.1210/jc.2009-0969 [doi] 
Sharma, M., Nazareth, I., & Petersen, I. (2016). Trends in incidence, prevalence 
and prescribing in type 2 diabetes mellitus between 2000 and 2013 in 
primary care: a retrospective cohort study. BMJ Open, 6(1), e010210. 
doi:10.1136/bmjopen-2015-010210 
Shea, S. A., Hilton, M. F., Orlova, C., Ayers, R. T., & Mantzoros, C. S. (2005). 
Independent circadian and sleep/wake regulation of adipokines and glucose 
in humans. J Clin Endocrinol Metab, 90(5), 2537-2544. doi:10.1210/jc.2004-
2232 
Sheehan, C. M., Frochen, S. E., Walsemann, K. M., & Ailshire, J. A. (2019). Are 
U.S. adults reporting less sleep?: Findings from sleep duration trends in the 
National Health Interview Survey, 2004-2017. Sleep, 42(2), zsy221. 
doi:10.1093/sleep/zsy221 
Shimokata, H., Muller, D. C., Fleg, J. L., Sorkin, J., Ziemba, A. W., & Andres, R. 
(1991). Age as independent determinant of glucose tolerance. Diabetes, 
40(1), 44-51. doi:10.2337/diab.40.1.44 
Silva, G. E., Goodwin, J. L., Sherrill, D. L., Arnold, J. L., Bootzin, R. R., Smith, T., 
Walsleben, J. A., Baldwin, C. M., & Quan, S. F. (2007). Relationship 
between reported and measured sleep times: the sleep heart health study 
(SHHS). J Clin Sleep Med, 3(6), 622-630.  
182 
 
Singh, B., & Saxena, A. (2010). Surrogate markers of insulin resistance: A review. 
World J Diabetes, 1(2), 36-47. doi:10.4239/wjd.v1.i2.36 
Sonksen, P. & Sonksen, J. (2000). Insulin: understanding its action in health and 
disease. British Journal of Anaesthesia, 85(1), 69-79. 
doi:10.1093/bja/85.1.69 
Spiegel, K., Leproult, R., L’Hermite-Balériaux, M., Copinschi, G., Penev, P. D., & 
Van Cauter, E. (2004). Leptin Levels Are Dependent on Sleep Duration: 
Relationships with Sympathovagal Balance, Carbohydrate Regulation, 
Cortisol, and Thyrotropin. The Journal of Clinical Endocrinology & 
Metabolism, 89(11), 5762-5771. doi:10.1210/jc.2004-1003 
Spiegel, K., Leproult, R., & Van Cauter, E. (1999). Impact of sleep debt on 
metabolic and endocrine function. The Lancet, 354(9188), 1435-1439. 
doi:http://dx.doi.org/10.1016/S0140-6736(99)01376-8 
St-Onge, M., Roberts, A. L., Chen, J., Kelleman, M., O'Keeffe, M., RoyChoudhury, 
A., & Jones, P. J. H. (2011). Short sleep duration increases energy intakes 
but does not change energy expenditure in normal-weight individuals. The 
American Journal of Clinical Nutrition, 94(2), 410-416.  
Stefan, L., Sporis, G., Kristicevic, T., & Knjaz, D. (2018). Associations between 
sleep quality and its domains and insufficient physical activity in a large 
sample of Croatian young adults: a cross-sectional study. BMJ Open, 8(7), 
e021902. doi:10.1136/bmjopen-2018-021902 
Štefan, L., Vrgoč, G., Rupčić, T., Sporiš, G., & Sekulić, D. (2018). Sleep Duration 
and Sleep Quality Are Associated with Physical Activity in Elderly People 
Living in Nursing Homes. International Journal of Environmental Research 
and Public Health, 15(11). doi:10.3390/ijerph15112512 
Stephan, F. K. (2002). The "other" circadian system: food as a Zeitgeber. J Biol 
Rhythms, 17(4), 284-292. doi:10.1177/074873040201700402 
Sternfeld, B., Gabriel, K. P., Jiang, S. F., Whitaker, K. M., Jacobs, D. R., Jr., 
Quesenberry, C. P., Jr., Carnethon, M., & Sidney, S. (2019). Risk Estimates 
for Diabetes and Hypertension with Different Physical Activity Methods. Med 
Sci Sports Exerc, 51(12), 2498-2505. doi:10.1249/mss.0000000000002083 
Steyn, N. P., Mann, J., Bennett, P. H., Temple, N., Zimmet, P., Tuomilehto, J., 
Lindstrom, J., & Louheranta, A. (2004). Diet, nutrition and the prevention of 
type 2 diabetes. Public Health Nutr, 7(1a), 147-165. 
doi:10.1079/phn2003586 
Sweeney, E. L., Jeromson, S., Hamilton, D. L., Brooks, N. E., & Walshe, I. H. 
(2017). Skeletal muscle insulin signaling and whole-body glucose 
metabolism following acute sleep restriction in healthy males. Physiological 
reports, 5(23), e13498. doi:10.14814/phy2.13498 
Taheri, S., Lin, L., Austin, D., Young, T., & Mignot, E. (2004). Short sleep duration is 
associated with reduced leptin, elevated ghrelin, and increased body mass 
index. PLoS Med, 1(3), e62-e62. doi:10.1371/journal.pmed.0010062 
183 
 
Tamaki, M., Nittono, H., Hayashi, M., & Hori, T. (2005). Spectral analysis of the first-
night effect on the sleep-onset period. Sleep and Biological Rhythms, 3(3), 
122-129. doi:10.1111/j.1479-8425.2005.00173.x 
The Sleep Council. (2017). The Great British Bedtime Report Retrieved from 
https://sleepcouncil.org.uk/wp-content/uploads/2017/12/The-Great-British-
Bedtime-Report-2017.pdf 
Tong, T. K., Kong, Z., Shi, X., & Shi, Q. (2017). Comparable effects of brief 
resistance exercise and isotime sprint interval exercise on glucose 
homeostasis in men. Journal of Diabetes Research, 2017, 1-8. 
doi:10.1155/2017/8083738 
Tschritter, O., Fritsche, A., Thamer, C., Haap, M., Shirkavand, F., Rahe, S., Staiger, 
H., Maerker, E., Haring, H., & Stumvoll, M. (2003). Plasma adiponectin 
concentrations predict insulin sensitivity of both glucose and lipid 
metabolism. Diabetes, 52(2), 239-243. doi:10.2337/diabetes.52.2.239 
Twedt, R., Bradley, M., Deiseroth, D., Althouse, A., & Facco, F. (2015). Sleep 
Duration and Blood Glucose Control in Women With Gestational Diabetes 
Mellitus. Obstet Gynecol, 126(2), 326-331. 
doi:10.1097/aog.0000000000000959 
Utzschneider, K. M., Prigeon, R. L., Tong, J., Gerchman, F., Carr, D. B., Zraika, S., 
Udayasankar, J., Montgomery, B., Mari, A., & Kahn, S. E. (2007). Within-
subject variability of measures of beta cell function derived from a 2 h OGTT: 
implications for research studies. Diabetologia, 50(12), 2516-2525. 
doi:10.1007/s00125-007-0819-5 
Van Cauter, E., Blackman, J. D., Roland, D., Spire, J. P., Refetoff, S., & Polonsky, 
K. S. (1991). Modulation of glucose regulation and insulin secretion by 
circadian rhythmicity and sleep. Journal of Clinical Investigation, 88(3), 934-
942.  
van Hees, V. T., Sabia, S., Jones, S. E., Wood, A. R., Anderson, K. N., Kivimäki, M., 
Frayling, T. M., Pack, A. I., Bucan, M., Trenell, M. I., Mazzotti, D. R., 
Gehrman, P. R., Singh-Manoux, B. A., & Weedon, M. N. (2018). Estimating 
sleep parameters using an accelerometer without sleep diary. Scientific 
reports, 8(1), 12975-12975. doi:10.1038/s41598-018-31266-z 
van Leeuwen, W. M. A., Hublin, C., Sallinen, M., Härmä, M., Hirvonen, A., & 
Porkka-Heiskanen, T. (2010). Prolonged sleep restriction affects glucose 
metabolism in healthy young men. International journal of endocrinology, 
2010, 108641-108641. doi:10.1155/2010/108641 
VanHelder, T., Symons, J. D., & Radomski, M. W. (1993). Effects of sleep 
deprivation and exercise on glucose tolerance. Aviat Space Environ Med, 
64(6), 487-492.  
Vgontzas, A. N., Zoumakis, E., Bixler, E. O., Lin, H. M., Follett, H., Kales, A., & 
Chrousos, G. P. (2004). Adverse effects of modest sleep restriction on 
sleepiness, performance, and inflammatory cytokines. The Journal of clinical 
endocrinology and metabolism, 89(5), 2119-2126. doi:10.1210/jc.2003-
031562 [doi] 
184 
 
Vondra, K., Brodan, V., Bass, A., Kuhn, E., Teisinger, J., Andel, M., & Veselkova, A. 
(1981). Effects of sleep deprivation on the activity of selected metabolic 
enzymes in skeletal muscle. Eur J Appl Physiol Occup Physiol, 47(1), 41-46. 
doi:10.1007/bf00422481 
Walch, O. J., Cochran, A., & Forger, D. B. (2016). A global quantification of "normal" 
sleep schedules using smartphone data. Sci Adv, 2(5), e1501705. 
doi:10.1126/sciadv.1501705 
Wang, X., Greer, J., Porter, R. R., Kaur, K., & Youngstedt, S. D. (2016). Short-term 
moderate sleep restriction decreases insulin sensitivity in young healthy 
adults. Sleep Health in Early Care and Education, 2(1), 63-68. 
doi:http://dx.doi.org/10.1016/j.sleh.2015.11.004 
Warburton, D. E., Nicol, C. W., & Bredin, S. S. (2006). Health benefits of physical 
activity: the evidence. Cmaj, 174(6), 801-809. doi:10.1503/cmaj.051351 
Weir, G. C., & Bonner-Weir, S. (2004). Five Stages of Evolving Beta-Cell 
Dysfunction During Progression to Diabetes. Diabetes, 53(suppl 3), S16. 
doi:10.2337/diabetes.53.suppl_3.S16 
Weir, J. B. D. V. (1949). New methods for calculating metabolic rate with special 
reference to protein metabolism. Journal of Physiology, 109, 1-9.  
Weiss A. R., Johnson N. L., Berger N. A., Redline S. (2010) Validity of activity-
based devices to estimate sleep. J Clin Sleep Med, 6(4), 336-342. 
Wever, R. A., Polasek, J., & Wildgruber, C. M. (1983). Bright light affects human 
circadian rhythms. Pflugers Arch, 396(1), 85-87. doi:10.1007/bf00584704 
Whitaker, K. M., Lutsey, P. L., Ogilvie, R. P., Pankow, J. S., Bertoni, A., Michos, E. 
D., Punjabi, N., & Redline, S. (2018). Associations between 
polysomnography and actigraphy-based sleep indices and glycemic control 
among those with and without type 2 diabetes: the Multi-Ethnic Study of 
Atherosclerosis. Sleep, 41(11). doi:10.1093/sleep/zsy172 
Williams, C. J., Hu, F. B., Patel, S. R., & Mantzoros, C. S. (2007). Sleep Duration 
and Snoring in Relation to Biomarkers of Cardiovascular Disease Risk 
Among Women With Type 2 Diabetes. Diabetes Care, 30(5), 1233. 
doi:10.2337/dc06-2107 
Wojtaszewski, J. F., & Richter, E. A. (2006). Effects of acute exercise and training 
on insulin action and sensitivity: focus on molecular mechanisms in muscle. 
Essays Biochem, 42, 31-46. doi:10.1042/bse0420031 
World Health Organization. (2006). World Health Organization. Definition and 
diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a 
WHO/IDF consultation. Retrieved from Geneva:  
Wu, H., Stone, W. S., Hsi, X., Zhuang, J., Huang, L., Yin, Y., Zhang, L., & Zhao, Z. 
(2010). Effects of different sleep restriction protocols on sleep architecture 
and daytime vigilance in healthy men. Physiological research, 59(5), 821-
829.  
185 
 
Wurtman R. J., Wurtman J. J., Regan M. M., McDermott J. M., Tasay R. H., & Breu 
J. J. (2003). Effect of normal meals rich in carbohydrates or proteins on 
plasma tryptophan and tyrosine ratios. Am J Clin Nutr, 77(1), 128–32. doi: 
10.1093/ajcn/77.1.128 
Yaggi, H. K., Araujo, A. B., & McKinlay, J. B. (2006). Sleep Duration as a Risk 
Factor for the Development of Type 2 Diabetes. Diabetes care, 29(3), 657.  
Yeung, C. H. C., Au Yeung, S. L., Fong, S. S. M., & Schooling, C. M. (2019). Lean 
mass, grip strength and risk of type 2 diabetes: a bi-directional Mendelian 
randomisation study. Diabetologia, 62(5), 789-799. doi:10.1007/s00125-019-
4826-0 
Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. 
K., Cushman, S. W., Cooney, G. J., Atcheson, B., White, M. F., Kraegen, E. 
W., & Shulman, G. I. (2002). Mechanism by which fatty acids inhibit insulin 
activation of insulin receptor substrate-1 (IRS-1)-associated 
phosphatidylinositol 3-kinase activity in muscle. J Biol Chem, 277(52), 
50230-50236. doi:10.1074/jbc.M200958200 
Zhang, X., Gregg, E. W., Williamson, D. F., Barker, L. E., Thomas, W., Bullard, K. 
M., Imperatore, G., Williams, D. E., & Albright, A. L. (2010). A1C level and 
future risk of diabetes: a systematic review. Diabetes care, 33(7), 1665-
1673. doi:10.2337/dc09-1939 
Zhu, B., Shi, C., Park, C. G., Zhao, X., & Reutrakul, S. (2019). Effects of sleep 
restriction on metabolism-related parameters in healthy adults: A 
comprehensive review and meta-analysis of randomized controlled trials. 
Sleep Med Rev, 45, 18-30. doi:10.1016/j.smrv.2019.02.002 
 
 
